

Am

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
10 October 2002 (10.10.2002)

PCT

(10) International Publication Number
WO 02/079152 A1(51) International Patent Classification⁷: **C07D 209/14**Wakefield Street, Hamden, CT 06517 (US). **HIGGINS, Mendi** [US/US]; 8105 Town Ridge, Middletown, CT 06457 (US).

(21) International Application Number: PCT/US02/06627

(22) International Filing Date: 5 March 2002 (05.03.2002)

(74) Agents: **MAKUJINA, Shah** et al.; BRISTOL-MYERS SQUIBB COMPANY, P. O. Box 4000, Lawrenceville-Princeton Road, Princeton, NJ 08543-4000 (US).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/279,888	29 March 2001 (29.03.2001)	US
60/293,122	23 May 2001 (23.05.2001)	US
60/327,804	9 October 2001 (09.10.2001)	US

(71) Applicant (for all designated States except US): **BRISTOL-MYERS SQUIBB COMPANY** [US/US]; P. O. Box 4000, Lawrenceville-Princeton Road, Princeton, NJ 08543-4000 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MATTSON, Ronald** [US/US]; 65 Smithfield Avenue, Meriden, CT 06451 (US). **DENHART, Derek** [CA/US]; 188 North Whittlesey Avenue, Wallingford, CT 06492 (US). **DESKUS, Jeffrey** [US/US]; 82 Stage Harbor Road, Marlborough, CT 06447 (US). **DITTA, Jonathan** [US/US]; 51 Russett Lane, Middletown, CT 06457 (US). **MARCIN, Lawrence** [US/US]; 81 Peck Road, Bethany, CT 06524 (US). **EPPELSON, James** [US/US]; 5 Arrowwood Drive, Cromwell, CT 06416 (US). **CATT, John** [US/US]; 6633 Cheshire Drive, Newburgh, IN 47630 (US). **KING, Dalton** [US/US]; 114

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CYCLOPROPYLINDOLE DERIVATIVES AS SELECTIVE SEROTONIN REUPTAKE INHIBITORS



(I)

(57) Abstract: The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts or solvates thereof and pharmaceutically acceptable formulations comprising said compounds useful for the treatment of depression, anxiety disorders, premature ejaculation, chronic pain, obsessive-compulsive disorder, feeding disorders, premenstrual dysphoric disorder, panic disorders and psychotic disorders including bipolar disorder and schizophrenia.

WO 02/079152 A1

CYCLOPROPYLINDOLE DERIVATIVES AS SELECTIVE SEROTONIN REUPTAKE INHIBITORS

Field of the Invention

5 The present invention relates to cyclopropylindole derivatives and pharmaceutical compositions comprising said derivatives useful for the treatment of various psychiatric disorders and premature ejaculation.


Background of the Invention

10 Selective serotonin reuptake inhibitors (SSRIs) are effective for the treatment of mental depression and have been reported to be useful for treating chronic pain. See R.W. Fuller, Pharmacologic Modification of Serotonergic Function: Drugs for the Study and Treatment of Psychiatric and Other Disorders," *J. Clin. Psychiatry*, 47:4 (Suppl.) April 1986, pp. 4-8 and Selective Serotonin Reuptake Inhibitors.
15 Edited by JP Feighner and WF Boyer, Chichester, England. John Wiley & Sons, 1991, pp 89-108. SSRI's have also demonstrated efficacy for the treatment of anxiety disorders. More recently, SSRI's have demonstrated efficacy in the treatment of premature ejaculation. See Kim and Paick, Short-term Analysis of the Effects of As Needed Use of Sertraline at 5 pm for the Treatment of Premature Ejaculation,
20 *Urology* 54:544-547 (1999); Kim and Paick, Self Therapy with Sertraline given PRN at 5 pm in treatment of Premature Ejaculation, *Journal of Urology* 54:544-547 (1998); McMahon and Touma, Treatment of Premature Ejaculation with Paroxetine Hydrochloride As Needed: 2 Single-Blind Placebo Controlled Crossover Studies *Journal of Urology* 161:1826-1830 (1999); Haensal *et al.*, Clomipramine and sexual
25 function in men with premature ejaculation and controls *Journal of Urology* 158:1310-1315 (1998); and McMahon and Touma, Treatment of Premature Ejaculation with Paroxetine Hydrochloride *International Journal Impotence Research* 11:241-246 (1999). Thus novel SSRI's effective for the treatment of these and other disorders would be greatly advantageous.

30

Summary of the Invention

Thus according to a first embodiment of a first aspect of the present invention are provided compounds of Formula (I)



and pharmaceutically acceptable salts or solvates thereof

wherein

5 A¹ and A² are each independently C₁₋₄alkylene or a bond;

A³ is C₁₋₄alkylene or C₁₋₄alkylidene;

A⁴ is C₁₋₄alkylene or a bond and is attached to X, X¹ or X²;

X, X¹, X² and X³ are independently C or CH;

J is C₁₋₄alkyl;

10 p is 0 or 1;

R¹ and R² are independently H, C₁₋₃alkyl, C₃₋₆cycloalkyl, phenyl, -O-phenyl, -N(H)C(O)O-C₁₋₄alkyl or C₁₋₄alkyl-N(H)C(O)O-;

said C₃₋₆cycloalkyl, phenyl or O-phenyl being

independently and optionally substituted with

15 C₁₋₄alkyl, C₁₋₃alkoxy or halo;

or are independently selected from the group of heterocyclic

moieties consisting of thienyl, furanyl, pyrrolyl,

pyrrolinyl, pyrrolidinyl, imidazolyl, imidazoliny,

imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl,

20 pyridyl, pyrimidinyl, piperidinyl, piperazinyl,

morpholino, adamantyl, indolyl, isoindolyl, indolinyl,

quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl,

-3-

isoquinolinyl, dihydroisoquinolinyl and tetrahydroisoquinolinyl, wherein said heterocyclic moieties are optionally substituted with halo, C₁₋₄alkyl, C₁₋₄alkoxy or cyano;

5 or wherein -A¹-R¹ and -A²-R² together with the nitrogen to which they are attached form pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, 10 adamantyl, indolyl, isoindolyl, indolinyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl or tetrahydroisoquinolinyl and are optionally substituted with halo, C₁₋₄alkyl, C₁₋₄alkoxy, cyano or benzyl;

15 R³ is H or C₁₋₄alkyl;

m is 0 or 1;

R⁴ and R⁵ are independently hydrogen, cyano, halo, nitro or C₁₋₃perfluoroalkyl;

20 wherein said R⁴ or R⁵ may be independently attached to X, X¹, X² or X³;

n is 0 or 1;

G is N, O or S;

G¹ is N or CH;

Y is (D)H wherein D is C; and

25 Z is (E)H wherein E is C;

provided that

both R⁴ and R⁵ are not attached to the same of said X, X¹, X² or X³;

if G is O or S, then m is 0;

if G is N, then m is 1;

if R¹ is -N(H)C(O)OC₁₋₄alkyl, C₁₋₄alkyl-N(H)C(O)O- or said heterocyclic moiety wherein said heterocyclic moiety contains a nitrogen atom and said nitrogen atom is attached to A¹, then A¹ is C₂₋₄alkylene;

if R² is -N(H)C(O)OC₁₋₄alkyl, C₁₋₄alkyl-N(H)C(O)O- or said heterocyclic moiety wherein said heterocyclic moiety contains a nitrogen atom and said nitrogen atom is attached to A², then A² is C₂₋₄alkylene;

if R¹ is N(H)C(O)O-C₁₋₄alkyl, C₁₋₄alkyl-N(H)C(O)O- or a heterocyclic moiety selected from the group consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazoliny, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, isoindolyl, indolinyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl and tetrahydroisoquinolinyl, wherein said heterocyclic moieties are optionally substituted with halo, C₁₋₄alkyl, C₁₋₄alkoxy or cyano, then R² is H or C₁₋₃alkyl;

if R² is -N(H)C(O)O-C₁₋₄alkyl, C₁₋₄alkyl-N(H)C(O)O- or a heterocyclic moiety selected from the group consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazoliny, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, isoindolyl, indolinyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl and tetrahydroisoquinolinyl, wherein said heterocyclic moieties are optionally

-5-

substituted with halo, C₁₋₄alkyl, C₁₋₄alkoxy or cyano,
then R¹ is H or C₁₋₃alkyl;

if A⁴, R⁴ or R⁵ are attached to X, then X is C;

if A⁴, R⁴ or R⁵ are attached to X¹, then X¹ is C;

5 if A⁴, R⁴ or R⁵ are attached to X², then X² is C;

if R⁴ or R⁵ are attached to X³, then X³ is C;

if R⁴ is F and is attached to X and if A³ is methylene, then -

A¹-R¹ and -A²-R² together with the nitrogen to which
they are attached is not N-methyl-piperazinyl; and

10 if R⁴ is F and is attached to X and if A³ is methylene, then -A¹-
R¹ and -A²-R² together with the nitrogen to which they
are attached is not tetrahydroquinoliny.

According to another embodiment of the first aspect of the present invention
15 are provided compounds of Formula (I) according to the first embodiment of the first
aspect wherein p is 0.

According to another embodiment of the first aspect of the present invention
are provided compounds of Formula (I) according to the first embodiment of the first
aspect wherein G is N and G¹ is CH.

20 According to another embodiment of the first aspect of the present invention
are provided compounds of Formula (I) according to the first embodiment of the first
aspect wherein G is S and G¹ is CH.

According to another embodiment of the first aspect of the present invention
are provided compounds of Formula (I) according to the first embodiment of the first
25 aspect wherein G is N and G¹ is N.

According to another embodiment of the first aspect of the present invention
are provided compounds of Formula (I) according to the first embodiment of the first
aspect wherein G is S and G¹ is N.

30 According to another embodiment of the first aspect of the present invention
are provided compounds of Formula (I) according to the first embodiment of the first
aspect wherein G is O and G¹ is N.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein R¹ is methyl and R² is methyl.

5 According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein A¹ is a bond, R¹ is methyl, A² is a bond and R² is methyl.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein R³ is H and m is 1.

10 According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein R⁴ and R⁵ are halo.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein R⁴ is hydrogen.

15 According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein R⁴ is fluoro.

20 According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein R⁴ is cyano.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein R⁴ and R⁵ are each fluoro.

25 According to another embodiment of the first aspect of the present invention are compounds of Formula (I) wherein D in relation to the four moieties to which it is attached has an absolute configuration of S; E in relation to the four moieties to which it is attached has an absolute configuration of S; and wherein the hydrogen atom attached to D is in the *trans* configuration to the hydrogen atom attached to E.

30 According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein A³ is C₁₋₄alkylene.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein A³ is C₁₋₄alkylidene.

5 According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein A³ is methylene.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein A⁴ is a bond.

10 According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein A⁴ is methylene.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein A⁴ is attached X¹.

15 According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein A⁴ is attached X.

20 According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein R⁴ is attached X.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein A¹ is a bond, A² is a bond, R¹ is methyl and R² is methyl.

25 According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein R¹ is independently selected from the group of heterocyclic moieties consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazoliny, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, isoindolyl, indoliny, quinoliny, dihydroquinoliny, tetrahydroquinoliny, isoquinoliny, dihydroisoquinoliny and tetrahydroisoquinoliny, wherein said heterocyclic moieties

30

are optionally substituted with halo, C₁₋₄alkyl, C₁₋₄alkoxy or cyano; A¹ is C₁₋₄alkylene; R² is H or C₁₋₃alkylene; and A² is a bond.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein R¹ is independently selected from the group of heterocyclic moieties consisting of thienyl, imidazolyl, pyridyl, piperidiny, piperazinyl, morpholino, adamantyl, indolyl, tetrahydroquinoliny and tetrahydroisoquinoliny; A¹ is C₁₋₄alkylene; R² is H or C₁₋₃alkylene; and A² is a bond.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein R² is independently selected from the group of heterocyclic moieties consisting of thienyl, furanyl, pyrrolyl, pyrroliny, pyrrolidiny, imidazolyl, imidazoliny, imidazolidiny, pyrazolyl, pyrazoliny, pyrazolidiny, pyridyl, pyrimidiny, piperidiny, piperazinyl, morpholino, adamantyl, indolyl, isoindolyl, indoliny, quinoliny, dihydroquinoliny, tetrahydroquinoliny, isoquinoliny, dihydroisoquinoliny and tetrahydroisoquinoliny, wherein said heterocyclic moieties are optionally substituted with halo, C₁₋₄alkyl, C₁₋₄alkoxy or cyano; A² is C₁₋₄alkylene; R¹ is H or C₁₋₃alkylene; and A¹ is a bond.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein R² is independently selected from the group of heterocyclic moieties consisting of thienyl, imidazolyl, pyridyl, piperidiny, piperazinyl, morpholino, adamantyl, indolyl, tetrahydroquinoliny and tetrahydroisoquinoliny; A² is C₁₋₄alkylene; R¹ is H or C₁₋₃alkylene; and A¹ is a bond.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein R¹ and R² are independently H, C₁₋₃alkyl, C₃₋₆cycloalkyl, phenyl, -O-phenyl, or -N(H)C(O)O-C₁₋₄alkyl.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein R¹ and R² are independently H, C₁₋₃alkyl, or -N(H)C(O)O-C₁₋₄alkyl.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first

aspect wherein R^1 and R^2 are independently H, C_{1-3} alkyl, C_{3-6} cycloalkyl, phenyl, or -O-phenyl.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein R^1 and R^2 are independently H, C_{1-3} alkyl, or are independently selected from the group of heterocyclic moieties consisting of thienyl, imidazolyl, pyridyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, tetrahydroquinoliny and tetrahydroisoquinoliny.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein R^2 is H or C_{1-3} alkyl and R^1 is C_{3-6} cycloalkyl, phenyl, -O-phenyl, or -N(H)C(O)O- C_{1-4} alkyl.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein R^2 is H or C_{1-3} alkyl and R^1 is N(H)C(O)O- C_{1-4} alkyl.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein R^2 is H or C_{1-3} alkyl and R^1 is C_{3-6} cycloalkyl, phenyl or -O-phenyl.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein R^2 is H or C_{1-3} alkyl and R^1 is selected from the group of heterocyclic moieties consisting of thienyl, imidazolyl, pyridyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, tetrahydroquinoliny and tetrahydroisoquinoliny.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein R^1 is H or C_{1-3} alkyl and R^2 is C_{3-6} cycloalkyl, phenyl, -O-phenyl, or -N(H)C(O)O- C_{1-4} alkyl.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein R^1 is H or C_{1-3} alkyl and R^2 is N(H)C(O)O- C_{1-4} alkyl.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein R^1 is H or C_{1-3} alkyl and R^2 is C_{3-6} cycloalkyl, phenyl or -O-phenyl.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein R^1 is H or C_{1-3} alkyl and R^2 is selected from the group of heterocyclic moieties consisting of thienyl, imidazolyl, pyridyl, piperidiny, piperazinyl, morpholino, adamantyl, indolyl, tetrahydroquinoliny and tetrahydroisoquinoliny.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein $-A^1-R^1$ and $-A^2-R^2$ together with the nitrogen to which they are attached form pyrrolidiny, piperidiny, piperazinyl, morpholino, adamantyl, tetrahydroquinoliny or tetrahydroisoquinoliny and are optionally substituted with benzyl.

According to another embodiment of the first aspect of the present invention are provided compounds of Formula (I) according to the first embodiment of the first aspect wherein

A^1 and A^2 are each independently C_{1-4} alkylene or a bond;
 A^3 is C_{1-4} alkylene;
 A^4 is a bond and is attached to X or X^1 ;
 R^1 and R^2 are independently H, C_{1-3} alkyl, C_{3-6} cycloalkyl, phenyl, -O-phenyl or -N(H)C(O)O- C_{1-4} alkyl;

said C_{3-6} cycloalkyl, phenyl or O-phenyl being independently and optionally substituted with C_{1-4} alkyl, C_{1-3} alkoxy or halo;

or are independently selected from the group of heterocyclic moieties consisting of thienyl, imidazolyl, pyridyl, piperidiny, piperazinyl, morpholino, adamantyl, indolyl, tetrahydroquinoliny and tetrahydroisoquinoliny;

or wherein $-A^1-R^1$ and $-A^2-R^2$ together with the nitrogen to which they are attached form pyrrolidiny, piperidiny, piperazinyl, morpholino, adamantyl,

tetrahydroquinoliny1 or tetrahydroisoquinoliny1 and are optionally substituted with benzyl;

R^3 is H or C_{1-4} alkyl;

m is 0 or 1;

5 R^4 is cyano or halo and is attached to X or X^1 ;

n is 0;

X and X^1 are each C;

X^2 and X^3 are each CH;

G is N, O or S;

10 G^1 is N or CH;

Y is (D)H wherein D is C; and

Z is (E)H wherein E is C;

provided that

if G is O or S; then m is 0;

15 if G is N, then m is 1;

if R^1 is $-N(H)C(O)OC_{1-4}$ alkyl or said heterocyclic moiety wherein said heterocyclic moiety contains a nitrogen atom and said nitrogen atom is attached to A^1 , then A^1 is C_{2-4} alkylene;

20 if R^2 is $-N(H)C(O)OC_{1-4}$ alkyl or said heterocyclic moiety wherein said heterocyclic moiety contains a nitrogen atom and said nitrogen atom is attached to A^2 , then A^2 is C_{2-4} alkylene;

25 if R^1 is $-N(H)C(O)O-C_{1-4}$ alkyl or said heterocyclic moiety, then R^2 is H or C_{1-3} alkyl;

if R^2 is $-N(H)C(O)O-C_{1-4}$ alkyl or said heterocyclic moiety, then R^1 is H or C_{1-3} alkyl;

-12-

if R^4 is F and is attached to X and if A^3 is methylene, then -
 A^1-R^1 and $-A^2-R^2$ together with the nitrogen to which
they are attached is not N-methyl-piperazinyl; and

5 if R^4 is F and is attached to X and if A^3 is methylene, then $-A^1-$
 R^1 and $-A^2-R^2$ together with the nitrogen to which they
are attached is not tetrahydroquinolinyl.

According to another embodiment of the first aspect of the present invention
are provided compounds of Formula (I) according to the first embodiment of the first
aspect wherein said compounds exhibit greater SERT binding than hD_{2L} binding as
10 described herein.

According to another embodiment of the first aspect of the present invention
are provided compounds of Formula (I) according to the first embodiment of the first
aspect wherein said compounds exhibit less SERT binding than hD_{2L} binding as
described herein.

15 According to various embodiments of a second aspect of the present invention
are provided pharmaceutically acceptable formulations comprising compounds of
Formula (I) as defined herein.

The compounds of the present invention may be useful in the treatment or
prevention of disorders in which the regulation of monoamine transporter function is
20 implicated. Disease states that may be implicated include hypertension, depression
(e.g., depression in cancer patients, depression in Parkinson's patients,
postmyocardial infarction depression, subsyndromal symptomatic depression,
depression in infertile women, paediatric depression, major depression, single
episode depression, recurrent depression, child abuse induced depression, and post
25 partum depression), generalized anxiety disorder, phobias (e.g., agoraphobia, social
phobia and simple phobias), posttraumatic stress syndrome, avoidant personality
disorder, premature ejaculation, eating disorders (e.g., anorexia nervosa and bulimia
nervosa), obesity, chemical dependencies (e.g., addictions to alcohol, cocaine, heroin,
phenobarbital, nicotine and benzodiazepines), cluster headache, migraine, pain,
30 Alzheimer's disease, obsessive-compulsive disorder, panic disorder, memory
disorders (e.g., dementia, amnesic disorders, and age-related cognitive decline
(ARCD)), Parkinson's diseases (e.g., dementia in Parkinson's disease, neuroleptic-

induced parkinsonism and tardive dyskinesias), endocrine disorders (e.g., hyperprolactinaemia), vasospasm (particularly in the cerebral vasculature), cerebellar ataxia, gastrointestinal tract disorders (involving changes in motility and secretion), negative symptoms of schizophrenia, premenstrual syndrome, fibromyalgia syndrome, stress incontinence, Tourette's syndrome, trichotillomania, kleptomania, male impotence, attention deficit hyperactivity disorder (ADHD), chronic paroxysmal hemicrania, headache (associated with vascular disorders), emotional lability, pathological crying and sleeping disorder (cataplexy).

Disorders of particular interest include depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder, post-traumatic stress disorder, substance abuse disorders and sexual dysfunction including (in particular) premature ejaculation. The compounds of the present invention may be administered alone or as part of a combination therapy.

Premature ejaculation may be defined as persistent or recurrent ejaculation before, upon or shortly after penile penetration of a sexual partner. It may also be defined as ejaculation occurring before the individual wishes [see The Merck Manual, 16th edition, p. 1576, published by Merck Research Laboratories, 1992].

Thus according to various embodiments of a third aspect of the present invention are provided methods of treating conditions selected from the group consisting of depression, anxiety disorders, premature ejaculation, urinary incontinence, chronic pain, obsessive-compulsive disorder, feeding disorders, premenstrual dysphoric disorder, hot flashes, panic disorders, posttraumatic stress disorder and social phobia comprising the administration to a human in need thereof an effective amount of pharmaceutically acceptable formulations comprising compounds of Formula (I) as defined herein.

According to various embodiments of a fourth aspect of the present invention are provided methods of treating psychotic disorders including bipolar disorder and schizophrenia comprising the administration to a human in need thereof an effective amount of pharmaceutically acceptable formulations comprising compounds of Formula (I) exhibiting greater than or equal hD_{2L} binding than SERT binding as defined herein.

According to various embodiments of a fifth aspect of the present invention are provided methods of enhancing the treatment of conditions selected from the

group consisting of depression, anxiety disorders, premature ejaculation, urinary incontinence, chronic pain, obsessive-compulsive disorder, feeding disorders, premenstrual dysphoric disorder, panic disorders, posttraumatic stress disorder and social phobia comprising the administration to a human in need thereof an effective
5 amount of pharmaceutically acceptable formulations comprising compounds of Formula (I) having SERT binding as defined herein and a pharmaceutically acceptable formulation of agents selected from the group consisting of (Lithium, 5-hydroxytryptophan, or a 5-HT_{1B/1D} antagonist such as (R)-N-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydronaphthalen-2-yl]-4-morpholino-benzamide.

10 According to a first embodiment of a sixth aspect of the present invention are provided methods of treating refractory depression comprising the administration to a human in need thereof an effective amount of a pharmaceutically acceptable formulation comprising compounds of Formula (I) as defined herein and a pharmaceutically acceptable formulation containing a reversible and selective MAO-
15 A inhibitor.

According to another embodiment of the sixth aspect of the present invention are provided methods of treating refractory depression comprising the administration to a human in need thereof an effective amount of pharmaceutically acceptable formulations comprising compounds of Formula (I) as defined herein and a
20 pharmaceutically acceptable formulation containing one or more reversible and selective MAO-A inhibitors selected from the group consisting of moclobemide, brofaromine and befloxatone.

According to another embodiment of the sixth aspect of the present invention
25 are provided methods of treating refractory depression comprising the administration to a human in need thereof an effective amount of pharmaceutically acceptable formulation comprising compounds of Formula (I) as defined herein and a pharmaceutically acceptable formulation containing a 5-HT_{1A} antagonist.

According to another embodiment of the sixth aspect of the present invention
30 are provided methods of treating refractory depression comprising the administration to a human in need thereof an effective amount of pharmaceutically acceptable formulations comprising compounds of Formula (I) as defined herein and a

pharmaceutically acceptable formulation containing a 5-HT_{1A} antagonist selected from the group consisting of pindolol and WAY-100,635.

According to another embodiment of the sixth aspect of the present invention are provided methods of treating refractory depression comprising the administration
5 to a human in need thereof an effective amount of pharmaceutically acceptable formulations comprising compounds of Formula (I) as defined herein and a pharmaceutically acceptable formulation containing a 5-HT_{1B} antagonist.

According to another embodiment of the sixth aspect of the present invention are provided methods of treating refractory depression comprising the administration
10 to a human in need thereof an effective amount of pharmaceutically acceptable formulations comprising compounds of Formula (I) as defined herein and a pharmaceutically acceptable formulation containing a partial 5-HT_{1A/1B} antagonist.

According to another embodiment of the sixth aspect of the present invention are provided methods of treating refractory depression comprising the administration
15 to a human in need thereof an effective amount of pharmaceutically acceptable formulations comprising compounds of Formula (I) as defined herein and a pharmaceutically acceptable formulation containing buspirone.

According to another embodiment of the sixth aspect of the present invention are provided methods of treating refractory depression comprising the administration
20 to a human in need thereof an effective amount of pharmaceutically acceptable formulations comprising compounds of Formula (I) as defined herein and a pharmaceutically acceptable formulation containing methylphenidate.

According to a seventh aspect of the present invention are provided methods of treating obsessive compulsive disorder comprising the administration to an
25 adolescent or child in need thereof an effective amount of pharmaceutically acceptable formulations comprising compounds of Formula (I) as defined herein and a pharmaceutically acceptable formulation containing clomipramine.

According to a first embodiment of an eighth aspect of the present invention are provided methods of treating refractory psychotic depression comprising the
30 administration to a human in need thereof an effective amount of pharmaceutically acceptable formulations comprising compounds of Formula (I) as defined herein and a pharmaceutically acceptable formulation of an antipsychotic agent.

According to another embodiment of the eighth aspect of the present invention are provided methods of treating refractory psychotic depression comprising the administration to a human in need thereof an effective amount of pharmaceutically acceptable formulations comprising compounds of Formula (I) as defined herein and a pharmaceutically acceptable formulation of an antipsychotic agent selected from the group consisting of aripiprazole, olanzapine, risperdal, clozapine, ziprasidone, haldol, thiothixene and quetiapine fumarate.

According to a ninth aspect of the present invention are provided methods of treating exogenous obesity comprising the administration to a human in need thereof an effective amount of pharmaceutically acceptable formulations comprising compounds of Formula (I) as defined herein and a pharmaceutically acceptable formulation of phentermine.

According to a first embodiment of a tenth aspect of the present invention are provided methods of treating disorders or conditions which can be facilitated by altering circadian rhythms comprising the administration to a human in need thereof an effective amount of pharmaceutically acceptable formulations comprising compounds of Formula (I) as defined herein and a pharmaceutically acceptable formulation of a nitric oxide synthase inhibitor.


According to another embodiment of the tenth aspect of the present invention are provided methods of treating disorders or conditions which can be facilitated by altering circadian rhythms comprising the administration to a human in need thereof an effective amount of pharmaceutically acceptable formulations comprising compounds of Formula (I) as defined herein and a pharmaceutically acceptable formulation of a selective neuronal nitric oxide synthase inhibitor.

According to another embodiment of the tenth aspect of the present invention are provided methods of treating disorders or conditions which can be facilitated by altering circadian rhythms comprising the administration to a human in need thereof an effective amount of pharmaceutically acceptable formulations comprising compounds of Formula (I) as defined herein and a pharmaceutically acceptable formulation of a nitric oxide synthase inhibitor said conditions selected from the group consisting of blindness, obesity, seasonal affective disorder, bipolar disorder, jet lag, circadian sleep rhythms disorder, sleep deprivation, parasomnias, REM sleep disorders, hypersomnia, sleep-wake cycle disorders, narcolepsy and sleep disorders

associated with shift work or irregular work schedules, nocturnal enuresis and restless-legs syndrome.


According to another embodiment of the tenth aspect of the present invention are provided methods of treating disorders or conditions which can be facilitated by altering circadian rhythms comprising the administration to a human in need thereof an effective amount of pharmaceutically acceptable formulations comprising compounds of Formula (I) as defined herein and a pharmaceutically acceptable formulation of a selective neuronal nitric oxide synthase inhibitor said conditions selected from the group consisting of blindness, obesity, seasonal affective disorder, bipolar disorder, jet lag, circadian sleep rhythms disorder, sleep deprivation, parasomnias, REM sleep disorders, hypersomnia, sleep-wake cycle disorders, narcolepsy and sleep disorders associated with shift work or irregular work schedules, nocturnal enuresis and restless-legs syndrome.

According to a first embodiment of an eleventh aspect of the present invention is provided a process for the preparation of a compound of Formula (d)



(d)


by reacting a compound of formula (b)



(b)


with a compound of formula (c)

-18-




in the presence of ethyl diazoacetate and toluene, wherein R^4 is cyano, halo, nitro or
 5 C_{1-3} perfluoroalkyl and X is *p*-toluenesulfonyl, benzenesulfonyl, methanesulfonyl or
 trifluoromethanesulfonyl.

According to another embodiment of the eleventh aspect of the present
 invention is provided a process for the preparation of a compound of Formula (d¹)




10

by reacting a compound of formula (b)



15 with a compound of formula (c)

-19-



in the presence of tert-butyl diazoacetate and toluene, wherein R^4 is cyano, halo, nitro or C_{1-3} perfluoroalkyl and X is *p*-toluenesulfonyl, benzenesulfonyl, methanesulfonyl or trifluoromethanesulfonyl.

According to a twelvth aspect of the present invention is provided a method of treating sexual dysfunction in a mammal in need thereof comprising the administration of a pharmaceutically acceptable salt or solvate of a compound of Formula (I) and a compound selected from the group of known erectile dysfunction agents including sildenafil.

Other embodiments of the present invention may comprise suitable combinations of two or more of the embodiments and/or aspects disclosed herein.

Yet other embodiments and aspects of the invention will be apparent according to the description provided below.

Detailed Description of the Invention

The description of the invention herein should be construed in congruity with the laws and principals of chemical bonding. For example, it may be necessary to remove a hydrogen atom in order accommodate a substituent at any given location.


An embodiment or aspect which depends from another embodiment or aspect, will describe only the variables having values or provisos that differ from the embodiment or aspect from which it depends.

If a variable is quantified with a value of zero, then any bond attaching said variable should no longer be represented, *e.g.*, if n in $(R^3)_n$ equals 0, then the bond attaching R^3 to G should no longer be represented.

As used herein, "halo" or "halogen" includes fluoro, chloro, bromo and iodo.

As used herein, " C_{1-4} alkylene" means a one to four carbon alkane having one hydrogen atom removed from two different carbon atoms in said alkane, *e.g.*, $-CH_2CH_2CH_2-$.

As used herein, "C₁₋₄alkylidene" means a one to four carbon alkane having two hydrogen atoms removed from one carbon atom in said alkane, *e.g.*,



It should be understood that the alternating double bond designations in the six-membered ring of the 5,6-membered fused structure represented in Formula (I) are relative and represent the delocalized π orbital electrons of said ring.

It is to be understood that the present invention may include any and all possible stereoisomers, geometric isomers, diastereoisomers, enantiomers, anomers and optical isomers, unless a particular description specifies otherwise.

The compounds of this invention may exist in the form of pharmaceutically acceptable salts. Such salts may include addition salts with inorganic acids such as, for example, hydrochloric acid and sulfuric acid, and with organic acids such as, for example, acetic acid, citric acid, methanesulfonic acid, toluenesulfonic acid, tartaric acid and maleic acid. Further, in case the compounds of this invention contain an acidic group, the acidic group may exist in the form of alkali metal salts such as, for example, a potassium salt and a sodium salt; alkaline earth metal salts such as, for example, a magnesium salt and a calcium salt; and salts with organic bases such as a triethylammonium salt and an arginine salt. In the case of a sublingual formulation a saccharin salt or maleate salt may be of particular benefit. The compounds of the present invention may be hydrated or non-hydrated.

The compounds of this invention can be administered in such oral dosage forms as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders, granules, elixirs, tinctures, suspensions, syrups and emulsions. The compounds of this invention may also be administered intravenously, intraperitoneally, subcutaneously, or intramuscularly, all using dosage forms well known to those skilled in the pharmaceutical arts. The compounds can be administered alone, but generally will be administered with a pharmaceutical carrier selected upon the basis of the chosen route of administration and standard pharmaceutical practice. Compounds of this invention can also be administered in intranasal form by topical use of suitable intranasal vehicles, or by transdermal routes, using transdermal skin patches. When compounds of this invention are

administered transdermally the dosage will be continuous throughout the dosage regimen.


The dosage and dosage regimen and scheduling of a compounds of the present invention must in each case be carefully adjusted, utilizing sound professional judgment and considering the age, weight and condition of the recipient, the route of administration and the nature and extent of the disease condition. In accordance with good clinical practice, it is preferred to administer the instant compounds at a concentration level which will produce effective beneficial effects without causing any harmful or untoward side effects.

Synthesis

Compounds of the present invention may be synthesized according to the general schema provided below. Variables provided in the schema below are defined in accordance with the description of compounds of the above Formulae unless otherwise specified.


A preferred method for the preparation of trans-cyclopropanes of Formula I is illustrated in Scheme 1. A appropriately substituted heterocyclic aldehyde, where Pg is a protecting group such as p-toluenesulfonyl when G is nitrogen, is reacted with a appropriated olefinating reagent, such as a Horner-Emmons reagent. The resulting heterocyclic trans-acrylic acid derivative, preferably the N-methoxy-N-methyl amide, is cyclopropanated using reagents such as diazomethane and palladium(II)acetate, or trimethylsulfoxonium iodide with an appropriate base. The resulting cyclopropyl amide derivative is reduced to the aldehyde using reagents such as LAH, or the like. Subsequent reductive amination using an appropriately substituted amine with an reducing agent such as sodium triacetoxyborohydride, sodium cyanoborohydride, or the like, gives the cyclopropyl methyl amine. Removal of protecting groups, such as the p-toluenesulfonyl group, when G is nitrogen, using mild basic hydrolysis, gives the trans-cyclopropyl compounds of Formula 1.

Scheme 1




A preferred method of preparing cis-cyclopropyl compounds of Formula I is described in Scheme 2. This method is similar to that in Scheme 1, except for the use of olefinating reagents, such as the trifluoroethyl Horner-Emmons reagent, that selectively give the heterocyclic cis-acrylic acid derivatives, where Pg is a protecting group such as p-toluenesulfonyl when G is nitrogen. Further reaction of the cis-acrylic acid derivatives, in a manner similar to that described in Scheme 1, provides the cis-cyclopropyl compounds of Formula I.

Scheme 2



- A preferred method for the preparation of compounds of Formula I where A^3 is a branched alkylidene chain is illustrated in Scheme 3. The N-methoxy-N-methylcyclopropyl carboxamide intermediate, where Pg is a protecting group such as p-toluenesulfonyl when G is nitrogen, is reacted with a nucleophile, such as an alkyl magnesium halide or alkyl lithium. The resulting cyclopropyl alkyl ketone is reductively aminated and subsequently deprotected in a manner similar to that described in Scheme 1 to give compounds of Formula I where A^3 is a branched alkylidene chain.

Scheme 3




15

Another preferred method for the preparation of compounds of Formula I is illustrated in Scheme 4. An appropriately substituted vinyl heterocycle, where Pg is a

protecting group such as p-toluenesulfonyl when G is nitrogen, is reacted with an appropriate diazoacetate ester, such as ethyl or tert-butyl diazoacetate, in the presence of a catalyst such as the Nishiyama catalyst. [(R)-*trans*-Cl₂Ru(pybox-ip)(CH₂=CH₂)] was prepared from 2,6-bis(4R)-(+)-isopropyl-2-oxazolin-2-yl]pyridine (Aldrich Chemical Co.) according to: Nishiyama, H.; Itoh, Y.; Matsumoto, H.; Park, S.-B.; Itoh, K. *J. Am. Chem. Soc.* **1994**, *116*, 2223.] The resulting cyclopropyl ester is reduced to the alcohol using reagents such as DIBAL, LAH, or the like. The resulting alcohol is then oxidized to the corresponding aldehyde using standard methods, such as PCC or DMSO/oxalyl chloride. The resulting aldehyde is then converted to the compounds of Formula 1 by the methods outlined in Scheme 1.


Scheme 4



The vinyl heterocycle intermediates, where Pg is a protecting group such as p-toluenesulfonyl when G is nitrogen, can be prepared in several ways (Scheme 5). Treatment of an appropriate aldehyde with an organometallic reagent such as a methyl magnesium bromide, or the like, with subsequent dehydration of the resulting alcohol using reagents such as p-toluene sulfonic acid, or the like, is one preferred method for the preparation of the vinyl heterocycle intermediates. Another preferred method consists of acetylation of the heterocycle using reagents such as acetyl chloride and diethylaluminum chloride, or the like, followed by the optional protection of the heterocycle using p-toluenesulfonyl chloride and triethyl amine, or the like.

Reduction of the acetyl group using sodium borohydride, or the like, with subsequent dehydration of the resulting alcohol gives the vinyl heterocycle.

Scheme 5




5

The preparation of indazole compounds of Formula 1 is described in Scheme 6. The aryl cyclopropyl ketone intermediate is prepared by methods known to those skilled in the art, such as a palladium mediated coupling of an aryl boronate with a cyclopropane thioester. This ketone intermediate is reacted with an appropriately substituted hydrazine, such as *p*-toluenesulfonylhydrazide, and subsequently cyclized to an indazole under mild basic conditions, such as potassium carbonate. The resulting cyclopropyl ester is converted to compounds of Formula 1 by methods similar to those described in Scheme 3.

15


Scheme 6.



The preparation of compounds of Formula 1, where G is sulfur, is described in Scheme 7. The appropriately substituted carboxaldehyde is carried through a reaction sequence in a manner similar to that described in Scheme 1 to give the compounds of

5 Formula I, where G is sulfur.

Scheme 7




10

The preparation of indole and indazole compounds of Formula 1, where R³ is lower alkyl, is described in Scheme 8, along with the preparation quaternary alkyl ammonium salts of compounds of Formula 1. Indole and indazole compounds of


Formula 1, where R^3 is H, are reacted with bases such as sodium hydride or potassium tert-butoxide in the presence of alkylating reagents, such as dimethyl sulfate or diethyl sulfate, to give derivatives where R^3 is lower alkyl. Quaternary alkyl ammonium salts of compounds of Formula 1, are prepared by reaction of tertiary amine compounds of Formula 1 with alkyl halides, such as methyl iodide.

Scheme 8



- 10 Another preferred method for preparing compounds of Formula 1, where A^4 is attached at points X, X^1 , or X^2 , is described in Scheme 9. An appropriately substituted heterocycle, with a reacting group Rg (such as iodo, bromo, or trifluoromethanesulfonyl groups) is present at points X or X^2 is reacted with an
- 15 like. The resulting substituted acrylamide derivative is converted to compounds of Formula I by methods similar to those described in Scheme 1. The substituted acrylamide derivative can also be prepared from appropriately substituted heterocyclic aldehyde, where the aldehyde is attached at points X, X^1 , or X^2 . Olefination of the aldehyde with the Horner-Emmons reagent under conditions
- 20 described in Scheme 1 also gives the substituted acrylamide derivative which can be converted to compounds of Formula I by methods similar to those described in Scheme 1.


Scheme 9



Other suitable means of synthesizing said compounds may also be available. More detailed descriptions of synthesizing compounds of the present invention are also provided. The required starting materials and reagents, such as substituted indoles and indolecarboxaldehydes, for these methods can be obtained from commercial sources. Other starting materials that are not commercially available can be prepared by standard methods known to those skilled in the art.

Example 1

Trans-2-[5-Cyanoindol-3-yl]-1-(*N,N*-dimethylaminomethyl)cyclopropane



Phosphorus oxychloride (10.9 ml, 117 mmol) was added dropwise over 30 min to anhydrous dimethylformamide (50 ml) that was maintained at 10-20°C (internal temperature). The resulting mixture was stirred for 30 min and then chilled to 0° C. A solution of commercially available 5-cyanoindole (15 g, 106 mmol) in anhydrous dimethylformamide (30 ml) was added over 10 min. The ice bath was removed and the solution was allowed to warm to room temperature. After 2 h, a very thick paste resulted. The off-white paste was carefully quenched with ice chips. An aqueous solution of sodium hydroxide (2.12 g NaOH/100 ml H₂O) was added. After a mild exotherm, a clear yellow solution resulted. The solution was poured into water (~400 ml) and a fine solid immediately precipitated. The mixture was filtered

through a 600 ml glass fritted funnel of medium porosity. The yellow filtrate was diluted with an equal volume of water and left to stand for 16 h. A yellow precipitate was collected by vacuum filtration. The solid was dried overnight under vacuum to afford 13.6 g (75% yield) of (5-cyanoindol-3-yl)carboxaldehyde: ¹H NMR (500
5 MHz, DMSO-d₆) 12.58 (1 H, br s.), 10.00 (1 H, s), 8.51 (1 H, d, J = 3.1 Hz), 8.46 (1 H, d, J = 0.6 Hz), 7.22 (1 H, dd, J = 8.6, 0.5 Hz), 7.64 (1 H, dd, J = 8.5, 1.6 Hz); MS m/e 171 (M + H)⁺.

p-Toluenesulfonyl chloride (15.2 g, 79.5 mmol) was added to a solution of (5-
10 cyanoindol-3-yl)carboxaldehyde (13.5 g, 79.5 mmol) and triethylamine (12.2 ml, 87.5 mmol) in anhydrous dichloromethane (250 ml). The mixture was left to stir for 24 h at room temperature. The solid precipitate was collected using a Buchner funnel and washed with ethanol. The white solid was dried under vacuum to afford 16.85 g (65% yield) of [5-cyano-1-(*p*-toluenesulfonyl)indol-3-yl]carboxaldehyde: mp 243° C
15 (dec.); ¹H NMR (400 MHz, DMSO-d₆) 10.09 (1 H, s), 9.07 (1 H, s), 8.49 (1 H, d, J = 1.1 Hz), 8.16 (1 H, dd, J = 8.6, 0.3 Hz), 8.06 (2 H, d, J = 8.5 Hz), 7.87 (1 H, dd, J = 8.7, 1.7), 7.48 (2 H, d, J = 8.1 Hz), 2.36 (3 H, s); MS m/e 325 (M + H)⁺. Anal. calcd. for C₁₇H₁₂N₂O₃S: C, 62.95; H, 3.72; N, 8.63. Found: C, 62.94; H, 3.68; N, 8.62.

A solution of diethyl (*N*-methoxy-*N*-methylcarbamoylmethyl) phosphonate
20 (12.81 ml, 62.1 mmol) in anhydrous tetrahydrofuran (50 ml) was added to a stirred suspension of oil free sodium hydride (1.49 g, 62.1 mmol) in anhydrous tetrahydrofuran (900 ml) maintained at 0 °C. The reaction was warmed to room temperature and was stirred for 2 h. After cooling to 0°C, [5-cyano-1-(*p*-toluenesulfonyl)indol-3-yl]carboxaldehyde (16.8 g, 51.8 mmol) was added. The
25 resulting mixture was stirred at 0°C for 1 hr. The reaction was quenched with aqueous hydrochloric acid (0.1 N) and poured into water (250 ml). After being made acidic with hydrochloric acid (1.0 N), the aqueous portion was extracted with ethyl acetate (3 x 150 ml). The combined organic layers were washed with brine (50 ml) and dried over anhydrous magnesium sulfate. The filtrate was concentrated in vacuo.
30 The crude product was purified by recrystallization from ethyl acetate to afford a total of 19.1 g (12.5 g first crop, 6.58 g second crop, 91% yield) of (*E*)-[5-Cyano-1-(*p*-toluenesulfonyl)indol-3-yl]-*N*-methoxy-*N*-methyl-acrylamide as a white solid: mp 177-178° C; ¹H NMR (500 MHz, DMSO-d₆) 8.70 (1 H, s), 8.47 (1 H, s), 8.14 (1 H,

d, J = 8.7 Hz), 7.98 (2 H, d, J = 8.4 Hz), 7.81 (1 H, dd, J = 8.7, 1.4 Hz), 7.72 (1 H, d, J = 16.0 Hz), 7.44 (2 H, d, J = 8.2 Hz), 7.21 (1 H, d, J = 16.0 Hz), 3.77 (3 H, s), 3.24 (3 H, s), 2.34 (3 H, s); MS m/e 410 (M + H)⁺. Anal. calcd. for C₂₁H₁₉N₃O₄S: C, 61.60; H, 4.67; N, 10.26. Found: C, 61.57; H, 4.64; N, 10.15.

5

The following procedure was carried out behind a safety shield using plastic coated glassware free of scratches and ground glass joints. 1-Methyl-3-nitro-1-nitrosoguanidine (14.4 g, 98 mmol) was carefully added portionwise over 30 min to a Erlenmeyer flask containing a swirled mixture of aqueous sodium hydroxide (100 ml, 10 5 N) and diethyl ether (250 ml) at 0°C. After vigorous bubbling had ceased, the organic layer (containing diazomethane) was decanted into a chilled (0°C) Erlenmeyer flask containing potassium hydroxide chips (20 g). The mixture was swirled for 10 min and the yellow solution was decanted into a dropping funnel. The solution of diazomethane was added over 30 min to an open flask containing a stirred 15 mixture of (E)-[5-Cyano-1-(p-toluenesulfonyl)indol-3-yl]-N-methoxy-N-methylacrylamide (8.0 g, 19.6 mmol) and palladium acetate (132 mg, 0.58 mmol) in dichloromethane (200 ml) maintained at 0 °C. After stirring for 1 h, a second batch of freshly prepared diazomethane (98 mmol) in ~250 ml of diethyl ether was added over 30 min. After stirring for 1 h, the reaction was quenched with glacial acetic acid 20 (4 ml) and poured into an aqueous saturated solution of sodium bicarbonate (250 ml). The aqueous layer was extracted with ethyl acetate (3 x 100 ml). The organic layers were washed with brine, dried over anhydrous magnesium sulfate, and concentrated in vacuo. The crude product was triturated with ethyl acetate (150 ml) and cooled with vigorous stirring to 0 °C for 1 h. The product was collected by vacuum 25 filtration, and rinsed with cold ethyl acetate (25 ml). The white solid was dried under vacuum to afford 4.46 g (54% yield) of [trans-2-[5-Cyano-1-(p-toluenesulfonyl)indol-3-yl]cycloprop-1-yl]-N-methoxy-N-methylcarboxamide. An analytical sample was obtained by recrystallization from ethyl acetate/hexane: mp 174-175° C; ¹H NMR (400 MHz, DMSO-d₆) 8.23 (1 H, d, J = 1.1 Hz), 8.07 (1 H, d, J = 8.6 Hz), 7.91 (2 H, d, J = 8.4 Hz), 7.86 (1 H, s), 7.75 (1 H, dd, J = 8.6, 1.5 Hz), 7.40 30 (2 H, d, J = 8.2 Hz), 3.64 (3 H, s), 3.16 (3 H, s), 2.43 (2 H, m), 2.33 (3 H, s), 1.43 (2 H, m); MS m/e 424 (M + H)⁺. Anal. calcd. for C₂₂H₂₁N₃O₄S: C, 62.39; H, 4.99; N, 9.92. Found: C, 62.33; H, 5.02; N, 9.80.

Powdered lithium aluminum hydride (1.79 g, 47.3 mmol) was carefully added portionwise to a stirred solution of [*trans*-(1*R*,2*R*)-2-[5-cyano-1-(*p*-toluenesulfonyl)indol-3-yl]cycloprop-1-yl]-*N*-methoxy-*N*-methylcarboxamide (4.0 g, 9.45 mmol) in anhydrous tetrahydrofuran (250 ml) at -40 °C. The resulting mixture was stirred at -40 °C for 2 h. The reaction was quenched with ethyl acetate (25 ml) and allowed to warm to room temperature. After 30 min, water (1.79 ml) was added followed by a solution of aqueous sodium hydroxide (15% w/v, 3.58 ml). After stirring for 30 min at room temperature the aluminum salts were removed by vacuum filtration. The salts were rinsed with ethyl acetate (100 ml) and the combined filtrates were concentrated in vacuo. The crude material was purified by silica gel column chromatography (hexane/ethyl acetate, 4:1, 3:1) to afford 2.86 g (74% yield) of *trans*-2-[5-Cyano-1-(*p*-toluenesulfonyl)indol-3-yl]cyclopropanecarboxaldehyde as a white solid. An analytical sample was obtained by recrystallization from ethyl acetate/hexane: mp 165-167° C; ¹H NMR (400 MHz, DMSO-*d*₆) 9.08 (1 H, d, *J* = 5.5 Hz), 8.32 (1 H, d, *J* = 1.1 Hz), 8.06 (1 H, d, *J* = 8.6 Hz), 7.90 (2 H, d, *J* = 8.6 Hz), 7.89 (1 H, s), 7.75 (1 H, dd, *J* = 8.6, 1.5 Hz), 7.40 (2 H, d, *J* = 8.2 Hz), 2.77 (1 H, m), 2.33 (3 H, s), 2.13 (1 H, m), 1.74 (2 H, m); MS *m/e* 363 (*M* - H)⁺. Anal. calcd. for C₂₀H₁₆N₂O₃S: C, 65.91; H, 4.42; N, 7.68. Found: C, 65.90; H, 4.30; N, 7.38.

A mixture of *trans*-2-[5-Cyano-1-(*p*-toluenesulfonyl)indol-3-yl]cyclopropanecarboxaldehyde (2.0 g, 5.49 mmol), dimethylamine (8.2 ml, 16.5 mmol, 2.0 M/THF), and anhydrous ethanol (70 ml) were heated to 80 °C with stirring until all solids were dissolved (20 min). The reaction vessel was removed from the heating source and sodium triacetoxyborohydride was added. After stirring for 30 min, the reaction vessel was placed in an ice-bath and quenched with aqueous hydrochloric acid (40 ml, 1 N). The resulting mixture was stirred for 20 min and then poured into a saturated aqueous solution of sodium bicarbonate (100 ml) and brine (50 ml). The aqueous layer was extracted with ethyl acetate (3 x 100 ml). The combined organic extracts were washed with brine (20 ml), dried over anhydrous magnesium sulfate, filtered, and concentrated in vacuo. The solid residue was dried under vacuum for 24 h and the crude product subjected directly to reaction conditions used for cleavage of the *N*-tosyl group. A sample of *trans*-2-[5-cyano-1-(*p*-toluenesulfonyl)indol-3-yl]-1-(*N,N*-dimethylaminomethyl)cyclopropane was purified by silica gel column


-32-

chromatography for analytical purposes: ^1H NMR (400 MHz, DMSO- d_6) 8.24 (1 H, d, $J = 1.0$ Hz), 8.06 (1 H, d, $J = 8.6$ Hz), 7.89 (2 H, d, $J = 8.4$ Hz), 7.74 (1 H, dd, $J = 8.6, 1.6$ Hz), 7.67 (1 H, s), 7.39 (2 H, d, $J = 8.1$ Hz), 2.32 (5 H, m), 2.21 (6 H, s), 1.83 (1 H, m), 1.21 (1 H, m), 1.07 (1 H, m), 0.80 (1 H, m); MS m/e 394 ($M + \text{H}$) $^+$.

5 Water (5 ml) and an aqueous solution of sodium hydroxide (2 ml, 10 N) were sequentially added to a flask charged with a solution of crude *trans*-2-[5-cyano-1-(*p*-toluenesulfonyl)indol-3-yl]-1-(*N,N*-dimethylaminomethyl)cyclo propane dissolved in anhydrous ethanol (60 ml). The resulting mixture was heated at 70 °C for 45 min. After cooling to room temperature, the reaction was quenched with aqueous
10 hydrochloric acid (21 ml, 1 N) and then poured into a mixture of saturated aqueous sodium bicarbonate (100 ml) and brine (50 ml). The aqueous layer was extracted with 10% methanol/ethyl acetate (4 x 100 ml). The combined organic layers were washed with brine (25 ml), dried over anhydrous magnesium sulfate, filtered, and concentrated in vacuo. The crude material was purified by silica gel column
15 chromatography using silica gel pretreated with 2% triethylamine in chloroform/methanol (9:1). The column was eluted using a step gradient of a ternary solvent mixture [chloroform/methanol/(2 M ammonia/methanol), 90/10/0, 85/15/1, 80/20/1, 80/20/2]. The product was obtained as an off-white solid foam (1.2 g, 98% yield) after drying under vacuum. Recrystallization from ethanol/water provided a
20 total of 934 mg (583 mg first crop, 351 mg second crop, 77% yield) of *trans*-2-[5-cyanoindol-3-yl]-1-(*N,N*-dimethylaminomethyl)cyclopropane: mp 120-121° C; ^1H NMR (400 MHz, DMSO- d_6) 11.34 (1 H, br s), 8.09 (1 H, s), 7.47 (1 H, d, $J = 8.4$ Hz), 7.40 (1 H, dd, $J = 8.4, 1.5$ Hz), 7.23 (1 H, d, $J = 2.0$ Hz), 2.37 (2 H, m), 2.21 (6 H, s), 1.80 (1 H, m), 1.09 (1 H, m), 0.91 (1 H, m), 0.73 (1 H, m); MS m/e 240 ($M +$
25 H) $^+$. Anal. calcd. for $\text{C}_{15}\text{H}_{17}\text{N}_3$: C, 75.28; H, 7.16; N, 17.55. Found: C, 75.05; H, 7.04; N, 17.60.

Example 2

Trans-1-(*N,N*-dimethylaminomethyl)-2-[5-fluoroindol-3-yl]cyclopropane



p-Toluenesulfonyl chloride (11.7 g, 61.3 mmol) was added to a solution of commercially available (5-fluoroindol-3-yl)carboxaldehyde (10.0 g, 61.3 mmol) and triethylamine (9.40 ml, 67.4 mmol) in anhydrous dichloromethane (250 ml). The mixture was left to stir for 6 h at room temperature. The solid precipitate was collected using a Buchner funnel and washed with ethanol. The white solid was dried under vacuum to afford 14.6 g (75% yield) of [5-fluoro-1-(*p*-toluenesulfonyl)indol-3-yl]carboxaldehyde: mp 225-226 °C (dec.); ¹H NMR (400 MHz, DMSO-*d*₆) 10.05 (1 H, s), 8.95 (1 H, s), 8.00 (3 H, m), 7.80 (1 H, dd, *J* = 8.8 Hz, 2.6 Hz), 7.46 (2 H, d, *J* = 8.1 Hz), 7.33 (1 H, t, *J* = 9.2 Hz), 2.35 (3 H, s); MS *m/e* 318 (*M* + *H*)⁺. Anal. Calcd. For C₁₆H₁₂FN₂O₃S: C, 60.55; H, 3.81; N 4.41. Found: C, 60.28; H, 3.78; N, 4.24.

A solution of diethyl (*N*-methoxy-*N*-methylcarbamoylmethyl) phosphonate (5.64 ml, 6.54 g, 27.4 mmol) in anhydrous tetrahydrofuran (25 ml) was added to a stirred suspension of oil free sodium hydride (1.05 g, 27.4 mmol) in anhydrous tetrahydrofuran (350 ml) maintained at 0 °C. The reaction was warmed to room temperature and was stirred for 2 h. After cooling to 0°C, [5-fluoro-1-(*p*-toluenesulfonyl)indol-3-yl]carboxaldehyde (7.24 g, 22.8 mmol) was added. The resulting mixture was stirred at 0°C for 30 min. The reaction was quenched with aqueous hydrochloric acid (0.1 N) and poured into water (150 ml). After being made acidic with hydrochloric acid (1.0 N), the aqueous portion was extracted with ethyl acetate (3 x 100 ml). The combined organic layers were washed with brine (50 ml) and dried over anhydrous sodium sulfate. The filtrate was concentrated in vacuo. The crude product was purified by recrystallization from ethyl acetate to afford a total of 8.03 g (88% yield) of (*E*)-[5-fluoro-1-(*p*-toluenesulfonyl)indol-3-yl]-*N*-methoxy-*N*-methylacrylamide as a white solid: mp 199-200 °C (dec.); ¹H NMR (400 MHz, DMSO-*d*₆) 8.56 (1 H, s), 7.99 (1 H, m), 7.93 (2 H, d, *J* = 8.4 Hz), 7.68 (2 H, m), 7.42 (2 H, d, *J* = 8.1 Hz), 7.28 (1 H, t, *J* = 9.2 Hz), 7.12 (1 H, d, *J* = 16 Hz), 3.77 (3 H, s), 3.22 (3 H, s), 2.33 (3 H, s); MS *m/e* 403 (*M* + *H*)⁺. Anal. Calcd. For C₂₀H₁₉FN₂O₄S: C, 59.69; H, 4.75; N 6.96. Found: C, 59.60; H, 4.70; N, 6.86.

The following procedure was carried out behind a safety shield using plastic coated glassware free of scratches and ground glass joints. 1-Methyl-3-nitro-1-nitrosoguanidine (29.2 g, 199 mmol) was carefully added portionwise over 30 min to an Erlenmeyer flask containing a swirled mixture of aqueous sodium hydroxide (100

ml, 5 N) and diethyl ether (250 ml) at 0°C. After vigorous bubbling had ceased, the organic layer (containing diazomethane) was decanted into a chilled (0°C) Erlenmeyer flask containing potassium hydroxide chips (20 g). The mixture was swirled for 10 min and the yellow solution was decanted into a dropping funnel. The solution of diazomethane was added over 30 min to an open flask containing a stirred mixture of (*E*)-[5-Fluoro-1-(*p*-toluenesulfonyl)indol-3-yl]-*N*-methoxy-*N*-methylacrylamide (8.0 g, 19.9 mmol) and palladium acetate (130 mg, 0.58 mmol) in dichloromethane (200 ml) maintained at 0 °C. After stirring for 10 min., the reaction was quenched with glacial acetic acid (4 ml) and poured into an aqueous saturated solution of sodium bicarbonate (250 ml). The aqueous layer was extracted with ethyl acetate (3 x 100 ml). The organic layers were washed with brine, dried over anhydrous magnesium sulfate, and concentrated in vacuo. The crude product was purified by silica gel column chromatography (hexanes/ethyl acetate, 4:1) to afford 8.23 g (99 % yield) of [*trans*-2-[5-fluoro-1-(*p*-toluenesulfonyl)indol-3-yl]cycloprop-1-yl]-*N*-methoxy-*N*-methylcarboxamide: ¹H NMR (400 MHz, CDCl₃) 7.89 (1 H, m), 7.72 (2 H, d, *J* = 8.4 Hz), 7.30 (1 H, s), 7.23 (3 H, m), 7.04 (1 H, t, *J* = 9.0 Hz), 3.71 (3 H, s), 3.26 (3 H, s), 2.40 (2 H, m), 2.34 (3 H, s), 1.59 (1 H, m), 1.25 (1 H, m); MS *m/e* 417 (*M* + *H*)⁺.

Powdered lithium aluminum hydride (600 mg, 15.8 mmol) was carefully added portionwise to a stirred solution of [*trans*-(1*R*,2*R*)-2-[5-fluoro-1-(*p*-toluenesulfonyl)indol-3-yl]cycloprop-1-yl]-*N*-methoxy-*N*-methylcarboxamide (2.2 g, 5.28 mmol) in anhydrous tetrahydrofuran (100 ml) at -78 °C. The resulting mixture was stirred at -78 °C for 2 h. The reaction was quenched with ethyl acetate (15 ml) and allowed to warmed to room temperature. After 30 min, water (1.0 ml) was added followed by a solution of aqueous sodium hydroxide (15% w/v, 2.0 ml). After stirring for 30 min at room temperature the aluminum salts were removed by vacuum filtration. The salts were rinsed with ethyl acetate (100 ml) and the combined filtrates were concentrated in vacuo. The crude material was purified by silica gel column chromatography (hexane/ethyl acetate, 4:1, 3:1) to afford 1.43 g (76% yield) of *trans*-2-[5-fluoro-1-(*p*-toluenesulfonyl)indol-3-yl]cyclopropanecarboxaldehyde as a off-white solid: ¹H NMR (400 MHz, DMSO-*d*₆) 9.08 (1 H, d, *J* = 5.6 Hz), 7.90 (1 H, m), 7.84 (2 H, d, *J* = 8.4 Hz), 7.75 (1 H, s), 7.51 (1H, dd, *J* = 9.1, 2.6 Hz), 7.38 (2 H, d, *J* = 8.1 Hz), 7.20 (1 H, t, *J* = 9.2 Hz), 2.69 (1 H, m), 2.32 (3 H, s), 2.09 (1 H, m),

-35-

1.68 (2 H, m); MS m/e 358 ($M + H$)⁺. Anal. calcd. for $C_{19}H_{16}FNO_3S$: C, 63.85; H, 4.51; N, 3.91. Found: C, 63.55; H, 4.69; N, 3.71.

A mixture of *trans*-2-[5-Fluoro-1-(*p*-toluenesulfonyl)indol-3-yl]cyclopropane-carboxaldehyde (3.18 g, 8.90 mmol), dimethylamine (8.9 ml, 17.8 mmol, 2.0 M/THF), and anhydrous ethanol (100 ml) were heated to 80 °C with stirring until all solids were dissolved (20 min). The reaction vessel was removed from the heating source and sodium triacetoxyborohydride (7.55 g, 35.6 mmol) was added. After stirring for 1 h, the reaction vessel was placed in an ice-bath and quenched with aqueous hydrochloric acid (40 ml, 1 N). The resulting mixture was stirred for 20 min and then poured into a saturated aqueous solution of sodium bicarbonate (100 ml) and brine (50 ml). The aqueous layer was extracted with ethyl acetate (3 x 100 ml). The combined organic extracts were washed with brine (20 ml), dried over anhydrous magnesium sulfate, filtered, and concentrated in vacuo. The solid residue was dried under vacuum for 24 h and the crude *trans*-1-(*N,N*-dimethylaminomethyl)-2-[5-fluoro-1-(*p*-toluene-sulfonyl)indol-3-yl]cyclopropane subjected directly to reaction conditions used for cleavage of the *N*-tosyl group: ¹H NMR (400 MHz, DMSO- d_6) 7.90 (1 H, m), 7.83 (2 H, d, $J = 8.4$ Hz), 7.64 (1 H, s), 7.57 (1 H, dd, $J = 9.1, 2.5$ Hz), 7.38 (2 H, d, $J = 8.0$ Hz), 7.20 (1 H, t, $J = 9.2$ Hz), 3.04 (2 H, m), 2.71 (6 H, s), 2.32 (3 H, s), 2.02 (1 H, m), 1.40 (1 H, m), 1.21 (1 H, m), 1.03 (1 H, m); MS m/e 387 ($M + H$)⁺.


Water (5 ml) and an aqueous solution of sodium hydroxide (2 ml, 10 N) were sequentially added to a flask charged with a solution of crude *trans*-1-(*N,N*-dimethylaminomethyl)-2-[5-fluoro-1-(*p*-toluenesulfonyl)indol-3-yl]cyclopropane (3.40 g, 8.80 mmol) dissolved in anhydrous ethanol (50 ml). The resulting mixture was heated at 70 °C for 16 h. After cooling to room temperature, the reaction was quenched with aqueous hydrochloric acid (21 ml, 1 N) and then poured into a mixture of saturated aqueous sodium bicarbonate (100 ml) and brine (50 ml). The aqueous layer was extracted with 10% methanol/ethyl acetate (4 x 100 ml). The combined organic layers were washed with brine (25 ml), dried over anhydrous sodium sulfate, filtered, and concentrated *in vacuo*. The crude material was purified by silica gel column chromatography using silica gel pretreated with 2% triethylamine in chloroform/methanol (9:1). The column was eluted using a step gradient of a ternary solvent mixture [chloroform/methanol/(2 M

-36-

ammonia/methanol), 90/10/0, 85/15/1, 80/20/1, 80/20/2]. *Trans*-2-[5-cyanoindol-3-yl]-1-(*N,N*-dimethylaminomethyl)cyclopropane was obtained as a yellow residue (1.34 g, 68 % yield) after drying under vacuum: ^1H NMR (400 MHz, DMSO-d_6) 10.8 (1 H, br s), 7.29 (2 H, m), 7.09 (1 H, s), 6.90 (1 H, t, $J = 9.2$ Hz), 2.39 (1 H, m), 2.19 (7 H, m), 1.69 (1 H, m), 1.06 (1 H, m), 0.85 (1 H, m), 0.68 (1 H, m); MS m/e 233 ($M + H$) $^+$.

Example 3

Trans-2-[5-Cyanoindol-3-yl]-1-[*N,N*-methyl-benzylaminomethyl]-cyclopropane



10


To a 1-dram vial were added *trans*-2-[5-cyano-1-(*p*-toluenesulfonyl)indol-3-yl]-cyclopropanecarboxaldehyde (0.11 M in tetrahydrofuran, 0.5ml, 0.055 mmol), *N*-methylbenzylamine (0.275 M in methanol, 1.0ml, 0.275 mmol), and sodium triacetoxyborohydride (0.058 g, 0.275 mmol). The vial was sealed with a Teflon cap and gently heated at 40°C for 4 hr on a shaken heating block. Sodium hydroxide (2.5 M in 50% methanol/water, 1.0ml) was added and shaking at 55°C continued for 1 hr. The solvent was evaporated by centrifugal evaporation and the solid residue partitioned between 1M sodium hydroxide and ethyl acetate. The organic phase was washed with 1M sodium hydroxide and evaporated. The residue was purified by preparative reverse phase high-performance liquid chromatography, eluting with a methanol/water/trifluoroacetic acid gradient, to afford the product as an oily trifluoroacetic acid salt (13.3 mg, 55%).

LC-MS: 1.09 min; 316.2 (MH) $^+$.

25

Example 4

(1*S*,2*S*)-*trans*-1-(*N,N*-dimethylaminomethyl)-2-[5-fluoroindol-3-yl]-cyclopropane



Sodium Hydride (66mg of 60% in oil, 1.65 mmol) was washed with hexanes (2 ml) to remove oil and was suspended in THF (40 ml). (+)-3-(Diethylphosphonylacetyl)bornane-10,2-sultam (0.65 g, 1.65 mmol) in THF (10 ml) was then added over 10 min. The reaction was stirred for one hr at room temperature, then [5-fluoro-1-(*p*-toluenesulfonyl)indol-3-yl]carboxaldehyde (437 mg, 1.38 mmol) was added in one portion. The reaction was stirred 24 hr at room temperature and the solvent was removed *in vacuo*. The residue was taken up in water (100 ml) and was extracted with ethyl acetate (2x 20 ml). The organic phase was dried with magnesium sulfate and evaporated to dryness. The crude product was purified by chromatography on silica. Elution with 15% to 25% ethyl acetate in hexanes provided 478 mg (62%) of (+)-N-[(E)-3-[5-fluoro-1-(*p*-toluenesulfonyl)indol-3-yl]-2-propenoyl]bornane-10,2-sultam as a white solid. ¹H NMR (400 MHz, CDCl₃) 7.94 (1 H, dd, J = 9.1, 4.4 Hz), 7.90 (1H,s), 7.85 (1 H, d, J = 15.6 Hz), 7.76 (2 H, d, J = 8.4 Hz), 7.50 (1 H, dd, J = 9.0, 2.4 Hz), 7.26 (2 H, d, J = 8.1 Hz), 7.21 (1 H, d, J = 15.6 Hz), 7.10 (1 H, td, J = 8.9, 2.4 Hz), 3.99 (1 H, dd, J = 7.5, 5.1 Hz), 3.51 (2 H, AB, Δν = 28 Hz, J = 13.7 Hz), 2.36 (3 H, s), 2.26-2.10 (2 H, m), 1.97-1.87 (3 H, m), 1.49-1.32 (2 H, m), 1.21 (3 H, s), 1.00 (3 H, s); MS m/e 557.3 (M + H)⁺.

A solution of diazomethane in ether was prepared by slowly adding 1-methyl-3-nitro-1-nitrosoguanidine (872 mg, 5.9 mmol) to a mixture of diethyl ether (50 ml) and 5N NaOH (100 ml) at 0 °C and then decanting the ether layer. The ether layer was dried with potassium hydroxide and transferred to a dropping funnel. This ethereal diazomethane solution was then added dropwise over 15 min to a solution of (+)-N-[(E)-3-[5-fluoro-1-(*p*-toluenesulfonyl)indol-3-yl]-2-propenoyl]-bornane-10,2-sultam (330 mg, 0.59 mmol) and palladium(II)acetate (7 mg, 0.03 mmol) in dichloromethane (50 ml) at a temperature of -10 °C. The reaction was stirred a further 15 min with the temperature maintained below -5 °C, and was then quenched by the addition of acetic acid (2 ml). Water (50 ml) and 10 N NaOH (10 ml) were added and the layers were separated. The aqueous layer was extracted with ethyl acetate (2x 20 ml) and the combined organic layers were dried with magnesium sulfate and evaporated to dryness. The crude product was purified by chromatography on silica (15% to 20% ethyl acetate /in hexanes) to afford 188 mg (56%) of N-[(1*S*,2*S*)-*trans*-2-[5-fluoro-1-(*p*-toluenesulfonyl)indol-3-yl]cycloprop-1-yl]carbonylbornane-10,2-sultam as a white solid.

A solution of N-[(1*S*,2*S*)-*trans*-2-[5-fluoro-1-(*p*-toluenesulfonyl)indol-3-yl]cycloprop-1-yl]carbonylbornane-10,2-sultam (238 mg, 0.42 mmol) in THF (10 ml) was cooled to -40 °C (dry ice / acetonitrile). Lithium aluminum hydride (63 mg, 1.67 mmol) was added, with further additions (63 mg each) after 1 hr and 1.5 hr (reaction temperature maintained at -40 °C throughout). After a total reaction time of 2 hr ethyl acetate (5 ml) was added and the reaction was allowed to warm to room temperature. Water (200 ml) was added, and after 5 min, 1N NaOH (600 ml) was added. After another 5 min, more water (200 ml) was added, and the reaction was stirred a final 5 min. Some magnesium sulfate was added and the mixture was filtered through celite and sand and rinsed with ethyl acetate. The filtrate was evaporated to dryness. The crude material was partially purified on a short pad of silica by elution with 50% ethyl acetate in hexanes. (1*S*,2*S*)-*trans*-2-[5-fluoro-1-(*p*-toluenesulfonyl)indol-3-yl]cyclopropane-methanol appeared as an off-white solid (150 mg, 100%): ¹H NMR (400 MHz, CDCl₃) 7.89 (1 H, dd, *J* = 9.0, 4.4 Hz) 7.70 (2 H, d, *J* = 8.4 Hz), 7.30-7.20 (4 H, m), 7.03 (1 H, td, *J* = 9.0, 2.6 Hz), 3.73 (1 H, dd, *J* = 11.2, 6.4 Hz), 3.59 (1 H, dd, *J* = 11.2, 7.2 Hz), 2.34 (3 H, s), 1.72 (1 H, dt, *J* = 9.6, 5.3 Hz), 1.34 (1 H, m), 0.96-0.86 (2 H, m); MS *m/e* 360.1 (*M* + *H*)⁺.

Oxalyl chloride (58 ml, 0.67 mmol) in dichloromethane (10 ml) at -78 °C was treated with DMSO (54 ml, 0.76 mmol) dropwise. After addition the reaction was stirred for 10 min and a solution of (1*S*,2*S*)-*trans*-2-[5-fluoro-1-(*p*-toluenesulfonyl)indol-3-yl]-cyclopropanemethanol (150 mg, 0.42 mmol) in dichloromethane (5 ml) was added dropwise. After a further 15 min, triethylamine (341 ml, 2.45 mmol) was added dropwise. The reaction was stirred a further 5 min at -78 °C and was then allowed to warm to room temperature. The reaction was washed with water (3x 5 ml), dried with magnesium sulfate and evaporated to dryness to give (1*S*,2*S*)-*trans*-2-[5-fluoro-1-(*p*-toluenesulfonyl)indol-3-yl]-cyclopropanecarboxaldehyde as a yellow oil.

The (1*S*,2*S*)-*trans*-2-[5-fluoro-1-(*p*-toluenesulfonyl)indol-3-yl]-cyclopropanecarboxaldehyde was dissolved in hot ethanol (5 ml) and treated with dimethylamine (0.45 ml of a 2M solution in THF, 0.90 mmol). After stirring 5 min, sodium triacetoxyborohydride (380 mg, 1.8 mmol) was added and the reaction was stirred 30 min. The solvent was removed *in vacuo* and the residue was taken up in brine (5 ml) and extracted with ethyl acetate (4 x 10 ml). The organic layer was dried


-39-

with magnesium sulfate and evaporated to 125 mg (78% over 3 steps from sultam) (1*S*,2*S*)-*trans*-1-(*N,N*-dimethylaminomethyl)-2-[5-fluoro-1-(*p*-toluenesulfonyl)indol-3-yl]cyclopropane as a yellow oil: ¹H NMR (400 MHz, CDCl₃) 7.87 (1 H, dd, *J* = 9.0, 4.4 Hz), 7.73 (2 H, d, *J* = 8.4 Hz), 7.32-7.27 (2 H, m), 7.23 (2 H, d, *J* = 8.1 Hz), 7.06 (1 H, td, *J* = 9.1, 2.5 Hz), 3.16 (1 H, dd, *J* = 11.1, 6.5 Hz), 2.96 (1 H, dd, *J* = 11.2, 7.3 Hz), 2.82 (3 H, s), 2.08 (6 H, s), 2.03 (1 H, m), 1.44 (1 H, m), 1.18 (2 H, t, *J* = 7.2 Hz); MS *m/e* 387.4 (*M* + *H*)⁺.

A solution of (1*S*,2*S*)-*trans*-1-dimethylamino-2-[5-fluoro-1-(*p*-toluenesulfonyl)-indol-3-yl]-cyclopropane (125 mg, 0.32 mmol) and 10 N sodium hydroxide (0.48 ml, 4.9 mmol) in ethanol (10 ml) and water (1 ml) was heated at reflux for 5 hr. The reaction was cooled to room temperature, poured into brine (100 ml) and extracted with ethyl acetate (2x 20 ml) and 9:1 ethyl acetate / methanol (3x 50 ml). The organic layer was dried with magnesium sulfate and evaporated. The residue was purified by chromatography on silica with 90:10:1 chloroform / methanol / 2M ammonia in methanol to provide (1*S*,2*S*)-*trans*-1-(*N,N*-dimethylaminomethyl)-2-[5-fluoroindol-3-yl]-cyclopropane as a clear oil that solidified on standing (68 mg, 71% over 4 steps from sultam): mp 88-90° C; [α_D] = +51.4° (*c* = 2.45 mg/ml, ethanol); ¹H NMR (400 MHz, CDCl₃) 8.05 (1 H, brs), 7.33 (1 H, dd, *J* = 9.6, 2.5 Hz), 7.24 (1 H, dd, *J* = 8.8, 4.4 Hz), 6.98-6.88 (2 H, m), 2.45 (1 H, dd, *J* = 11.0, 6.5 Hz), 2.37 (1 H, dd, *J* = 11.1, 6.8 Hz), 2.35 (6 H, s), 1.68 (1 H, m), 1.21 (1 H, m), 0.87 (1 H, m), 0.76 (1 H, m); MS *m/e* 233.1 (*M* + *H*)⁺.

Example 5

(1*S*,2*S*)-*trans*-2-[5-cyanoindol-3-yl]-1-(*N,N*-dimethylaminomethyl)-cyclopropane



25

Sodium Hydride (0.69 g of 60% in oil, 17.3 mmol) was washed with hexanes (5 ml) to remove oil and was suspended in THF (500 ml) at 0 °C. (+)-3-(Diethylphosphonylacetyl)bornane-10,2-sultam (6.8 g, 17.3 mmol) in THF (50 ml) was then added over 10 min. The reaction was stirred for 1 hr at room temperature,

30

then re-cooled to 0 °C before adding [5-cyano-1-(*p*-toluene-sulfonyl)indol-3-yl]carboxaldehyde (4.67 mg, 14.4 mmol) in one portion. The reaction was stirred 24 hr at room temperature and the solvent was removed *in vacuo*. The residue was taken up in water (100 ml) and was extracted with ethyl acetate (3x 50 ml). The organic phase was dried with magnesium sulfate and allowed to stand for 16 hr. The resulting crystals were collected by filtration. The filtrate was evaporated and the residue was recrystallized from ethyl acetate and hexanes to give a second crop of crystals. A total of 4.71 g (58%) (+)-N-[(E)-3-[5-cyano-1-(*p*-toluenesulfonyl)indol-3-yl]-2-propenoyl]-bornane-10,2-sultam was collected as a white solid: mp 203-205° C; ¹H NMR (400 MHz, CDCl₃): δ 8.15 (1 H, s), 8.09 (1 H, d, J = 8.8 Hz), 7.98 (1 H, s), 7.81 (1 H, d, J = 15.7 Hz), 7.80 (2 H, d, J = 8.4 Hz), 7.62 (1 H, dd, J = 8.6, 1.4 Hz), 7.29 (2 H, d, J = 8.1 Hz), 7.25 (1 H, d, J = 15.6 Hz), 3.99 (1 H, dd, J = 7.4, 5.2 Hz), 3.53 (2 H, AB, Δv = 32 Hz, J = 13.8 Hz), 2.38 (3 H, s), 2.25-2.12 (2 H, m), 2.01-1.87 (3 H, m), 1.48-1.32 (2 H, m), 11.21 (3 H, s), 1.00 (3 H, s); MS m/e 564.3 (M + H)⁺.

The following reaction was performed behind a blast shield using glassware without ground glass joints. A solution of diazomethane in ether was prepared by slowly adding 1-methyl-3-nitro-1-nitrosoguanidine (13.3 g, 90 mmol) to a mixture of diethyl ether (200 ml) and 5N NaOH (200 ml) at 0 °C and then decanting the ether layer. The ether layer was dried with potassium hydroxide and transferred to a dropping funnel. This ethereal diazomethane solution was then added dropwise over 30 min to a solution of (+)-N-[(E)-3-[5-cyano-1-(*p*-toluenesulfonyl)indol-3-yl]-2-propenoyl]bornane-10,2-sultam (5.1 g, 9.0 mmol) and palladium(II)acetate (100 mg, 0.45 mmol) in dichloromethane (200 ml) at a temperature of -10 °C. The reaction was stirred a further 20 min with the temperature maintained below -5 °C, and was then quenched by the addition of acetic acid (6 ml). To the reaction 1 N NaOH (10 ml) was added and the layers were separated. The aqueous layer was extracted with ethyl acetate (2x 30 ml) and the combined organic layers were dried with magnesium sulfate and evaporated to dryness. The crude product was purified by chromatography on silica (20% ethyl acetate /in hexanes) to afford the 3.23 g (62%) of the product as a white solid. This material was recrystallized from 350 ml of boiling EtOH to provide 1.18 g of crystals. The mother liquor was evaporated and

recrystallized from 100 ml of boiling EtOH to provide a second crop of 1.22g. The total amount of recrystallized N-[(1*S*,2*S*)-*trans*-2-[5-cyano-1-(*p*-toluenesulfonyl)indol-3-yl]cycloprop-1-yl]carbonylbornane-10,2-sultam was 2.40 g (46%) as a white solid: mp 188-190° C; ¹H-NMR (400 MHz, CDCl₃) 8.03 (1 H, d, J = 8.6 Hz), 7.99 (1 H, d, J = 1.0 Hz), 7.75 (2 H, d, J = 8.4 Hz), 7.57 (1 H, d, J = 1.2 Hz), 7.54 (1 H, dd, J = 8.6, 1.5 Hz), 7.25 (2 H, m), 3.96 (1 H, dd, J = 7.4, 5.1 Hz), 3.53 (2 H, AB, Δν = 18 Hz, J = 13.8 Hz), 2.57 (1 H, dt, J = 7.7, 4.8 Hz), 2.45 (1 H, m), 2.36 (3 H, s), 2.16-2.04 (2 H, m), 2.00-1.87 (3 H, m), 1.81 (1 H, dt, J = 9.1, 4.3 Hz), 1.55 (3 H, s), 1.50-1.32 (2 H, m), 1.29 (1 H, m), 1.21 (3 H, s), 1.00 (3 H, s); MS m/e 578.2 (M + H)⁺.

A solution of N-[(1*S*,2*S*)-*trans*-2-[5-cyano-1-(*p*-toluenesulfonyl)indol-3-yl]cycloprop-1-yl]carbonylbornane-10,2-sultam (2.30 g, 3.98 mmol) in THF (100 ml) was cooled to -40 °C (dry ice / acetonitrile). Lithium aluminum hydride (600 mg, 15.9 mmol) was added, with a further addition (600 mg) after 1 hr (reaction temperature maintained at -40 °C throughout). After a total reaction time of 1.5 hr ethyl acetate (50 ml) was added and the reaction was allowed to warm to room temperature. Water (1.2 ml) was added, and after 10 min 1N NaOH (3.6 ml) was added. After another 5 min, more water (1.2 ml) was added, and the reaction was stirred a final 15 min. Some magnesium sulfate was added and the mixture was filtered through celite and sand and rinsed with ethyl acetate. The filtrate was evaporated to dryness. The crude material was partially purified on a short pad of silica by elution with 50% ethyl acetate in hexanes. The (1*S*,2*S*)-*trans*-2-[5-cyano-1-(*p*-toluenesulfonyl)indol-3-yl]-cyclo-propanemethanol appeared as a white solid (1.18 mg, 81%): mp 140-141° C; ¹H NMR (400 MHz, CDCl₃) 8.03 (1 H, dd, J = 8.6, 0.6 Hz), 8.00 (1 H, d, J = 1.5 Hz), 7.74 (2 H, d, J = 8.6 Hz), 7.55 (1 H, dd, J = 8.6, 1.5 Hz), 7.33 (1 H, d, J = 1.0 Hz), 7.26 (2 H, d, J = 8.5 Hz), 3.77 (1 H, m), 3.60 (1 H, m), 2.37 (3 H, s), 1.77 (1 H, m,), 1.37 (1 H, m), 0.95 (2 H, t, J = 7.0 Hz); MS m/e 349.1 (M -OH+ H)⁺.

Oxalyl chloride (0.42 ml, 4.8 mmol) in dichloromethane (50 ml) at -78 °C was treated with DMSO (0.39 ml, 5.4 mmol) dropwise. After addition the reaction was stirred for 15 min and a solution of (1*S*,2*S*)-*trans*-2-[5-cyano-1-(*p*-toluenesulfonyl)indol-3-yl]-cyclopropanemethanol (1.17 g, 3.2 mmol) in


dichloromethane (10 ml) was added dropwise. After a further 15 min, triethylamine (2.45 ml, 17.6 mmol) was added dropwise. The reaction was stirred a further 5 min at -78 °C and was then allowed to warm to room temperature. The reaction was washed with water (2x 10 ml), dried with magnesium sulfate and evaporated to dryness to give a yellow oil.

The crude (1*S*,2*S*)-*trans*-2-[5-cyano-1-(*p*-toluenesulfonyl)indol-3-yl]-cyclopropanecarboxaldehyde from the above procedure was dissolved in hot ethanol (50 ml) and treated with dimethylamine (3.2 ml of a 2M solution in THF, 6.4 mmol). After stirring 5 min, sodium triacetoxyborohydride (2.71 g, 12.8 mmol) was added in several portions over 10 min while the reaction was cooled in a 10 °C water bath. After stirring 45 min at room temperature the solvent was removed *in vacuo* and the residue was taken up in brine (10 ml) and 1N sodium hydroxide was added until solids disappeared. The reaction was extracted with ethyl acetate (4x 10 ml), the organic layer was dried with magnesium sulfate and evaporated to give (1*S*,2*S*)-*trans*-1-(*N,N*-dimethylaminomethyl)-2-[5-cyano-1-(*p*-toluenesulfonyl)indol-3-yl]-cyclopropane as a yellow oil.

The crude (1*S*,2*S*)-*trans*-1-(*N,N*-dimethylaminomethyl)-2-[5-cyano-1-(*p*-toluenesulfonyl)indol-3-yl]-cyclopropane was dissolved in ethanol (25 ml) and water (4 ml) with 10 N sodium hydroxide (2 ml, 20 mmol) and was heated at 70 °C for 1 hr. The reaction was cooled to room temperature, poured into brine (100 ml) and extracted with ethyl acetate (2x 50 ml) and 9:1 ethyl acetate / methanol (3x 50 ml). The organic layer was dried with magnesium sulfate and evaporated. The residue was purified by chromatography on silica with 90:10:1 chloroform / methanol / 2M ammonia in methanol to provide the product (1*S*,2*S*)-*trans*-2-[5-cyanoindol-3-yl]-1-(*N,N*-dimethylaminomethyl)cyclopropane as a yellow oil. (590 mg, 77% over 3 steps from alcohol): $[\alpha_D] = +17.5^\circ$ ($c = 2.92$ mg/ml, ethanol); ^1H NMR (400 MHz, CDCl_3) 8.82 (1 H, brs), 8.04 (1 H, s), 7.38 (1 H, dd, $J = 7.2, 1.4$ Hz), 7.34 (1 H, dd, 7.2, 0.5 Hz), 6.96 (1 H, d, $J = 1.6$ Hz), 2.49 (1 H, dd, $J = 12.4, 6.4$ Hz), 2.37 (1 H, dd, $J = 12.4, 7.0$ Hz), 2.37 (6 H, s), 1.76 (1 H, m), 1.23 (1 H, m), 0.90 (1 H, m), 0.84 (1 H, m); MS m/e 240.1 ($M + H$) $^+$.

Example 6



***trans*-2-[5-Cyanoindol-3-yl]-1-[N,N-methyl-2-amino(isopropylcarbamoyl)ethylaminomethyl]-cyclopropane**

**(2-Bromo-ethyl)-carbamic acid isopropyl ester**


A mixture of bromoethylamine hydrobromide (5.0 g, 24.4 mmol), isopropyl chloroformate (1.0 M in tetrahydrofuran, 16.3 ml, 16.3 mmol), and anhydrous dichloromethane (100 ml) was treated with triethylamine (4.5 ml, 33 mmol) and stirred at ambient temperature for 18 hr. The mixture was diluted with dichloromethane (200 ml), washed with 1 M hydrochloric acid, 1 M sodium hydroxide, and brine, dried over sodium sulfate and evaporated to give (2-bromo-ethyl)-carbamic acid isopropyl ester clear oil. ¹H-NMR δ (CDCl₃) 5.01 (1 H, br s), 4.92 (m, 1 H), 3.58 (m, 2 H), 3.48 (m, 2 H), 1.25 (m, 6 H).

To a 1-dram vial were added (2-bromo-ethyl)-carbamic acid isopropyl ester (30 mg, 0.143 mmol), *trans*-2-[5-cyano-1-(*p*-toluenesulfonyl)indol-3-yl]-1-[N-methylaminomethyl]-cyclopropane (0.13 M in methanol, 1.0 ml, 0.13 mmol), and triethylamine (0.10 ml, 0.72 mmol). The vial was sealed with a Teflon cap and heated to 60°C on a shaken heating block for 18 hr. Sodium hydroxide (1 M, 1 ml) was added and heating at 60°C continued for 1 hr. The solvent was evaporated and the residue partitioned between 1 M sodium hydroxide and ethyl acetate. The aqueous phase was extracted with ethyl acetate and the pooled extracts dried over sodium sulfate and concentrated to an oily solid. Purification by preparative reverse phase high-performance liquid chromatography afforded the product as an oily trifluoroacetic acid salt. LC-MS: 1.15 min; 355.28 (MH)⁺.


Examples 7-115 were prepared by the methods illustrated in previous examples:

Example 7***trans*-1-(N-Benzylaminomethyl)-2-[5-cyanoindol-3-yl]-cyclopropane**5 LC-MS: 1.08 min; 302.19 (MH)⁺.**Example 8*****trans*-2-[5-Cyanoindol-3-yl]-1-[N-(2-methoxybenzyl)aminomethyl]-cyclopropane**

10


LC-MS: 1.16 min; 332.19 (MH)⁺.**Example 9*****trans*-2-[5-Cyanoindol-3-yl]-1-[N-(3-methoxybenzyl)aminomethyl]-cyclopropane**

15

LC-MS: 1.13 min; 332.19 (MH)⁺.**Example 10**20 ***trans*-2-[5-Cyanoindol-3-yl]-1-[N-(4-methoxybenzyl)aminomethyl]-cyclopropane**LC-MS: 1.13 min; 332.17 (MH)⁺.

Example 11


trans-2-[5-Cyanoindol-3-yl]-1-[N-(2-fluorobenzyl)aminomethyl]-cyclopropane



5 LC-MS: 1.08 min; 320.17 (MH)⁺.

Example 12

trans-2-[5-Cyanoindol-3-yl]-1-[N-(3-fluorobenzyl)aminomethyl]-cyclopropane




10

LC-MS: 1.09 min; 320.17 (MH)⁺.

Example 13

trans-2-[5-Cyanoindol-3-yl]-1-[N-(4-fluorobenzyl)aminomethyl]-cyclopropane




15

LC-MS: 1.10 min; 320.16 (MH)⁺.



Example 14

20 *trans*-2-[5-Cyanoindol-3-yl]-1-[N-(2-pyridylmethyl)aminomethyl]-cyclopropane



LC-MS: 0.95 min; 303.16 (MH)⁺.


-46-

Example 15***trans*-2-[5-Cyanoindol-3-yl]-1-[N-(3-pyridyl)methylaminomethyl]-cyclopropane**5 LC-MS: 0.71 min; 303.16 (MH)⁺.**Example 16*****trans*-2-[5-Cyanoindol-3-yl]-1-[N-(4-pyridyl)methylaminomethyl]-cyclopropane**

10

LC-MS: 0.69 min; 303.16 (MH)⁺.**Example 17*****trans*-2-[5-Cyanoindol-3-yl]-1-[N-2-(2-fluorophenyl)ethylaminomethyl]-cyclopropane**


15

LC-MS: 1.15 min; 334.17 (MH)⁺.

-47-

Example 18


trans-2-[5-Cyanoindol-3-yl]-1-[N-2-(3-fluorophenyl)ethylaminomethyl]-cyclopropane



5 LC-MS: 1.15 min; 334.18 (MH)⁺.

Example 19

trans-2-[5-Cyanoindol-3-yl]-1-[N-2-(4-fluorophenyl)ethylaminomethyl]-cyclopropane




10

LC-MS: 1.15 min; 334.18 (MH)⁺.


Example 20

15 *trans*-2-[5-Cyanoindol-3-yl]-1-[N-2-(3-pyridyl)ethylaminomethyl]-cyclopropane




LC-MS: 0.77 min; 317.19 (MH)⁺.


-48-

Example 21*trans*-2-[5-Cyanoindol-3-yl]-1-[N-3-phenylpropylaminomethyl]-cyclopropaneLC-MS: 1.20 min; 330.20 (MH)⁺.

5

Example 22*trans*-2-[5-Cyanoindol-3-yl]-1-[N-3-(3-pyridyl)propylaminomethyl]-cyclopropane

10

LC-MS: 0.67 min; 330.18 (MH)⁺.**Example 23***trans*-2-[5-Cyanoindol-3-yl]-1-[N-2-(4-imidazolyl)ethylaminomethyl]-cyclopropane


15

LC-MS: 0.68 min; 306.17 (MH)⁺.

-49-

Example 24

trans-2-[5-Cyanoindol-3-yl]-1-[N-3-(1-imidazolyl)propylaminomethyl]-
cyclopropane




5

LC-MS: 0.69 min; 320.21 (MH)⁺.

Example 25

trans-2-[5-Cyanoindol-3-yl]-1-[N-2-thiophenylmethylaminomethyl]-
cyclopropane




10

LC-MS: 1.03 min; 322.15 (MH)⁺.



15

Example 26

trans-2-[5-Cyanoindol-3-yl]-1-[N-2-(2-thiophenyl)ethylaminomethyl]-
cyclopropane




20 LC-MS: 1.07 min; 322.15 (MH)⁺.

Example 27***trans*-2-[5-Cyanoindol-3-yl]-1-[N-2-(3-indolyl)ethylaminomethyl]-cyclopropane**5 LC-MS: 1.16 min; 355.19 (MH)⁺.**Example 28*****trans*-2-[5-Cyanoindol-3-yl]-1-[N-cyclopropylmethylaminomethyl]-cyclopropane**



10

LC-MS: 0.91 min; 266.15 (MH)⁺.**Example 29*****trans*-2-[5-Cyanoindol-3-yl]-1-[N-cyclohexylaminomethyl]-cyclopropane**


15

LC-MS: 1.08 min; 294.19 (MH)⁺.

-51-



Example 30***trans*-2-[5-Cyanoindol-3-yl]-1-[N-cyclohexylmethylaminomethyl]-cyclopropane**5 LC-MS: 1.19 min; 308.22 (MH)⁺.**Example 31*****trans*-2-[5-Cyanoindol-3-yl]-1-[N-isobutylaminomethyl]-cyclopropane**

10


LC-MS: 1.10 min; 268.17 (MH)⁺.**Example 32**15 ***trans*-2-[5-Cyanoindol-3-yl]-1-[N-3-methyl-butylaminomethyl]-cyclopropane**LC-MS: 1.08 min; 282.12 (MH)⁺.

20

-52-

Example 33***trans*-2-[5-Cyanoindol-3-yl]-1-(4-methyl-piperidin-1-yl-methyl)-cyclopropane**5 LC-MS: 0.98 min; 294.20 (MH)⁺.**Example 34*****trans*-1-(4-Benzyl-piperidin-1-ylmethyl)-2-[5-cyanoindol-3-yl]-cyclopropane**



10

LC-MS: 1.26 min; 370.23 (MH)⁺.**Example 35*****trans*-2-[5-Cyanoindol-3-yl]-1-(piperazin-1-yl-methyl)-cyclopropane**


15

LC-MS: 0.64 min; 281.16 (MH)⁺.

-53-

Example 36***trans*-1-[4-Benzyl-piperazin-1-yl-methyl]-2-[5-cyanoindol-3-yl]-cyclopropane**5 LC-MS: 0.87 min; 371.23 (MH)⁺.**Example 37*****trans*-2-[5-Cyanoindol-3-yl]-1-[1,2,3,4-tetrahydro-1*H*-isoquinolin-2-yl-methyl]-cyclopropane**


10

LC-MS: 1.06 min; 328.19 (MH)⁺.**Example 38**15 ***trans*-2-[5-Cyanoindol-3-yl]-1-[N,N-dipropylaminomethyl]-cyclopropane**LC-MS: 1.01 min; 296.22 (MH)⁺.

-54-

Example 39


trans-2-[5-Cyanoindol-3-yl]-1-[N,N-methyl-phenylethylaminomethyl]-cyclopropane



5

LC-MS: 1.13 min; 330.20 (MH)⁺.**Example 40**


trans-2-[5-Cyanoindol-3-yl]-1-[N-phenylethylamino]-cyclopropane





10

LC-MS: 1.12 min; 316.20 (MH)⁺.**Example 41**


15 *trans*-2-[5-Cyanoindol-3-yl]-1-[N-2-(2-methoxyphenyl)ethylamino]-cyclopropane

LC-MS: 1.20 min; 346.19 (MH)⁺.

-55-

Example 42*trans*-2-[5-Cyanoindol-3-yl]-1-[N-2-(3-methoxyphenyl)ethylamino]-cyclopropane5 LC-MS: 1.15 min; 346.19 (MH)⁺.**Example 43***trans*-2-[5-Cyanoindol-3-yl]-1-[N-2-(4-methoxyphenyl)ethylamino]-cyclopropane



10

LC-MS: 1.15 min; 346.19 (MH)⁺.**Example 44***trans*-2-[5-Cyanoindol-3-yl]-1-[N-2-phenoxy-ethylamino]-cyclopropane


15

LC-MS: 1.15 min; 332.19 (MH)⁺.

-56-

Example 45***trans*-2-[5-Cyanoindol-3-yl]-1-[N-propylamino]-cyclopropane**5 LC-MS: 0.77 min; 254.14 (MH)⁺.**Example 46*****trans*-2-[5-Cyanoindol-3-yl]-1-[pyrrolidin-1-yl-methyl]-cyclopropane**


10

LC-MS: 0.85 min; 266.15 (MH)⁺.**Example 47*****trans*-2-[5-Cyanoindol-3-yl]-1-[piperidin-1-yl-methyl]-cyclopropane**


15

LC-MS: 0.90 min; 280.17 (MH)⁺.


-57-

Example 48***trans*-2-[5-Cyanoindol-3-yl]-1-[N,N-diethylamino]-cyclopropane**



5

LC-MS: 0.89 min; 268.16 (MH)⁺.**Example 49*****trans*-1-(N-Benzylaminomethyl)-2-[5-fluoroindol-3-yl]-cyclopropane**


10

LC-MS: 1.17 min; 295.15 (MH)⁺.**Example 50**15 ***trans*-2-[5-Fluoroindol-3-yl]-1-[N-(2-methoxybenzyl)aminomethyl]-cyclopropane**LC-MS: 1.24 min; 325.20 (MH)⁺.

-58-


Example 51***trans*-2-[5-Fluoroindol-3-yl]-1-[N-(3-methoxybenzyl)aminomethyl]-cyclopropane**5 LC-MS: 1.21 min; 325.19 (MH)⁺.**Example 52*****trans*-2-[5-Fluoroindol-3-yl]-1-[N-(4-methoxybenzyl)aminomethyl]-cyclopropane**

10


LC-MS: 1.21 min; 325.20 (MH)⁺.**Example 53*****trans*-1-[N-(2-Fluorobenzyl)aminomethyl]2-[5-fluoroindol-3-yl]-cyclopropane**

15


LC-MS: 1.17 min; 313.17 (MH)⁺.

Example 54***trans*-1-[N-(3-Fluorobenzyl)aminomethyl]2-[5-fluoroindol-3-yl]-cyclopropane**



5

LC-MS: 1.18 min; 313.17 (MH)⁺.**Example 55*****trans*-1-[N-(4-Fluorobenzyl)aminomethyl]2-[5-fluoroindol-3-yl]-cyclopropane**

10

LC-MS: 1.20 min; 313.17 (MH)⁺.**Example 56**15 ***trans*-2-[5-Fluoroindol-3-yl]-1-[N-(2-pyridylmethyl)aminomethyl]-cyclopropane**LC-MS: 1.02 min; 296.15 (MH)⁺.


-60-

Example 57*trans*-2-[5-Fluoroindol-3-yl]-1-[N-(3-pyridylmethyl)aminomethyl]-cyclopropane5 LC-MS: 0.71 min; 296.14 (MH)⁺.**Example 58***trans*-2-[5-Fluoroindol-3-yl]-1-[N-(4-pyridylmethyl)aminomethyl]-cyclopropane

10

LC-MS: 0.70 min; 296.15 (MH)⁺.**Example 59***trans*-2-[5-Fluoroindol-3-yl]-1-[N-(2-fluorophenyl)ethylaminomethyl]-cyclopropane


15

LC-MS: 1.25 min; 327.19 (MH)⁺.

-61-

Example 60


trans-2-[5-Fluoroindol-3-yl]-1-[N-(3-fluorophenyl)ethylaminomethyl]-cyclopropane



5

LC-MS: 1.24 min; 327.18 (MH)⁺.**Example 61**


trans-2-[5-Fluoroindol-3-yl]-1-[N-(4-fluorophenyl)ethylaminomethyl]-cyclopropane



10

LC-MS: 1.24 min; 327.19 (MH)⁺.**Example 62**

trans-2-[5-Fluoroindol-3-yl]-1-[N-3-phenylpropylaminomethyl]-cyclopropane



15


LC-MS: 1.31 min; 323.21 (MH)⁺.

20

-62-

Example 63


***trans*-2-[5-Fluoroindol-3-yl]-1-[N-3-(3-pyridyl)propylaminomethyl]-
cyclopropane**



5

LC-MS: 0.77 min; 325.22 (MH)⁺.**Example 64**


***trans*-2-[5-Fluoroindol-3-yl]-1-[N-2-(4-imidazolyl)ethylaminomethyl]-
cyclopropane**



10

LC-MS: 0.69 min; 299.15 (MH)⁺.**Example 65**

***trans*-2-[5-Fluoroindol-3-yl]-1-[N-3-(1-imidazolyl)propylaminomethyl]-
cyclopropane**




15

20 LC-MS: 0.71 min; 313.19 (MH)⁺.

-63-

Example 66


trans-2-[5-Fluoroindol-3-yl]-1-[N-2-thiopheneylmethylaminomethyl]-cyclopropane



5

LC-MS: 1.10 min; 301.11 (MH)⁺.**Example 67**


trans-2-[5-Fluoroindol-3-yl]-1-[N-2-(2-thiophenyl)ethylaminomethyl]-cyclopropane



10

LC-MS: 1.15 min; 315.14 (MH)⁺.**Example 68**

trans-2-[5-Fluoroindol-3-yl]-1-[N-2-(3-indolyl)ethylaminomethyl]-cyclopropane





15


LC-MS: 1.25 min; 348.18 (MH)⁺.

20

-64-

Example 69***trans*-1-[N-Cyclopropylmethylaminomethyl]-2-[5-fluoroindol-3-yl]-cyclopropane**5 LC-MS: 0.82 min; 257.18 (MH)⁺.**Example 70*****trans*-1-[N-Cyclohexylaminomethyl]-2-[5-fluoroindol-3-yl]-cyclopropane**


10

LC-MS: 1.16 min; 287.17 (MH)⁺.**Example 71*****trans*-1-[N-Cyclohexylmethylaminomethyl]-2-[5-fluoroindol-3-yl]-cyclopropane**


15

LC-MS: 1.28 min; 301.20 (MH)⁺.


-65-

Example 72***trans*-2-[5-Fluoroindol-3-yl]-1-[N-3-methyl-butylaminomethyl]-cyclopropane**

5

LC-MS: 1.17 min; 275.18 (MH)⁺.**Example 73*****trans*-1-(4-Benzyl-piperidin-1-yl-methyl)-2-[5-fluoroindol-3-yl]-cyclopropane**



10

LC-MS: 1.35 min; 363.20 (MH)⁺.**Example 74*****trans*-2-[5-Fluoroindol-3-yl]-1-(piperazin-1-yl-methyl)-cyclopropane**


15

LC-MS: 0.62 min; 274.14 (MH)⁺.

-66-

Example 75***trans*-1-[4-Benzyl-piperazin-1-yl-methyl]-2-[5-fluoroindol-3-yl]-cyclopropane**5 LC-MS: 0.91 min; 364.20 (MH)⁺.**Example 76*****trans*-1-[1,2,3,4-tetrahydro-1*H*-isoquinolin-2-yl-methyl]-2-[5-fluoroindol-3-yl]-cyclopropane**


10

LC-MS: 1.15 min; 321.19 (MH)⁺.**Example 77**15 ***trans*-1-[N,N-Dipropylaminomethyl]-2-[5-fluoroindol-3-yl]-cyclopropane**LC-MS: 1.08 min; 289.19 (MH)⁺.

-67-

Example 78


trans-2-[5-Fluoroindol-3-yl]-1-[N,N-methyl-phenylethylaminomethyl]-cyclopropane



5

LC-MS: 1.22 min; 323.21 (MH)⁺.**Example 79**


trans-2-[5-Fluoroindol-3-yl]-1-[N-phenylethylamino]-cyclopropane



10

LC-MS: 1.22 min; 309.18 (MH)⁺.**Example 80**

trans-2-[5-Fluoroindol-3-yl]-1-[N-2-(2-methoxyphenyl)ethylamino]-cyclopropane



15


LC-MS: 1.30 min; 339.19 (MH)⁺.

20

-68-

Example 81


***trans*-2-[5-Fluoroindol-3-yl]-1-[N-2-(3-methoxyphenyl)ethylamino]-cyclopropane**



5

LC-MS: 1.25 min; 339.19 (MH)⁺.**Example 82**


***trans*-2-[5-Fluoroindol-3-yl]-1-[N-2-(4-methoxyphenyl)ethylamino]-cyclopropane**



10

LC-MS: 1.24 min; 339.20 (MH)⁺.**Example 83**

***trans*-2-[5-Fluoroindol-3-yl]-1-[N-2-phenoxy-ethylamino]-cyclopropane**




15


LC-MS: 1.24 min; 325.19 (MH)⁺.

20


-69-

Example 84***trans*-2-[5-Fluoroindol-3-yl]-1-[pyrrolidin-1-yl-methyl]-cyclopropane**

5

LC-MS: 0.89 min; 259.12 (MH)⁺.**Example 85*****trans*-2-[5-Fluoroindol-3-yl]-1-[piperidin-1-yl-methyl]-cyclopropane**

10

LC-MS: 0.95 min; 273.14 (MH)⁺.**Example 86*****trans*-1-[N,N-Diethylamino]-2-[5-fluoroindol-3-yl]-cyclopropane**


15

20 LC-MS: 0.94 min; 261.14 (MH)⁺.

-70-

Example 87


trans-2-[5-Cyanoindol-3-yl]-1-[N,N-methyl-2-amino(ethylcarbamoyl)ethylaminomethyl]-cyclopropane



5

LC-MS: 0.99 min; 341.42 (MH)⁺.**Example 88**


trans-2-[5-Cyanoindol-3-yl]-1-[N,N-methyl-2-amino(propylcarbamoyl)ethylaminomethyl]-cyclopropane



10

LC-MS: 1.11 min; 355.28 (MH)⁺.**Example 89**

trans-2-[5-Cyanoindol-3-yl]-1-[N,N-methyl-2-amino(methylcarbamoyl)propylaminomethyl]-cyclopropane




15

20 LC-MS: 0.91 min; 341.27 (MH)⁺.

-71-

Example 90


trans-2-[5-Cyanoindol-3-yl]-1-[N,N-methyl-2-amino(ethylcarbamoyl)propylaminomethyl]-cyclopropane



5

LC-MS: 1.01 min; 355.40 (MH)⁺.**Example 91**


trans-2-[5-Cyanoindol-3-yl]-1-[N,N-methyl-2-amino(propylcarbamoyl)propylaminomethyl]-cyclopropane



10

LC-MS: 1.11 min; 369.29 (MH)⁺.**Example 92**

trans-2-[5-Cyanoindol-3-yl]-1-[N,N-methyl-2-amino(isopropylcarbamoyl)propylaminomethyl]-cyclopropane




15

20 LC-MS: 1.10 min; 369.29 (MH)⁺.

Example 93


trans-2-[5-Cyanoindol-3-yl]-1-[N,N-ethyl-2-amino(methylcarbamoyl)ethylaminomethyl]-cyclopropane



5

LC-MS: 0.93 min; 341.38 (MH)⁺.**Example 94**


trans-2-[5-Cyanoindol-3-yl]-1-[N,N-ethyl-2-amino(ethylcarbamoyl)ethylaminomethyl]-cyclopropane



10

LC-MS: 1.03 min; 355.40 (MH)⁺.**Example 95**

trans-2-[5-Cyanoindol-3-yl]-1-[N,N-ethyl-2-amino(propylcarbamoyl)ethylaminomethyl]-cyclopropane




15

20 LC-MS: 1.36 min; 369.42 (MH)⁺.

Example 96

***trans*-2-[5-Cyanoindol-3-yl]-1-[N,N-ethyl-2-amino(isopropylcarbamoyl)ethylaminomethyl]-cyclopropane**




5

LC-MS: 1.36 min; 369.39 (MH)⁺.

Example 97


***trans*-2-[5-Cyanoindol-3-yl]-1-[N,N-ethyl-2-amino(methylcarbamoyl)propylaminomethyl]-cyclopropane**



LC-MS: 1.01 min; 355.21 (MH)⁺.

Example 98

***trans*-2-[5-Cyanoindol-3-yl]-1-[N,N-ethyl-2-amino(ethylcarbamoyl)propylaminomethyl]-cyclopropane**




20 LC-MS: 1.08 min; 369.21 (MH)⁺.

-74-

Example 99


trans-2-[5-Cyanoindol-3-yl]-1-[N,N-ethyl-2-amino(propylcarbamoyl)propylaminomethyl]-cyclopropane



5

LC-MS: 1.35 min; 383.43 (MH)⁺.**Example 100**


trans-2-[5-Cyanoindol-3-yl]-1-[N,N-ethyl-2-amino(isopropylcarbamoyl)propylaminomethyl]-cyclopropane



10

LC-MS: 1.36 min; 383.41 (MH)⁺.**Example 101**

trans-2-[5-Fluoroindol-3-yl]-1-[N,N-methyl-2-amino(ethylcarbamoyl)ethylaminomethyl]-cyclopropane




15

20 LC-MS: 1.29 min; 334.39 (MH)⁺.

-75-

Example 102


trans-2-[5-Fluoroindol-3-yl]-1-[N,N-methyl-2-amino(propylcarbamoyl)ethylaminomethyl]-cyclopropane



5

LC-MS: 1.46 min; 348.43 (MH)⁺.**Example 103**


trans-2-[5-Fluoroindol-3-yl]-1-[N,N-methyl-2-amino(isopropylcarbamoyl)ethylaminomethyl]-cyclopropane



10

LC-MS: 1.42 min; 348.42 (MH)⁺.**Example 104**

trans-2-[5-Fluoroindol-3-yl]-1-[N,N-methyl-2-amino(methylcarbamoyl)propylaminomethyl]-cyclopropane




15

20 LC-MS: 1.20 min; 334.42 (MH)⁺.

-76-

Example 105


trans-2-[5-Fluoroindol-3-yl]-1-[N,N-methyl-2-amino(ethylcarbamoyl)propylaminomethyl]-cyclopropane



5

LC-MS: 1.33 min; 348.40 (MH)⁺.**Example 106**


trans-2-[5-Fluoroindol-3-yl]-1-[N,N-methyl-2-amino(propylcarbamoyl)propylaminomethyl]-cyclopropane



10

LC-MS: 1.46 min; 362.44 (MH)⁺.**Example 107**

trans-2-[5-Fluoroindol-3-yl]-1-[N,N-methyl-2-amino(isopropylcarbamoyl)propylaminomethyl]-cyclopropane




15

20 LC-MS: 1.44 min; 362.44 (MH)⁺.

-77-

Example 108


trans-1-[N,N-Ethyl-2-amino(methylcarbamoyl)ethylaminomethyl]-2-[5-fluoroindol-3-yl]-cyclopropane



5

LC-MS: 1.22 min; 334.37 (MH)⁺.**Example 109**


trans-1-[N,N-Ethyl-2-amino(ethylcarbamoyl)ethylaminomethyl]-2-[5-fluoroindol-3-yl]-cyclopropane



10

LC-MS: 1.17 min; 348.20 (MH)⁺.**Example 110**

trans-1-[N,N-Ethyl-2-amino(propylcarbamoyl)ethylaminomethyl]-2-[5-fluoroindol-3-yl]-cyclopropane




15

20 LC-MS: 1.51 min; 362.40 (MH)⁺.

Example 111

trans-1-[N,N-Ethyl-2-amino(isopropylcarbamoyl)ethylaminomethyl]-2-[5-fluoroindol-3-yl]-cyclopropane




5

LC-MS: 1.28 min; 362.21 (MH)⁺.

Example 112

trans-1-[N,N-Ethyl-2-amino(methylcarbamoyl)propylaminomethyl]-2-[5-fluoroindol-3-yl]-cyclopropane




10

LC-MS: 1.08 min; 348.19 (MH)⁺.

Example 113


trans-1-[N,N-Ethyl-2-amino(ethylcarbamoyl)propylaminomethyl]-2-[5-fluoroindol-3-yl]-cyclopropane




15

20 LC-MS: 1.17 min; 362.21 (MH)⁺.

-79-

Example 114*trans*-1-[N,N-Ethyl-2-amino(propylcarbamoyl)propylaminomethyl]-2-[5-fluoroindol-3-yl]-cyclopropane


5

LC-MS: 1.49 min; 376.40 (MH)⁺.**Example 115***trans*-1-[N,N-Ethyl-2-amino(isopropylcarbamoyl)propylaminomethyl]-2-[5-fluoroindol-3-yl]-cyclopropane

10

LC-MS: 1.47 min; 376.44 (MH)⁺.

15

Example 117*Cis*-2-[5-Cyanoindol-3-yl]-1-(N,N-dimethylaminomethyl)cyclopropane

20

A solution of bis(2,2,2-trifluoroethyl)(methoxycarbonylmethyl)phosphonate (470 μ L, 2.2 mmol) in anhydrous tetrahydrofuran (5 ml) was added to a stirred suspension of oil free sodium hydride (89 mg, 2.2 mmol) in anhydrous tetrahydrofuran (25 ml) maintained at 0 °C. The reaction was warmed to room temperature and was stirred for 1.5 h. After cooling to 0°C, [5-cyano-1-(*p*-toluenesulfonyl)indol-3-yl]carboxaldehyde (600 mg, 1.85 mmol) was added. The resulting mixture was stirred at room temperature for 5 hr. The solvent was evaporated and the residue taken up in brine (20 ml) and extracted with ethyl acetate

25

(3x 10 ml). The organic layers were dried with anhydrous magnesium sulfate and the solvent removed *in vacuo*. The product was purified by silica gel column chromatography with 15% ethyl acetate in hexanes to give 192 mg (27 % yield) of methyl (Z)-3-[5-Cyano-1-(*p*-toluenesulfonyl)indol-3-yl]-acrylate: ¹H NMR (300 MHz, CDCl₃): δ 9.08 (1 H, s), 8.10 (1 H, d, J = 8.3 Hz), 7.92 (1 H, d, J = 1.0 Hz), 7.86 (2 H, d, J = 8.4 Hz), 7.59 (1 H, dd, J = 8.6, 1.5 Hz), 7.29 (2 H, d, J = 8.1 Hz), 6.98 (1 H, d, J = 13.0 Hz), 6.08 (1 H, d, J = 12.6 Hz), 3.80 (3 H, s), 2.37 (3 H, s); MS m/e 395.1 (M + H)⁺.

The following procedure was carried out behind a safety shield using plastic coated glassware free of scratches and ground glass joints. 1-Methyl-3-nitro-1-nitrosoguanidine (850 mg, 5.8 mmol) was carefully added portionwise over 10 min to a Erlenmeyer flask containing a swirled mixture of aqueous sodium hydroxide (100 ml, 5 N) and diethyl ether (50 ml) at 0°C. After vigorous bubbling had ceased, the organic layer (containing diazomethane) was decanted into a chilled (0°C) Erlenmeyer flask containing potassium hydroxide chips (2 g). The mixture was swirled for 10 min and the yellow solution was decanted into a dropping funnel. The solution of diazomethane was added over 10 min to an open flask containing a stirred mixture of methyl (Z)-3-[5-Cyano-1-(*p*-toluenesulfonyl)indol-3-yl]-acrylate (220 mg, 0.58 mmol) and palladium acetate (7 mg, 0.029 mmol) in dichloromethane (50 ml) maintained at 0 °C. After stirring for 30 min, the reaction was quenched with glacial acetic acid (2 ml) and poured into aqueous sodium hydroxide (0.5 N, 40 ml). The aqueous layer was extracted with ethyl acetate (3 x 10 ml). The organic layers were dried over anhydrous magnesium sulfate, and concentrated *in vacuo*. The product was purified by silica gel column chromatography with 15% ethyl acetate in hexanes to afford 187 mg (82% yield) of methyl [*cis*-2-[5-Cyano-1-(*p*-toluenesulfonyl)indol-3-yl]cycloprop-1-yl]-acrylate: ¹H NMR (400 MHz, CDCl₃): δ 7.98 (1 H, d, J = 8.7 Hz), 7.89 (1 H, s), 7.73 (2 H, d, J = 6.7 Hz), 7.52 (2 H, m), 7.24 (2 H, d, J = 8.0 Hz), 3.34 (3 H, s), 2.38 (1 H, m), 2.34 (3 H, s), 2.22 (1 H, m), 1.61 (1 H, m), 1.25 (1 H, m); MS m/e 473.2 (M + H)⁺.

Powdered lithium aluminum hydride (120 mg, 3.16 mmol) was carefully added to a stirred solution of methyl [*cis*-2-[5-Cyano-1-(*p*-toluenesulfonyl)indol-3-yl]cycloprop-1-yl]-acrylate (185 mg, 0.47 mmol) in anhydrous tetrahydrofuran (10 ml) at -30 °C. The resulting mixture was stirred at -20 °C for 1.5 h. The reaction

was quenched with ethyl acetate (5 ml) and allowed to warm to room temperature. After 10 min, water (120 μ L) was added and after 5 min followed by a solution of aqueous sodium hydroxide (1N, 360 μ L). After a further 5 min water (120 ml) was added and the solution was stirred 20 min. The aluminum salts were removed by vacuum filtration. The salts were rinsed with ethyl acetate (100 ml) and the combined filtrates were concentrated in vacuo. The crude material was purified by silica gel column chromatography with 45% ethyl acetate in hexanes to afford 131 mg (76% yield) of *cis*-2-[5-Cyano-1-(*p*-toluenesulfonyl)indol-3-yl]cyclopropanemethanol as a white solid: ^1H NMR (400 MHz, CDCl_3): δ 8.04 (1 H, d, J = 8.6 Hz), 7.99 (1 H, d, J = 1.0 Hz), 7.74 (2 H, d, J = 6.8 Hz), 7.57 (1 H, dd, J = 8.6, 1.6 Hz), 7.44 (1 H, d, J = 1.3 Hz), 7.26 (2 H, d, J = 8.2 Hz), 3.50 (1 H, m), 3.16 (1 H, m), 2.36 (3 H, s), 2.05 (1 H, m), 1.60 (1 H, m), 1.19 (1 H, m), 0.99 (1 H, t, J = 5.5 Hz), 0.72 (1 H, q, J = 5.6 Hz); MS m/e 349 ($\text{M}-\text{OH}$).


To a -78°C solution of oxalyl chloride (52 μ L, 0.60 mmol) in anhydrous dichloromethane (20 ml) was added dimethylsulfoxide (50 μ L, 0.70 mmol) dropwise. After stirring 10 min, a solution of *cis*-2-[5-Cyano-1-(*p*-toluenesulfonyl)indol-3-yl]cyclopropanemethanol (129 mg, 0.35 mmol) in dichloromethane (5 ml) was added dropwise. After stirring 20 min at -78°C , triethylamine (294 μ L, 2.10 mmol) was added dropwise. The reaction was stirred for 5 min at -78°C and then allowed to warm to room temperature. The reaction was washed with water (2x 5 ml), dried with anhydrous magnesium sulfate and the solvent was evaporated to give the crude *cis*-2-[5-Cyano-1-(*p*-toluenesulfonyl)indol-3-yl]cyclopropanecarboxaldehyde.

A mixture of the crude *cis*-2-[5-Cyano-1-(*p*-toluenesulfonyl)indol-3-yl]cyclopropanecarboxaldehyde, dimethylamine (0.35 ml, 0.7 mmol, 2.0 M/THF), and anhydrous ethanol (10 ml) was heated with stirring until all solids were dissolved. The reaction vessel was removed from the heating source and sodium triacetoxyborohydride (300 mg, 1.41 mmol) was added. After stirring for 1 h, the solvent was evaporated. The residue was taken up in brine (10 ml) and aqueous 1N sodium hydroxide was added until solids disappeared. The aqueous layer was extracted with ethyl acetate ((4x 10 ml), dried over anhydrous magnesium sulfate, and concentrated in vacuo to give the crude *cis*-2-[5-cyano-1-(*p*-toluenesulfonyl)indol-3-yl]-1-(*N,N*-dimethylaminomethyl)cyclopropane.

Water (4 ml) and an aqueous solution of sodium hydroxide (2 ml, 10 N) were sequentially added to a flask charged with a solution of crude *cis*-2-[5-cyano-1-(*p*-toluenesulfonyl)indol-3-yl]-1-(*N,N*-dimethylaminomethyl)cyclopropane dissolved in anhydrous ethanol (15 ml). The resulting mixture was heated at 70 °C for 1 h. The solvent was evaporated and the residue was taken up in brine (10 ml). The aqueous layer was extracted with 10% methanol/ethyl acetate (3x 5 ml). The combined organic layers were dried over anhydrous magnesium sulfate and concentrated *in vacuo*. The crude material was purified by silica gel column chromatography and eluted using a step gradient of a solvent mixture [chloroform/ (2 M ammonia/methanol), 90/10, 80/20]. The *cis*-2-[5-cyanoindol-3-yl]-1-(*N,N*-dimethylaminomethyl)cyclopropane was obtained as a white solid (63 mg, 75% yield over 3 steps): ¹H NMR (400 MHz, CDCl₃): δ 8.47 (1 H, br s), 8.07 (1 H, s), 7.41 (2 H, apparent q, J = 8.0 Hz), 7.03 (1 H, s), 2.37 (1 H, dd, J = 12.6, 4.7 Hz), 2.18 (6 H, s), 1.97 (1 H, m), 1.69 (1 H, dd, J = 12.6, 8.6 Hz), 1.34 (1 H, m), 1.22 (1 H, m), 0.71 (1 H, q, J = 5.0 Hz); MS *m/e* 240 (M + H)⁺.

Example 118


Cis-2-[5-Fluoroindol-3-yl]-1-(*N,N*-dimethylaminomethyl)cyclopropane




20

Cis-2-[5-fluoroindol-3-yl]-1-(*N,N*-dimethylaminomethyl)cyclopropane was prepared in a similar manner: ¹H NMR (400 MHz, CDCl₃): δ 8.30 (1 H, br s), 7.34 (1 H, dd, J = 9.6, 2.5 Hz), 7.24 (1 H, dd, J = 8.8, 4.4 Hz), 6.93 (2 H, m), 2.42 (1 H, dd, J = 12.6, 4.8 Hz), 2.18 (6 H, s), 2.03 (1 H, m), 1.70 (1 H, dd, J = 12.6, 8.7 Hz), 1.27 (1 H, m), 1.18 (1 H, m), 0.67 (1 H, q, J = 4.8 Hz); MS *m/e* 233 (M + H)⁺.

25

Example 119***trans*-2-[5-Cyanoindol-3-yl]-1-(*N*-methylaminomethyl)cyclopropane**

5 Racemic *trans*-2-[5-cyanoindol-3-yl]-1-(*N*-methylaminomethyl)cyclopropane was prepared in two steps and 67% overall yield from racemic (*trans*)-2-[5-cyano-1-(*p*-toluenesulfonyl)indol-3-yl]cyclopropanecarboxaldehyde following the procedures outlined for the preparation of (1*S*,2*S*)-*trans*-2-[5-cyanoindol-3-yl]-1-(*N*-methylaminomethyl)cyclopropane: LC-MS (column = YMC ODS-A C18 S7, 3 x 50
10 mm, start %B = 0, final %B = 100, gradient time = 2 min, flow rate = 5 ml/min) m/e 226 (M + H)⁺, *t*_R 0.80 min.

Example 120**(1*S*,2*S*)-*trans*-2-[5-Cyanoindol-3-yl]-1-(*N*-methylaminomethyl)cyclopropane**

15


A mixture of (1*S*,2*S*)-(*trans*)-2-[5-cyano-1-(*p*-toluenesulfonyl)indol-3-yl]cyclopropanecarboxaldehyde (0.500 g, 1.37 mmol), methylamine (2.0 M/THF, 13.7 ml, 27.4 mmol, 20 equiv), acetic acid (1.57 ml, 27.4 mmol, 20 equiv) and
20 anhydrous ethanol (20 ml) were heated to with stirring until all solids were dissolved (10 min). After cooling to rt, sodium triacetoxyborohydride (0.871 g, 4.11 mmol, 3 equiv) was added. The mixture was heated with stirring at 70 °C for 1 h. The reaction contents were poured into aqueous solution of sodium hydroxide (1 M, 150 ml). The aqueous layer was extracted with ethyl acetate (3 x 100 ml). The combined
25 organic extracts were washed with brine (50 ml), dried over anhydrous magnesium sulfate, filtered, and concentrated in vacuo. The crude product was purified using silica gel column chromatography (90:10:2, CHCl₃/MeOH/Et₃N) to provide 460 mg (89% yield) of 3-[2-(1-dimethylamino-ethyl)-cyclopropyl]-1H-indole-5-carbonitrile:

LC-MS (column = Phenomenex Luna C18 S10, 3 x 50 mm, start %B = 0, final %B = 100, gradient time = 3 min, flow rate = 4 ml/min) m/e 380 (M + H)⁺, t_R 1.92 min.

Water (1.5 ml) and an aqueous solution of sodium hydroxide (0.6 ml, 10 N) were sequentially added to a flask charged with a solution of (1*S*,2*S*)-*trans*-2-[5-cyano-1-(*p*-toluenesulfonyl)indol-3-yl]-1-(*N*-methylaminomethyl)cyclopropane dissolved in anhydrous ethanol (15 ml). The resulting mixture was heated at 70 °C for 45 min. The reaction contents were poured into aqueous solution of sodium hydroxide (1 M, 50 ml) and brine (50 ml). The aqueous layer was extracted with 10% methanolic ethyl acetate (2 x 100 ml). The combined organic extracts were washed with brine (50 ml), dried over anhydrous magnesium sulfate, filtered, and concentrated in vacuo. The crude product was purified using silica gel column chromatography using a step gradient (90:10:2, 82:15:2; CHCl₃/MeOH/Et₃N) to provide 204 mg (75% yield) (1*S*,2*S*)-*trans*-2-[5-cyanoindol-3-yl]-1-(*N*-methylaminomethyl)cyclopropane: ¹H NMR (400 MHz, DMSO-d₆): δ 11.35 (1 H, br s), 8.16 (1 H, d, J = 0.6 Hz), 7.47 (1 H, d, J' = 6.8 Hz), 7.40 (1 H, dd, J = 6.7, 1.2 Hz), 7.21 (1 H, s), 2.50 (2 H, m), 2.34 (3 H, s), 1.81 (1 H, m), 1.10 (1 H, m), 0.87 (1 H, m), 0.76 (1 H, m); LC-MS (column = Phenomenex Luna C18 S10, 3 x 50 mm, start %B = 0, final %B = 100, gradient time = 4 min, flow rate = 4 ml/min) m/e 226 (M + H)⁺, t_R 1.13.

Example 121

trans-3-[2-(1-Dimethylamino-ethyl)-cyclopropyl]-1H-indole-5-carbonitrile



(diastereomeric mixture)


A solution of methylmagnesium bromide (3.0 M in diethyl ether, 0.826 ml, 2.48 mmol, 1.05 equiv) was added to a suspension of [*trans*-2-[5-cyano-1-(*p*-toluenesulfonyl)indol-3-yl]cycloprop-1-yl]-*N*-methoxy-*N*-methylcarboxamide (1 g, 2.36 mmol) in anhydrous diethyl ether (25 ml). The resulting mixture was stirred at 0 °C for 2 h. The reaction mixture was diluted anhydrous THF (15 ml) and stirred for an additional 3 h at 0 °C. The cold mixture was quenched with aqueous 1 M

hydrochloric acid (200 ml) and extracted with ethyl acetate (3 x 100 ml). The combined organic extracts were washed with brine (50 ml), dried over anhydrous magnesium sulfate, filtered, and concentrated. The crude reaction mixture was purified by silica gel column chromatography using a step gradient [2:1, 1:1 (hexanes/ethyl acetate)] to afford 0.518 g (58% yield) of *trans*-3-(2-acetyl-cyclopropyl)-1-(toluene-4-sulfonyl)-1H-indole-5-carbonitrile as a white solid: LC-MS (column = Phenomenex Luna C18 S10, 3 x 50 mm, start %B = 0, final %B = 100, gradient time = 2 min, flow rate = 5 ml/min) m/e 379 (M + H)⁺, *t*_R 2.45 min.

Sodium cyanoborohydride (51 mg, 0.792 mmol, 3 equiv) was added to a stirred mixture of *trans*-3-(2-acetyl-cyclopropyl)-1-(toluene-4-sulfonyl)-1H-indole-5-carbonitrile (100 mg, 0.264 mmol), dimethylamine (2.0 M in THF, 2.64 ml, 5.28 mmol, 20 equiv), acetic acid (302 μ L, 5.28 mmol, 20 equiv) and powdered 4 A molecular sieves (150 mg, activated) in 2-propanol (2.0 ml). The resulting mixture was stirred at 50 °C for 20 h. Ethanol (5 ml), water (0.5 ml), and a solution of sodium hydroxide (10 M in water, 0.6 ml) were added to the reaction. The mixture was heated with stirring at 50 °C for 1 h. The reaction contents were poured into an aqueous solution of sodium hydroxide (1 M, 25 ml) and brine (25 ml). The aqueous layer was extracted with ethyl acetate (3 x 100 ml). The combined organic extracts were washed with brine (20 ml), dried over anhydrous magnesium sulfate, filtered, and concentrated in vacuo. The crude product was purified using silica gel column chromatography (90:10:1, CHCl₃/MeOH/Et₃N) to provide 67 mg (100% yield) of 3-[2-(1-dimethylamino-ethyl)-cyclopropyl]-1H-indole-5-carbonitrile as a 1:1 mixture of diastereomers. viscous oil: LC-MS (column = Phenomenex Luna C18 S10, 3 x 50 mm, start %B = 0, final %B = 100, gradient time = 3 min, flow rate = 4 ml/min) m/e 254 (M + H)⁺, *t*_R 1.19 min.

Example 122

Separation of the diastereomers of *trans*-3-[2-(1-Dimethylamino-ethyl)-cyclopropyl]-1H-indole-5-carbonitrile




The two diastereomers were separated using reverse phase preparatory HPLC (column: YMC S5 ODS, 30 x 100 mm). The relative stereochemistry for the individual diastereomers was not determined.

5 **Example 122A:** Analytical data for diastereomer A: ^1H NMR (400 MHz, DMSO): δ 11.48 (1 H, br s), 8.15 (1 H, d, $J = 0.6$ Hz), 7.51 (1 H, dd, $J = 8.4, 0.4$ Hz), 7.43 (1 H, dd, $J = 8.5, 1.5$ Hz), 7.32 (1 H, d, $J = 2.2$ Hz), 3.01 (1 H, m), 2.80 (3 H, s), 2.79 (3 H, s), 2.05 (1 H, m), 1.42 (3 H, d, $J = 6.7$ Hz), 1.22 (3 H, m); LC-MS (column = Phenomenex Luna C18 S10, 3 x 50 mm, start %B = 0, final %B = 100, gradient time = 2 min, flow rate = 5 ml/min) m/e 254 ($M + H$) $^+$, t_R 0.84 min.

Example 122B: Analytical data for diastereomer B: ^1H NMR (400 MHz, DMSO) 11.48 (1 H, br s), 8.19 (1 H, m), 7.50 (1 H, dd, $J = 8.4, 0.4$ Hz), 7.43 (1 H, dd, $J = 8.4, 1.5$ Hz), 7.33 (1 H, d, $J = 2.2$ Hz), 3.05 (1 H, m), 2.80 (3 H, s), 2.79 (3 H, s), 2.28 (1 H, m), 1.36 (1 H, m), 1.34 (3 H, d, $J = 6.7$ Hz), 1.08 (1 H, m), 0.97 (1 H, m); LC-MS (column = Phenomenex Luna C18 S10, 3 x 50 mm, start %B = 0, final %B = 100, gradient time = 2 min, flow rate = 5 ml/min) m/e 254 ($M + H$) $^+$, t_R 0.87 min.


Example 123

20 *trans*-3-[2-(1-Diethylamino-ethyl)-cyclopropyl]-1H-indole-5-carbonitrile




(diastereomeric mixture)

Analytical data for *trans*-3-[2-(1-diethylamino-ethyl)-cyclopropyl]-1H-indole-5-carbonitrile: LC-MS (column = Phenomenex Luna C18 S10, 3 x 50 mm, start %B = 0, final %B = 100, gradient time = 3 min, flow rate = 4 ml/min) m/e 282 ($M + H$) $^+$, t_R 1.28 min.

Example 124***trans*-3-[2-(1-Pyrrolidin-1-yl-ethyl)-cyclopropyl]-1H-indole-5-carbonitrile****(diastereomeric mixture)**

5 Analytical data for *trans*-3-[2-(1-pyrrolidin-1-yl-ethyl)-cyclopropyl]-1H-indole-5-carbonitrile: LC-MS (column = Phenomenex Luna C18 S10, 3 x 50 mm, start %B = 0, final %B = 100, gradient time = 3 min, flow rate = 4 ml/min) m/e 280 (M + H)⁺, *t*_R 1.26 min.


10

Example 125***trans*-3-[2-(1-Methylamino-ethyl)-cyclopropyl]-1H-indole-5-carbonitrile****(diastereomeric mixture)**

15 Analytical data for *trans*-3-[2-(1-methylamino-ethyl)-cyclopropyl]-1H-indole-5-carbonitrile: LC-MS (column = Phenomenex Luna C18 S10, 3 x 50 mm, start %B = 0, final %B = 100, gradient time = 3 min, flow rate = 4 ml/min) m/e 240 (M + H)⁺, *t*_R 1.15, 1.23 min.

Example 126

20 ***trans*-3-[2-(1-Ethylamino-ethyl)-cyclopropyl]-1H-indole-5-carbonitrile**

**(diastereomeric mixture)**

Analytical data for *trans*-3-[2-(1-ethylamino-ethyl)-cyclopropyl]-1H-indole-5-carbonitrile: LC-MS (column = Phenomenex Luna C18 S10, 3 x 50 mm, start %B = 0, final %B = 100, gradient time = 3 min, flow rate = 4 ml/min) m/e 254 (M + H)⁺, t_R 1.24 min.

5

Preparative chiral HPLC resolution of racemic indole-cyclopropanes

The racemates were separated into their corresponding enantiomers on a 50 x 500 mm Chiralpak AD column using an eluent mixture of ethanol and hexane containing diethylamine modifier. With a flow rate of 60 ml/min, separation times were between 65 and 75 min. Injection loads were determined by the combination of compound solubility in 50:50 ethanol/hexane (more hexane if possible), and by the length of baseline separation time between each pair of enantiomers. Maximum loading for a single run with baseline separation was approximately 100-250 mg. The following preparative and analytical HPLC data exemplify these methods:

15

Example 127

Preparative chiral HPLC separation of racemic *trans*-2-[5-Cyanoindol-3-yl]-1-(*N,N*-dimethylaminomethyl)cyclopropane

20 Method:

Chiralpak AD column, 50 x 500mm with 20 μ m packing

Solvents: 10% Ethanol/hexane (0.15% diethyl amine added in hexane as modifier)

Flow: 60 ml/min for 65 min

UV detector at 280 nm


25 Loop volume: 10 ml

Injection load: 165 mg in 6.5 ml of 1:3 ethanol/hexane

Example 127a

(1*R*,2*R*)-*trans*-2-[5-Cyanoindol-3-yl]-1-(*N,N*-dimethylaminomethyl)cyclopropane maleate salt

30



(1*R*,2*R*)-*trans*-2-[5-Cyanoindol-3-yl]-1-(*N,N*-dimethylaminomethyl)cyclopropane (240 mg) eluted at 29.9 min. 100% purity with >99% ee (Chiralpak AD 4.6 x 250mm, 10% methanol, 90% hexane (0.15% diethylamine), 1.0 ml/min, R_t =7.62 min). ESI-LRMS: m/z 238.05 (M-H)⁻. Optical rotation: -17.0 (ethanol, 22 C, c =2.59 mg/ml). This material was converted to the maleate salt: >97% purity (reverse-phase HPLC), >99.5% purity with >99% ee (Chiralpak AD 4.6 mm X 250 mm, 10% methanol, 90% hexane (0.15% diethylamine), 1.0 ml/min, R_t =7.30 min) ESI-LRMS: m/z 238.04 (M-H)⁻ Optical rotation: +3.2 (ethanol, 22 C, c =2.54 mg/ml) and -9.9 (water, 22 C, c =3.33 mg/ml). EA calculated for C₁₅H₁₇N₃ · C₄H₄O₄: C, 64.21, H, 5.96, N, 11.82; Found: C, 63.31, H, 5.94, N, 11.34. ¹H NMR (DMSO-*d*₆): δ 11.47 (s, 1 H), 9.65 (br, 1 H), 9.35 (br, 1 H) 8.18 (d, 1 H, J =0.6 Hz), 7.44 (dd, 2 H, J = 15.9, 8.4 Hz), 7.32 (d, 1 H, J =0.6 Hz), 3.21 (dq, 2H, J = 57.0, 7.1, 33.2, 7.1 Hz), 2.84 (s, 6 H), 2.10 (q, 1 H, J = 4.2 Hz), 1.18 (m, 1 H), 1.15 (m, 1 H) and 1.02 (m, 1 H).

A sample of (1*R*,2*R*)-*trans*-2-[5-Cyanoindol-3-yl]-1-(*N,N*-dimethylamino methyl)cyclopropane maleate salt was enantioselectively synthesized in a manner similar to Example 5 using opposite camphorsultam chiral auxiliary: Optical rotation: $[\alpha]_D$ -10.64 (concentration = 7.83 mg/ml, H₂O); LC-MS (column = Phenomenex Luna C18 S10, 3 x 50 mm, start %B = 0, final %B = 100, gradient time = 2 min, flow rate = 5 ml/min) m/e 240 (M + H)⁺, t_R 0.77 min. Anal. calcd. for C₁₉H₂₁N₃O₄: C, 64.21; H, 5.95; N, 11.82. Found: C, 64.02; H, 5.83; N, 11.73.

(*S,S*)-*trans*-2-[5-Cyanoindol-3-yl]-1-(*N,N*-dimethylaminomethyl)cyclopropane (230 mg) eluted at 49.0 min and was identical to material enantioselectively synthesized in Example 5.

Total recovery: 240 mg of the (*R,R*)-enantiomer, 230 mg of the (*S,S*)-enantiomer; 470 mg of 500 mg submitted (94%).

Analytical Chiral HPLC Conditions: Chiralcel AD column, 4.6 x 250mm, 10 μ m; 90% (0.15%DEA) hexane/10%EtOH; 1.0ml/min for 16 min; Abs.:280nm

Example 128**Preparative chiral HPLC separation of racemic
trans-1-(*N,N*-dimethylaminomethyl)-2-[5-fluoroindol-3-yl]cyclopropane****5 Method:**Chiralpak AD column, 50 x 500mm with 20 μ m packing


Solvents: 5% Ethanol/hexane (0.15% diethyl amine added in hexane as modifier)

Flow: 60 ml/min for 75 min

UV detector at 280 nm

10 Loop volume: 10 ml


Injection load: 80 mg in 6.5 ml of 4:5 ethanol/hexane

Example 128a**15 (1*R*,2*R*)-*trans*-1-(*N,N*-dimethylaminomethyl)-2-[5-fluoroindol-3-yl]-
cyclopropane maleate salt**

(*R,R*)-*trans*-1-(*N,N*-dimethylaminomethyl)-2-[5-fluoroindol-3-yl]cyclopropane (90 mg) eluted at 47.6 min. 96% purity with >99% ee (Chiralpak AD 4.6 x 250mm, 5% methanol, 95% hexane (0.15% diethylamine), 0.5 ml/min, **20** R_t =21.57 min). ESI-LRMS: m/z 231.05 ($M-H$)⁻ Optical rotation: -51.1 (ethanol, 22 C, c =4.64 mg/ml)

A sample of (*1R,2R*)-*trans*-1-(*N,N*-dimethylaminomethyl)-2-[5-fluoroindol-3-yl]-cyclopropane maleate salt was enantioselectively synthesized in a manner similar to Example 4 using opposite camphorsultam chiral auxiliary: Optical rotation: $[\alpha]_D$
25 -29.52 (concentration = 3.93 mg/ml, H₂O). LC-MS (column = Phenomenex Luna C18 S10, 3 x 50 mm, start %B = 0, final %B = 100, gradient time = 3 min, flow rate = 4 ml/min) m/e 233 ($M + H$)⁺, t_R 1.18 min. Anal. calcd. for C₁₈H₂₁FN₂O₄: C, 62.06; H, 6.07; N, 8.04. Found: C, 62.10; H, 6.05; N, 8.02.

(*S,S*)-*trans*-1-(*N,N*-dimethylaminomethyl)-2-[5-fluoroindol-3-yl]cyclo
30 propane (120 mg) eluted at 60.8 min and was identical to material enantioselectively synthesized in Example 4. Total recovery: 90 mg of (*R,R*)-enantiomer, 120 mg of (*S,S*)-enantiomer; 210 mg of 231 mg submitted (91%).

Example 129**Preparative chiral HPLC resolution of racemic
Cis-2-[5-Cyanoindol-3-yl]-1-(*N,N*-dimethylaminomethyl)cyclopropane****(racemate)****Method:**

Chiralpak AD column, 21 x 250mm with 20µm packing

Solvents: 10% Ethanol/hexane (0.15% diethylamine added in hexane as modifier)


10 Flow: 20 ml/min for 45 min

UV detector at 241 nm


Loop volume: 10 ml

Injection load: 18 mg in 1 ml of 1:3 ethanol/hexane

15

Example 129a**(+)-Enantiomer**

The (+)-enantiomer eluted at 21.02 min. >99% purity (reverse-phase HPLC),
20 >97% purity with >99% ee (Chiralpak AD 4.6 x 250mm, 10% methanol, 90% hexane
(0.15% diethylamine), 1.0 ml/min, R_t =8.02 min, sign of rotation determined by laser
polarimetry) ESI-LRMS: m/z 237.94 (M-H)⁺


Example 129b**(-)-Enantiomer**

25

The (-)-enantiomer at 34.84 min. >97% purity (reverse-phase HPLC), >98% purity with >99% ee (Chiralpak AD 4.6 x 250mm, 10% methanol, 90% hexane (0.15% diethylamine), 1.0 ml/min, R_t =10.91 min, sign of rotation determined by laser polarimetry). ESI-LRMS: m/z 237.96 (M-H)⁻.

Example 130

Preparative chiral HPLC resolution of racemic *Cis*-2-[5-Fluoroindol-3-yl]-1-(*N,N*-dimethylaminomethyl)cyclopropane



Method:

Chiralpak AD column, 21 x 250mm with 20μm packing

Solvents: 5% Ethanol/hexane (0.15% diethylamine added in hexane as modifier)


Flow: 10 ml/min for 55 min

UV detector at 241 nm

Loop volume: 10 ml


Injection load: 17 mg in 1.1 ml of 1:1 ethanol/hexane

Example 130a



(+)-Enantiomer

The (+)-enantiomer eluted at 23.47 min. >99% purity (reverse-phase HPLC), >94% purity with >99% ee (Chiralpak AD 4.6 x 250mm, 5% methanol, 95% hexane (0.15% diethylamine), 10.5 ml/min, R_t =20.18 min, sign of rotation determined by laser polarimetry). ESI-LRMS: m/z 230.92 (M-H)⁻.







Example 130b

(-)-Enantiomer

- 5 The (-)-enantiomer at 39.08 min. >99% purity (reverse-phase HPLC), >96% purity with >99% ee (Chiralpak AD 4.6 x 250mm, 5% methanol, 95% hexane (0.15% diethylamine), 0.5 ml/min, R_t =30.97 min, sign of rotation determined by laser polarimetry). ESI-LRMS: m/z 230.94 (M-H)⁻.

- 10 The following examples were prepared by the methods illustrated above:


Example	Structure	LC-MS retention time (min) **	LC-MS (MH) ⁺
131		1.1	309.4
132		0.89	219.1
133		0.81	247.4
134		0.99	341.42
135		0.75	240.17
136		0.84	233.18
137		0.76	282.16

138		1.04	302.17
139		1.36	339.22
140		1.04	287.17
141		0.8	275.13
142		0.94	247.14
143		0.89	215.17

**See LCMS method below

Example 144

3-[2-(2-Diethylamino-ethyl)-cyclopropyl]-1H-indole-5-carbonitrile



5

Butyl lithium (1.4ml of 2.4M in hexane, 3.36 mmol) was added drop wise over a five min period under a nitrogen atmosphere to a stirred solution of methyltriphenylphosphonium bromide (1.186 g, 3.32 mmol) in dry THF (25 ml). The solution was stirred for 30 min at ambient temperature and then added dropwise to a solution of 3-(2-formyl-cyclopropyl)-1-(toluene-4-sulfonyl)-1H-indole-5-carbonitrile (1.10 g, 3.018 mmol) in 25ml THF. The mixture was stirred for 24 hr, and then quenched with saturated aqueous ammonium acetate (2ml). The mixture was concentrated *in vacuo* and then extracted with ethyl acetate (20 ml). The ethyl acetate extract was washed with water (10ml), then washed with brine (10 ml), dried

over sodium sulfate, and concentrated *in vacuo*. The residue was chromatographed on silica gel using methylene chloride as the eluent to give 1-(toluene-4-sulfonyl)-3-(2-vinyl-cyclopropyl)-1H-indole-5-carbonitrile (755 mg, 71%). ¹H NMR (300MHz, CDCl₃): δ 8.04(d, 1H), 7.91(s, 1H), 7.74(d, 2H), 7.56(d, 1H), 7.54(s, 1H), 7.25(m, 2H), 5.57(m, 1H), 5.19(d, 1H), 5.01(d, 1H), 2.36(s, 3H), 1.86(m, 1H), 1.63(m, 1H), 1.16(m, 2H). MS m/e 363.16 (MH⁺).

9-Borabicyclo[3.3.1]nonane (4.1ml of 0.5 M THF solution, 2.05 mmol) was added drop wise under a nitrogen atmosphere to a stirred solution of 1-(toluene-4-sulfonyl)-3-(2-vinyl-cyclopropyl)-1H-indole-5-carbonitrile (735 mg, 2.01 mmol) in dry THF (6ml). The solution was heated to 30°C for 6 hr and then cooled to 20°C. Absolute ethanol (12ml), sodium hydroxide (2.6 ml of a 1N solution, 2.6 mmol), and hydrogen peroxide (0.85ml of a 30% solution) were added sequentially to the stirred solution. The mixture was heated to 40°C for 1 hr and then cooled to room temperature. Sodium hydroxide (2ml of a 1N solution) was added and the mixture was extracted with ethyl acetate. The ethyl acetate extract was dried over sodium sulfate and concentrated *in vacuo*. The residue was chromatographed on silica gel using 3% acetone in methylene chloride as the eluent to give 3-[2-(2-hydroxy-ethyl)-cyclopropyl]-1-(toluene-4-sulfonyl)-1H-indole-5-carbonitrile (300mg, 45%). ¹H NMR (300MHz, CDCl₃): δ 8.01(d, 2H), 7.97(s, 1H), 7.73(d, 1H), 7.28(s, 1H), 7.24(d, 2H), 3.80(m, 2H), 2.35(s, 3H), 1.74-1.62(m, 4H), 1.08(m, 1H), 0.90(m, 1H), 0.83(m, 1H). MS m/e 381.17 (MH⁺).

Oxalyl chloride (0.5ml of 2.0 M solution in methylene chloride, 1.0 mmol) was diluted with dry methylene chloride (5.0ml) and cooled to -78°C under a nitrogen atmosphere. DMF (0.08ml, 1.12 mmol) was added via a micro syringe and the solution was stirred at -78°C for 10 min. A solution of 3-[2-(2-hydroxy-ethyl)-cyclopropyl]-1-(toluene-4-sulfonyl)-1H-indole-5-carbonitrile (250mg, 0.657 mmol) in dry methylene chloride (5ml) was added drop wise, and the solution was stirred at -78°C for 1 hr, and then triethylamine (1.0ml) was added. The solution was concentrated *in vacuo*, and the residue was dissolved in ethyl acetate (10 ml). The ethyl acetate solution was extracted with HCl (5 ml of 1 N solution), and with brine (5 ml). The ethyl acetate solution was dried over sodium sulfate and concentrated *in vacuo*. The residue was chromatographed on silica gel using methylene chloride as

the eluent to give 3-[2-(2-oxo-ethyl)-cyclopropyl]-1-(toluene-4-sulfonyl)-1H-indole-5-carbonitrile (167mg, 67%). ¹H NMR (500MHz, CDCl₃): δ 9.87(s, 1H), 8.03(d, 1H), 7.96(s, 1H), 7.74(d, 2H), 7.56(d, 1H), 7.35(s, 1H), 7.25(d, 2H), 2.59(m, 2H), 2.36(s, 3H), 1.67(m, 1H), 1.30(m, 1H), 1.30(m, 1H), 1.02(m, 1H), 0.89(m, 1H).


5 MS m/e 379.16(MH⁺).

A mixture of 3-[2-(2-oxo-ethyl)-cyclopropyl]-1-(toluene-4-sulfonyl)-1H-indole-5-carbonitrile (50 mg, 0.13 mmol), dimethylamine (0.2 ml of a 2M solution in THF, 0.4 mmol), and 112 mg (0.53 mmol) sodium triacetoxyborohydride in ethyl alcohol (2 ml), was stirred for 12 hr at 70°C. Sodium hydroxide (15 equivalents of a 1N solution) was added and the mixture was stirred for 45 min at 75°C. The reaction mixture was cooled, diluted with water (3 ml), and extracted twice with ethyl acetate (10 ml). The ethyl acetate extracts were dried over sodium sulfate and concentrated *in vacuo*. The residue was purified by preparative HPLC to give 3-[2-(2-diethylamino-ethyl)-cyclopropyl]-1-(toluene-4-sulfonyl)-1H-indole-5-carbonitrile (8.2mg, 22%).

15 MS m/e 282.22 (MH⁺).

Example 145

3-[2-(2-Pyrrolidin-1-yl-ethyl)-cyclopropyl]-1H-indole-5-carbonitrile




20

A procedure similar to Example 144, but using pyrrolidine in the last step, was used to give 3-[2-(2-pyrrolidin-1-yl-ethyl)-cyclopropyl]-1H-indole-5-carbonitrile (3.4mg, 9.4%). MS m/e 280.19 (MH⁺).

25

Example 146



Alternate synthesis of
(1S,2S)-trans-2-[5-cyano-1-(p-toluenesulfonyl)indol-3-yl]-cyclopropanemethanol

(1*S*,2*S*)-*trans*-2-[5-cyano-1-(*p*-toluenesulfonyl)indol-3-yl]-cyclopropanemethanol is a key intermediate in the synthesis of (1*S*,2*S*)-*trans*-2-[5-cyanoindol-3-yl]-1-(*N,N*-dimethylaminomethyl)-cyclopropane (Example 5). This intermediate can be alternatively prepared by the following method:

5 Butyllithium (2.5 M solution in hexanes, 10 ml, 25 mmol, 1.25 equiv) was added over 5 min to a suspension of the methyltriphenylphosphonium bromide (10.7 g, 30 mmol, 1.5 equiv) in anhydrous tetrahydrofuran (250 ml) maintained at 0 °C under an atmosphere of dry nitrogen. After complete addition, the reaction mixture was allowed to warm to room temperature and stir for 1 h. The resulting orange
10 colored solution, containing a small amount of unreacted solid phosphonium salt, was chilled to -15 °C. Solid (5-cyanoindol-3-yl)carbox-aldehyde was added and the reaction mixture was allowed to warm to -5 °C over a period of 1 h. The reaction was quenched with water (250 ml) and extracted with ethyl acetate (3 x 100 ml). The organic extract was washed with brine (50 ml), dried over anhydrous magnesium
15 sulfate, filtered, and concentrated in vacuo. The crude product was purified using silica gel column chromatography (step gradient: 5:1, 4:1 hexane/ethyl acetate) to afford 4.56 g (71% yield) of 1-(*p*-toluenesulfonyl)-3-vinylindole-5-carbonitrile as a white solid. An analytically sample was obtained by recrystallization from ethyl acetate/hexane: mp 134-135° C; ¹H NMR (400 MHz, CDCl₃): δ 8.08 (1 H, d, 7.3
20 Hz), 8.06 (1 H, d, 1.1 Hz), 7.78 (2 H, d, J = 8.4 Hz), 7.70 (1 H, s), 7.58 (1 H, dd, J = 7.5, 1.5 Hz), 7.27 (2 H, d, J = 8.8 Hz), 6.73 (1 H, dd, J = 17.8, 11.3), 5.78 (1 H, d, J = 17.8 Hz), 5.43 (1 H, d, J = 11.5 Hz), 2.37 (3 H, s); MS m/e 323 (M + H)⁺. Anal. calcd. for C₁₈H₁₄N₂O₂S: C, 67.06; H, 4.37; N, 8.69. Found: C, 66.86; H, 4.36; N, 8.42.

25 A solution of ethyl diazoacetate (0.489 g, 4.29 mmol, 2.75 equiv) in toluene (4.5 ml) was added via syringe pump over a period of 16 h to a mixture of 1-(*p*-toluenesulfonyl)-3-vinylindole-5-carbonitrile (0.5 g, 1.56 mmol) and (*R*)-*trans*-Cl₂Ru(pybox-ip)(CH₂=CH₂) (39 mg, 0.078 mmol, 0.05 equiv) in toluene (15 ml) maintained at 50 °C under an atmosphere of dry nitrogen. After 16 h, a small aliquot
30 of the crude reaction mixture was withdrawn and passed through a silica gel plug (2:1, hexanes/ethyl acetate). ¹H-NMR analysis of the plugged aliquot revealed a 8.6:1 (*trans*/*cis*) mixture of product diastereomers. Without concentration, the crude

reaction mixture was purified using silica gel column chromatography (3.5: 1, hexanes /ethyl acetate) to afford 0.315 g (49% yield) of (1*S*,2*S*)-*trans*-2-[5-cyano-1-(*p*-toluenesulfonyl)indol-3-yl]-cyclopropane-carboxylic acid ethyl ester as a white crystalline solid. Chiral HPLC analysis revealed the mixture to be enriched to the extent of 88.4% enantiomeric excess: ¹H NMR (400 MHz, CDCl₃): δ 8.04 (1 H, dd, 5 8.6, 0.4 Hz), 7.90 (1 H, dd, J = 1.4, 0.5 Hz), 7.75 (2 H, d, J = 8.4 Hz), 7.57 (1 H, dd, J = 8.6, 1.6 Hz), 7.38 (1 H, d, J = 1.0 Hz), 7.27 (2 H, d, J = 7.8 Hz), 4.22 (2 H, q, J = 7.1), 2.46 (1 H, m), 2.37 (3 H, s), 1.86 (1 H, m), 1.61 (1 H, m), 1.31 (3 H, t, J = 7.1 Hz), 1.26 (1 H, m); MS (CI) m/e 409 (M + H)⁺. Chiral HPLC: Chiralpak AD (4.6 x 10 250 mm, 10 μm), 85:15 (hexanes/EtOH), 0.5 ml/min, absorbance 225 nm; *t*_R (*R,R*)-25.2 min (5.8%), *t*_R (*S,S*) 41.4 min (94.2%). Optical rotation: [α]_D 59.3 (concentration = 5.85 mg/ml, CH₂Cl₂).

A solution of diisobutylaluminumhydride (1M solution in THF, 3.34 ml, 3.34 mmol, 5 equiv) was added to a solution of (1*S*,2*S*)-*trans*-2-[5-cyano-1-(*p*-toluenesulfonyl)indol-3-yl]-cyclopropanecarboxylic acid ethyl ester (0.272 g, 0.665 15 mmol, 87.5% enantiomeric excess, contaminated with approximately 12% of the diastereomeric *cis*-cyclopropane isomer) in THF (15 ml) at -25 °C. The resulting mixture was left to stir for 1.5 h and subsequently quenched with 0.1 N aqueous hydrochloric acid (10 ml). The crude mixture was poured into 1 N aqueous 20 hydrochloric acid (100 ml) and extracted with ethyl acetate (2 x 100 ml). The organic layers were combined, washed with brine (25 ml), dried over anhydrous magnesium sulfate, and concentrated in vacuo. The crude product was purified using silica gel column chromatography (step gradient: 2.5:1, 2:1 hexane/ethyl acetate) to afford 204 mg of a white solid. The solid was recrystallized from ethyl 25 acetate/hexanes to afford 167 mg (68% yield) of (1*S*,2*S*)-*trans*-2-[5-cyano-1-(*p*-toluenesulfonyl)indol-3-yl]-cyclopropanemethanol (87.5% enantiomeric excess, based on enantiomeric purity of starting ethyl ester): ¹H NMR (400 MHz, CDCl₃): δ 8.03 (1 H, dd, J = 8.6, 0.6 Hz), 8.00 (1 H, dd, J = 1.5, 0.6 Hz), 7.74 (2 H, d, J = 8.4 Hz), 7.55 (1 H, dd, J = 8.6, 1.6 Hz), 7.33 (1 H, d, J = 1.0 Hz), 7.26 (2 H, d, J = 8.0 30 Hz), 3.69 (2 H, m), 2.37 (3 H, s), 1.78 (1 H, m), 1.37 (1 H, m), 0.95 (2 H, t, J = 7.0 Hz); MS (ESI) m/e 365 (M - H)⁻.


Yet another alternative method for preparing (1*S*,2*S*)-*trans*-2-[5-cyano-1-(*p*-toluenesulfonyl)indol-3-yl]-cyclopropanemethanol is as follows:

A solution of *tert*-butyl diazoacetate (0.608 g, 4.28 mmol, 2.75 equiv) in toluene (4.4 ml) was added via syringe pump over a period of 16 h to a mixture of 1-
5 (*p*-toluenesulfonyl)-3-vinylindole-5-carbonitrile (0.5 g, 1.56 mmol) and (*R*)-*trans*-
 $\text{Cl}_2\text{Ru}(\text{pybox-ip})(\text{CH}_2=\text{CH}_2)$ (39 mg, 0.078 mmol, 0.05 equiv) in toluene (15 ml) maintained at 62 °C under an atmosphere of dry nitrogen. HPLC analysis of a crude reaction aliquot revealed a 18:1 (*trans*/*cis*) mixture of product diastereomers. Without concentration, the crude reaction mixture was purified using silica gel
10 column chromatography (5 : 1, hexanes /ethyl acetate) to afford 0.537 g (79% yield) of enantiomerically enriched (1*S*,2*S*)-*trans*-2-[5-cyano-1-(*p*-toluenesulfonyl)indol-3-yl]-cyclopropanecarboxylic acid *tert*-butyl ester as a white solid. An analytical sample was obtained by recrystallization from EtOAc/hexane. The extent of enantiomeric enrichment (% ee) was determined after diisobutylaluminum hydride
15 reduction of the *t*-butyl ester to the corresponding alcohol (see subsequent experiment for details). ¹H-NMR (400 MHz, CDCl₃): δ 8.04 (1 H, dd, 8.6, 0.4 Hz), 7.89 (1 H, d, J = 1.0 Hz), 7.75 (2 H, d, J = 8.4 Hz), 7.57 (1 H, dd, J = 8.6, 1.5 Hz), 7.37 (1 H, d, J = 0.9 Hz), 7.27 (2 H, d, J = 8.6 Hz), 2.36 (4 H, m), 1.79 (1 H, m), 1.53 (1 H), 1.50 (9 H, s), 1.19 (1 H, m); MS (ESI) *m/e* 454 (M + NH₄)⁺. Optical rotation: [α]_D 91.9
20 (concentration = 5.89 mg/ml, CH₂Cl₂). Anal. calcd. for C₂₄H₂₄N₂O₄S: C, 66.03; H, 5.54; N, 6.41. Found: C, 66.02; H, 5.54; N, 6.29.

A solution of diisobutylaluminumhydride (1M solution in THF, 3.88 ml, 3.88 mmol, 5 equiv) was added to a solution of enantiomerically enriched (1*S*,2*S*)-*trans*-2-[5-cyano-1-(*p*-toluenesulfonyl)indol-3-yl]-cyclopropane-carboxylic acid *tert*-butyl
25 ester (0.338 g, 0.0776 mmol, contaminated with approximately 6% of the diastereomeric *cis*-cyclopropane isomer) in THF (15 ml) at -10 °C. The resulting mixture was left to stir for 2 h and subsequently quenched with 1 N aqueous hydrochloric acid (10 ml). The crude mixture was poured into 1 N aqueous hydrochloric acid (100 ml) and extracted with ethyl acetate (2 x 100 ml). The
30 organic layers were combined, washed with brine (25 ml), dried over anhydrous magnesium sulfate, and concentrated in vacuo. The crude product was purified using silica gel column chromatography (step gradient: 2.5:1, 2:1 hexane/ethyl acetate) to

afford 108 mg (38% yield) of (1*S*,2*S*)-*trans*-2-[5-cyano-1-(*p*-toluenesulfonyl)indol-3-yl]-cyclopropanemethanol (77% enantiomeric excess as determined by chiral HPLC):
¹H NMR (400 MHz, CDCl₃) 8.03 (1 H, dd, *J* = 8.6, 0.6 Hz), 8.00 (1 H, dd, *J* = 1.5, 0.6 Hz), 7.74 (2 H, d, *J* = 8.4 Hz), 7.55 (1 H, dd, *J* = 8.6, 1.6 Hz), 7.33 (1 H, d, *J* = 1.0 Hz), 7.26 (2 H, d, *J* = 8.0 Hz), 3.69 (2 H, m), 2.37 (3 H, s), 1.78 (1 H, m), 1.37 (1 H, m), 0.95 (2 H, t, *J* = 7.0 Hz). Chiral HPLC: Chiralpak AD (4.6 x 250 mm, 10 μm), 60:40 (hexanes/EtOH), 0.8 ml/min, absorbance 220 nm; *t*_R (*R,R*)-7.83 min (11.6%), *t*_R (*S,S*) 24.82 min (88.4%).

10

Example 147**[2-(5-Fluoro-1H-indol-3-ylmethyl)-cyclopropylmethyl]-dimethylamine**


A solution of diethylaluminum chloride in dichloromethane (16 ml, 1 M, 16 mmol) was added to a solution of 5-fluoroindole in dichloromethane at 0°. After stirring for 10 min at 0°, a solution of *trans*-2-ethoxycarbonylcyclopropanecarboxylic acid chloride (16 mmol, prepared from 2.5 g 16 mmol 2-ethoxycarbonylcyclopropanecarboxylic acid and 1.9 g, 16 mmol, thionyl chloride) in dichloromethane was added at 0°. The reaction was stirred 1 hr at 0° and 3 hr at 20°. The reaction was poured over a mixture of 1 N HCl and ice. The mixture was extracted with ethyl acetate. The extracts were washed with 1 N NaOH solution and brine, dried and concentrated *in vacuo*. The residue was triturated with isopropyl ether and the crude *trans*-2-(5-fluoro-3-indolylcarbonyl)cyclopropanecarboxylic acid ethyl ester (1.25g) as beige solid.

The crude *trans*-2-(5-fluoro-3-indolylcarbonyl)cyclopropanecarboxylic acid ethyl ester (0.55g, 2 mmol) was suspended in ethanol and sodium hydroxide solution (4 ml, 1N, 4 mmol) was added. The resultant solution was stirred for 4 hr at 20° and 0.5 hr at reflux. The ethanol was removed *in vacuo* and the residue mixed with water. The mixture was extracted with ethyl acetate. The aqueous layer was separated and made acidic with 12 N HCl. The precipitate was collected and air dried to give *trans*-2-(5-fluoro-3-indolylcarbonyl)cyclopropanecarboxylic acid as an

off-white solid (0.30g), mp 276-277 dec. LC/MS mw = 247; retention time 1.19 min. Mol wt calc'd for $C_{13}H_{10}FNO_2$: 247.


A solution of trans-2-(5-fluoro-3-indolylcarbonyl)cyclopropanecarboxylic acid (1.5 g, 6 mmol) and carbonyl diimidazole in tetrahydrofuran was stirred for 0.5
5 hr. A solution of dimethylamine in tetrahydrofuran (3 ml, 2 M solution, 6 mmol) was added and the solution stirred for 3 hr. The solution was concentrated *in vacuo* and the residue dissolved in ethyl acetate. The organic solution was washed with 1 N HCl and saturated sodium bicarbonate solution. The solution was dried over sodium sulfate and concentrated *in vacuo*. The residue was triturated with isopropyl ether to
10 give 1.5 g of trans-2-(5-fluoro-3-indolylcarbonyl)cyclopropanecarboxylic acid dimethylamide, mp 239-241°C. LC/MS mw = 274; retention time 1.23 min. Mol wt calc'd for $C_{15}H_{15}FN_2O_2$: 274.

Trans-2-(5-fluoro-3-indolylcarbonyl)cyclopropanecarboxylic acid dimethylamide (0.27 g, 1 mmol) in tetrahydrofuran was added to a suspension of
15 lithium aluminum hydride (0.2 g, 0.5 mmol) in tetrahydrofuran. The mixture was heated at reflux for 4 hr and stirred at 20° for 12 hr. The reaction was quenched by the sequential addition of 0.5 ml of water, 0.5 ml 15% NaOH solution and 0.5 ml water. After stirring for 1 hr, the insoluble solids were removed by filtration and washed with acetone. The organic solution was concentrated *in vacuo* and the
20 residue dissolved in methanol and purified by absorption on SCX resin washing with methanol and elution with 1 M methanolic ammonia solution. The basic elutants were concentrated *in vacuo*, dissolved in fresh methanol and made acidic with 12 N HCl. The acidic solution was thoroughly concentrated *in vacuo* to give racemic [2-(5-fluoro-1H-indol-3-ylmethyl)-cyclopropyl-methyl]-dimethylamine (165 mg).
25 LC/MS mw = 247; retention time 0.96 min. Mol wt calc'd for $C_{15}H_{19}FN_2$: 246.


Example 148**(+)-[2-(5-Fluoro-1H-indol-3-ylmethyl)-cyclopropylmethyl]-dimethylamine**

Racemic trans-2-(5-fluoro-3-indolylcarbonyl)-cyclopropanecarboxylic acid dimethylamide was resolved by chiral HPLC chromatography on a Chiralcel OD column (50 x 500mm with 20 μ m packing) using 10% Isopropanol/hexane as the eluent at a flow rate of 60 mL/min for 60 minutes and a UV detector set at 220 nm. (-)-Trans-2-(5-fluoro-3-indolylcarbonyl)-cyclopropanecarboxylic acid dimethylamide eluted at 9.6 minutes, and (+)-trans-2-(5-fluoro-3-indolylcarbonyl)-cyclopropanecarboxylic acid dimethylamide at 41.8 minutes.

A solution of (-)-trans-2-(5-fluoro-3-indolylcarbonyl)-cyclopropanecarboxylic acid dimethylamide (180 mg, 0.66 mmol) in THF was added dropwise to a suspension of LAH (100 mg, 2.63 mmol) in THF at room temperature with stirring. The reaction was heated to reflux and stirred for 1 h. The reaction was then cooled to room temperature, diluted with ether, and quenched with aqueous NaOH (1 mL of 1 N solution). The resulting precipitate was filtered and washed with ether. The organic filtrate was concentrated *in vacuo*. The residue was dissolved in methylene chloride, and transferred directly to an SCX resin cartridge. The cartridge was washed with methanol, and then with methanolic ammonia (2.0 M) to give (+)-[2-(5-fluoro-1H-indol-3-ylmethyl)-cyclopropyl-methyl]-dimethylamine [150 mg, 94% yield, optical rotation +19.26° (c=1.38 mg/mL, ethanol, 20 °C)]. ¹H NMR (MeOH-*d*₄): δ 7.25 (dd, *J*= 8.8, 4.5 Hz, 1H), 7.17 (dd, *J*= 9.9, 2.5 Hz, 1H), 6.82 (dt, *J*= 2.4 Hz, 1H), 2.69 (dd, *J*= 6.5 Hz, 2H), 2.29 (dd, *J*= 4.86 Hz, 1H), 2.20 (s, 6H), 2.15 (dd, *J*= 12.8 Hz, 1H), 0.90 (m, 1H), 0.70 (m, 1H), 0.51 (m, 1H), and 0.39 (m, 1H), FIMS: 247.3 (M+H)⁺.

Example 149**(-)-[2-(5-Fluoro-1H-indol-3-ylmethyl)-cyclopropylmethyl]-dimethylamine**

In a manner similar to example 148, (+)-trans-2-(5-fluoro-3-indolylcarbonyl)-cyclopropanecarboxylic acid dimethylamide was reduced to give (-)-[2-(5-fluoro-1H-indol-3-ylmethyl)-cyclopropyl-methyl]-dimethylamine [140 mg, 88% yield, optical rotation -22.86° ($c=1.08$ mg/mL, ethanol, 20°C)].

Example 150***N,N*-dimethyl-2-(3-bromoindol-5-yl)cycloprop-1-yl methylamine**

A mixture of sodium hydride (0.44 g of a 60% suspension in mineral oil, 11 mmol) and diethyl-(*N*-methoxy-*N*-methyl-carbamoylmethyl)-phosphonate (3.0 g, 3 equiv.) in anhydrous THF was stirred at room temperature for 30 minutes. A solution of indole-5-carboxaldehyde (0.61 g, 4.18 mmol) was added dropwise to the mixture. The reaction was complete after 2 h after the addition of the starting indole. The mixture was quenched with water (50 ml), then diluted with ether. The organic layer was separated, dried over anhydrous magnesium sulfate, filtered, and concentrated *in vacuo* to give *N*-methoxy-*N*-methyl-3-(indol-5-yl)acrylamide as a yellow oil which solidified on standing to an off-white solid (1.53 g, quantitative yield). ^1H NMR (CDCl_3): δ 8.55 (br, 1H), 7.87 (d, $J=18.6$ Hz, 1H), 7.85 (s, 1H), 7.38 (d, $J=8.5$ Hz, 1H), 7.25 (d, $J=8.5$ Hz, 1H), 7.23 (m, 1H), 7.0 (d, $J=18.6$ Hz, 1H), 6.58 (m, 1H), 3.78 (s, 3H), and 3.32 (s, 3H). FIMS: 229.1 (M-H^+), reverse-phase HPLC purity: 88%.

A mixture of trimethyl sulfoxonium iodide (4.03 g, 18.3 mmol) and sodium hydride (0.61 g of a 60% suspension in mineral oil, 18.3 mmol) in anhydrous THF was stirred at room temperature for 3 h. A solution of *N*-methoxy-*N*-methyl-3-(indol-5-yl)acrylamide (1.4 g.) in anhydrous THF was added dropwise to the reaction. The reaction was stirred and heated to a gentle reflux for 16 hours. The reaction was quenched with an excess of water and extracted with ethyl acetate. The organic

extract was dried over anhydrous magnesium sulfate, filtered, and concentrated *in vacuo* a yellow oil. This oil was purified by chromatography on silica gel using 15-50% ethyl acetate in hexane as the eluent, to *trans N*-methoxy-*N*-methyl-2-(indol-5-yl)cycloprop-1-yl)carboxamide (0.28 g, 28%) ¹H NMR (CDCl₃): δ 8.10 (br, 1H), 7.41 (s, 1H), 7.31 (d, *J*= 8.4 Hz, 1H), 7.20 (t, *J*= 2.8 Hz, 1H), 7.00 (dd, *J*= 8.4, 1.7 Hz, 1H), 6.50 (m, 1H), 3.69 (s, 3H), 3.25 (s, 3H), 2.61 (m, 1H), 2.40 (br, 1H), 1.64 (m, 1H) and 1.37 (m, 1H).


Lithium aluminum hydride (87 mg, 2.30 mmol) was suspended in anhydrous THF at -45 °C. A THF solution of *trans N*-methoxy-*N*-methyl-2-(indol-5-yl)cycloprop-1-yl)carboxamide (0.28 g, 1.15 mmol) was added slowly over a period of 10 min with stirring. The reaction was stirred for 1 h at -45 °C, diluted with ether, and then quenched with aqueous NaOH (1 mL of 1 N solution) and warmed to room temperature. The white precipitate was filtered, washed with ether, and the organic filtrate was concentrated *in vacuo*. The residue was dissolved in ethyl acetate, dried over anhydrous magnesium sulfate, filtered, and concentrated *in vacuo* to give 2-(indol-5-yl)cycloprop-1-yl)carboxaldehyde (230 mg, 100%) as a yellow oil which was used without purification. ¹H NMR (CDCl₃): δ 9.32 (d, *J*= 4.8 Hz, 1H), 8.15 (br, 1H), 7.41 (s, 1H), 7.27 (d, *J*= 9.5 Hz, 1H), 7.21 (t, *J*= 2.9 Hz, 1H), 6.97 (dd, *J*= 8.4, 1.2 Hz, 1H), 6.50 (m, 1H), 2.76 (s, 1H), 2.17 (s, 1H), 1.76 (m, 1H), and 1.58 (m, 1H).

A solution of 2-(Indol-5-yl)cycloprop-1-yl)carboxaldehyde (230 mg) and dimethyl amine (2.84 mL of 2 M solution in THF, 5.68 mmol) in absolute ethanol was stirred at room temperature as sodium triacetoxyborohydride (1.20 g, 5.68 mmol) was added. After 15 minutes of stirring, the colorless, clear solution was concentrated to dryness *in vacuo*. The residue was dissolved in ethyl acetate and 1 N NaOH solution. The organic layer was separated, dried over anhydrous magnesium sulfate, and concentrated *in vacuo* to give *N,N*-dimethyl-2-(indol-5-yl)cycloprop-1-yl methylamine (240 mg, 100%) as an oil.

¹H NMR (CDCl₃): δ 8.10 (br, 1H), 7.35 (s, 1H), 7.27 (d, *J*= 8.4 Hz, 1H), 7.16 (t, *J*= 2.7 Hz, 1H), 6.94 (dd, *J*= 11.4, 1.8 Hz, 1H), 6.45 (m, 1H), 2.49 (dd, *J*= 6.3 Hz, 1H), 2.38 (dd, *J*= 19.2 Hz, 1H), 2.35 (s, 6H), 1.81 (m, 1H), 1.20 (m, 1H), 0.98 (m, 1H), and 0.82 (m, 1H).

A solution of *trans* *N,N*-dimethyl-2-(indol-5-yl)cycloprop-1-yl methylamine (75 mg, 0.35 mmol), and potassium *t*-butoxide (29 mg, 0.35 mmol) in anhydrous THF at 0 °C was stirred at 0 °C for 30 min before cyanogen bromide (37 mg, 0.35 mmol) was added. The reaction was warmed to room temperature and stirred for 16 h. The reaction was concentrated *in vacuo*, and the residue was dissolved in water, and extracted with ethyl acetate. The organic extracts were dried over anhydrous magnesium sulfate, filtered, and concentrated *in vacuo* to give *N,N*-dimethyl-2-(3-bromoindol-5-yl)cycloprop-1-yl methylamine (100 mg, 98%) as a colorless oil. ¹H NMR (MeOH-*d*₄): δ 7.26 (d, *J* = 8.4 Hz, 1H), 7.22 (s, 1H), 7.16 (s, 1H), 6.94 (dd, *J* = 8.7, 1.5 Hz, 1H), 2.58 (dd, *J* = 6.0, 1H), 2.35 (s, 6H), 2.31 (m, 1H), 1.80 (m, 1H), 1.22 (m, 1H), 1.03 (m, 1H), and 0.88 (m, 1H). FIMS: 293.1 (M-H), reverse-phase HPLC purity: 85%.

Example 151



5-(2-Dimethylaminomethyl-cyclopropyl)-1H-indole-3-carbonitrile

Phosphorous oxychloride (0.08 mL, 0.85 mmol, 0.91 equiv.) and dimethyl formamide (0.32 mL, 4.09 mmol, 4.4 equiv.) were combined at room temperature with stirring. After 15 min, *N,N*-dimethyl-2-(indol-5-yl)cycloprop-1-yl-methylamine was added dropwise in DMF (5 mL). After 2 hs of stirring at room temperature, ice and 1 N NaOH were added, then the mixture was diluted further with water and extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated *in vacuo* to give *N,N*-dimethyl-2-(3-formyl-indol-5-yl)cycloprop-1-yl-methylamine (120 mg) as an oil. ¹H NMR (MeOH-*d*₄): δ 9.84 (s, 1H), 8.04 (s, 1H), 7.97 (s, 1H), 7.36 (d, *J* = 8.4 Hz, 1H), 7.05 (dd, *J* = 15.5, 1.7 Hz, 1H), 2.59 (dd, *J* = 12.7, 6.7, 1H), 2.35 (s, 6H), 2.30 (m, 1H), 1.80 (m, 1H), 1.20 (m, 1H), 1.05 (m, 1H), and 0.88 (m, 1H).


In 5 mL of acetic acid was combined 120 mg of crude *N,N*-dimethyl-2-(3-formyl-indol-5-yl)cycloprop-1-yl-methylamine, ammonium hydrogen phosphate (0.48 g, 3.62 mmol, 7.3 equiv.), and nitropropane (0.04 mL, 0.5 mmol, 1 equiv.). The mixture was stirred and heated to a gentle reflux for 16 h. Water was added after

cooling reaction to room temperature, and the mixture was made basic by the addition of 1 N NaOH. The mixture was extracted with ethyl acetate and dried over anhydrous magnesium sulfate, filtered, and concentrated *in vacuo* to give *N,N*-dimethyl-2-(3-cyanoindol-5-yl)cycloprop-1-yl methylamine (90 mg, 75%) as a brown oil. The oil was purified by flash chromatography to give a brown solid with 92% purity by reverse-phase HPLC. ¹H NMR (MeOH-*d*₄): δ 7.88 (s, 1H), 7.40 (d, *J* = 7.5 Hz, 1H), 7.36 (d, *J* = 1.9 Hz, 1H), 7.04 (dd, *J* = 8.5, 1.7 Hz, 1H), 2.62 (dd, *J* = 7.3 Hz, 1H), 2.42 (m, 1H), 2.38 (s, 6H), 1.89 (m, 1H), 1.20 (m, 1H), 1.08 (m, 1H), and 0.90 (m, 1H). IR: 2214.5 cm⁻¹. FIMS: 238.2 (M-H).

10

Example 152

[2-(5,6-Difluoro-1H-indol-3-yl)-cyclopropylmethyl]-dimethyl-amine



3,4-Difluorotoluene (9.00 g, 70.3 mmol), ammonium nitrate (6.75 g, 84.3 mmol) and trifluoroacetic acid (25 ml) were stirred at ambient temperature for 18 h. The resulting solution was made basic to pH >10 with 5 N sodium hydroxide and, after cooling to ambient temperature, extracted with diethyl ether (3 x 40 ml). The combined organic layers were washed with brine (40 ml) and dried over anhydrous sodium sulfate. The filtrate was concentrated *in vacuo*. The crude product was purified by silica gel column chromatography, eluting with hexanes/ethyl acetate (9:1), to afford 3,4-difluoro-5-nitrotoluene (4.63 g, 40 %) as a light yellow oil. ¹H-NMR δ (400 MHz, CDCl₃) 7.94 (1 H, dd, *J* = 9.9, 7.3 Hz), 7.17 (1 H, dd, *J* = 10.3, 7.6 Hz), 2.61 (3 H, s).

A solution of 3,4-difluoro-5-nitrotoluene (7.33 g, 42.3 mmol) in anhydrous dimethylformamide (20 ml) was treated with dimethylformamide-dimethylacetal (6.06 g, 50.8 mmol) and stirred at 110°C for 3 h, then at 70 °C for 18 h. The resulting deep red solution was diluted with brine (150 ml) and extracted with dichloromethane (5 x 30 ml). The pooled organic extracts were washed once with brine and dried over anhydrous sodium sulfate. The filtrate was concentrated *in*

vacuo to afford [2-(4,5-difluoro-2-nitro-phenyl)-vinyl]-dimethyl-amine (7.0 g, 73 %) as a deep red oil that solidified upon standing. The crude product was used without further characterization.

A suspension of [2-(4,5-difluoro-2-nitro-phenyl)-vinyl]-dimethyl-amine (7.0 g, 30.7 mmol) and 10 % palladium on charcoal (1.4 g) in methyl alcohol was hydrogenated in a Parr apparatus at 50 psi for 2 h and then filtered through Celite. The filtrate was concentrated *in vacuo* and the crude product purified by silica gel column chromatography (hexanes/ethyl acetate, 8:2) to afford 5,6-difluoroindole (1.28 g, 28 %) as a yellow solid. ¹H-NMR δ (400 MHz, CDCl₃) 8.10 (1 H, br s), 7.36 (1 H, dd, J = 10.7, 7.8 Hz), 7.22 (1 H, t, J = 2.8 Hz), 7.17 (1 H, dd, J = 7.4, 3.1 Hz), 6.50 (1 H, m).

5,6-Difluoroindole was converted to 5,6-difluoroindole carboxaldehyde in a manner similar to (5-cyanoindol-3-yl)carboxaldehyde in Example 1. ¹H-NMR (400 MHz, CDCl₃) 9.87 (1 H, s), 8.15 (s, 1 H), 7.96 (1 H, dd, J = 8.0, 2.8 Hz), 7.38 (1 H, dd, J = 6.8, 3.8 Hz).

5,6-difluoroindole carboxaldehyde was then converted to 5,6-difluoro-1-(toluene-4-sulfonyl)-1H-indole-3-carbaldehyde in a manner similar to [5-cyano-1-(p-toluenesulfonyl)indol-3-yl]carbox-aldehyde in Example 1. ¹H-NMR (400 MHz, CDCl₃) 10.04 (1 H, s), 8.22 (1 H, s), 8.05 (1 H, dd, J = 7.7, 2.1 Hz), 7.83 (2 H, d, J = 6.7 Hz), 7.79 (1 H, dd, J = 10.4, 6.6 Hz), 7.34 (2 H, dd, J = 8.0, 2.7 Hz), 2.41 (3 H, s).

5,6-difluoro-1-(toluene-4-sulfonyl)-1H-indole-3-carbaldehyde was then converted to (trans)-3-[5,6-Difluoro-1-(toluene-4-sulfonyl)-1H-indol-3-yl]-N-methoxy-N-methyl-acrylamide in a manner similar to (trans)-[5-cyano-1-(p-toluenesulfonyl)-indol-3-yl]-N-methoxy-N-methylacrylamide in Example 1. LC-MS: 2.74 min; 421.1 (MH)⁺.

(Trans)-3-[5,6-Difluoro-1-(toluene-4-sulfonyl)-1H-indol-3-yl]-N-methoxy-N-methyl-acrylamide was converted to 2-[5,6-Difluoro-1-(toluene-4-sulfonyl)-1H-indol-3-yl]-cyclopropanecarboxylic acid methoxy-methyl-amide in a manner similar to [trans-2-[5-Cyano-1-(p-toluenesulfonyl)indol-3-yl]cycloprop-1-yl]-N-methoxy-N-methylcarboxamide in Example 1. LC-MS: 2.71 min; 435.1 (MH)⁺.


2-[5,6-Difluoro-1-(toluene-4-sulfonyl)-1H-indol-3-yl]-cyclopropane-carboxylic acid methoxy-methyl-amide was converted to 2-[5,6-Difluoro-1-(toluene-4-sulfonyl)-1H-indol-3-yl]-cyclopropanecarbaldehyde *trans*-2-[5-Cyano -1-(p-

toluenesulfonyl)-indol-3-yl]cyclopropane-carboxaldehyde in Example 1. ¹H-NMR (400 MHz, CDCl₃) 9.44 (1 H, d, J = 4.2 Hz), 7.81 (1 H, dd, J = 10.6, 6.7 Hz), 7.72 (2 H, dd, J = 6.6, 1.6), 7.28 (4 H, m), 2.51 (1 H, m), 2.37 (3 H, s), 2.09 (1 H, m), 1.71 (1 H, m), 1.46 (1 H, m). LC-MS: 2.63 min; 376.1 (MH)⁺.

5 A solution of *trans*-2-[5,6-difluoro-1-(*p*-toluenesulfonyl)indol-3-yl]cyclopropane-carboxaldehyde (0.48 g, 1.28 mmol), dimethylamine (3 ml, 6 mmol, 2M/THF) and tetrahydrofuran (15 ml) was treated with sodium triacetoxyborohydride (1.35 g, 6.39 mmol) and stirred at ambient temperature for 1 h. The resulting solution was evaporated *in vacuo* and the residue treated with 10 N sodium hydroxide (10 ml) and methyl alcohol (10 ml). The solution was heated at a gentle reflux for 2 h then cooled and concentrated *in vacuo*. The residue was dissolved in ethyl acetate and washed with 1 N sodium hydroxide, and brine, and dried over anhydrous sodium sulfate. The filtrate was concentrated *in vacuo* to an amber colored oil. Silica gel column chromatography (chloroform/2M ammonia in methanol, 9:1) afforded [2-(5,6-difluoro-1H-indol-3-yl)-cyclopropylmethyl]-dimethyl-amine (100 mg, 31 %) as a light oil which solidified upon standing. ¹H-NMR (400 MHz, CDCl₃) 8.09 (1 H, br s), 7.40 (1 H, m), 7.10 (1 H, dd, J = 10.6, 6.6), 6.89 (1 H, d, J = 2.2 Hz), 2.38 (2 H, m), 2.34 (6 H, s), 1.69 (1 H, m), 1.18 (1 H, m), 0.90 (1 H, m), 0.78 (1 H, m).
15
20 LC-MS: 1.95 min; 251 (MH)⁺.

Example 153

5-(2-Dimethylaminomethyl-cyclopropylmethyl)-1H-indole-3-carbonitrile



Commercially available 5-bromoindole-3-carboxaldehyde (11.3 g, 50.4 mmol), ammonium hydrogen phosphate (47.0 g, 353 mmol), 1-nitropropane (4.49 g, 50.4 mmol), and glacial acetic acid (100 ml) were heated at a gentle reflux for 18 h. The resulting mixture was concentrated *in vacuo* and the residue mixed with 5 N sodium hydroxide (500 ml) and ice chips. The precipitate was collected by filtration and rinsed several times with water. The filtrate was concentrated *in vacuo* to afford 5-bromo-3-cyanoindole (7.23 g, 65%) as a dark solid. ¹H-NMR (400 MHz, CDCl₃) δ
25
30

10.0 (1 H, s), 8.68 (1 H, br s), 8.51 (1 H, s), 7.85 (1 H, s), 7.43 (1 H, dd, $J = 8.6, 1.9$ Hz), 7.32 (1 H, d, $J = 8.6$ Hz).

A suspension of potassium hydride (2.16 g, 18.8 mmol, 35% mineral oil dispersion) and anhydrous tetrahydrofuran at 0°C was treated with a solution of 5-bromo-3-cyanoindole dissolved in tetrahydrofuran (15 ml) by dropwise addition. After 15 min the solution was cooled to -78°C and treated with *n*-butyllithium (21 ml, 52.5 mmol, 2.5M/hexanes) by dropwise addition. The resulting mixture was stirred for 30 min after the addition was complete and then treated with commercially available diethyl-*trans*-cyclopropane carboxylate (12.7 g, 68.4 mmol) in a steady stream. The solution was stirred for 18 h, gradually warming to ambient temperature, and then carefully poured into 1 N hydrochloric acid (100 ml) and extracted with ethyl acetate (3x50 ml). The combined organic extracts were washed with brine (1x50 ml), dried over anhydrous sodium sulfate and concentrated *in vacuo*. Silica gel column chromatography (hexanes, ethyl acetate 1:1) afforded 2-(3-Cyano-1H-indole-5-carbonyl)-cyclopropanecarboxylic acid ethyl ester (1.12 g, 23 %) as tan solid. LC-MS: 1.40 min; 283 (MH)⁺.

A suspension of lithium aluminum hydride (0.3 g, 7.94 mmol) in anhydrous tetrahydrofuran (50 ml) was cooled to -45°C and treated with a solution of the 2-(3-Cyano-1H-indole-5-carbonyl)-cyclopropanecarboxylic acid ethyl ester (1.12 g dissolved in 10 ml THF). The mixture was stirred for 1 h and quenched with water followed by sodium hydroxide solution. The aluminum salts were removed by filtration. The filtrate was concentrated *in vacuo* to afford 2-[(3-cyano-1H-indol-5-yl)-hydroxy-methyl]-cyclopropanecarboxylic acid ethyl ester (1.0 g) as an amber oil. LC-MS: 1.49 min; 291.1 (MNa)⁺.

A solution of the 2-[(3-cyano-1H-indol-5-yl)-hydroxy-methyl]-cyclopropanecarboxylic acid ethyl ester (1.0 g, 3.5 mmol), dichloromethane (25 ml), and trifluoroacetic acid (5 ml) was cooled to 0°C and treated with triethylsilane (0.57 g, 5.0 mmol). The solution was stirred for 30 min and then diluted with an additional 50 ml dichloromethane and neutralized with 1 N sodium hydroxide. The organic layer was washed with brine (1x50 ml) and dried over anhydrous sodium sulfate. The filtrate was concentrated *in vacuo* to a deep amber oil. Silica gel column chromatography (hexanes, ethyl acetate 1:1) afforded 2-(3-cyano-1H-indol-5-

ylmethyl)-cyclopropane-carboxylic acid ethyl ester (0.62 g, 56 %) as a light yellow oil. LC-MS: 1.38 min; 269.1 (MH)⁺.

2-(3-Cyano-1H-indol-5-ylmethyl)-cyclopropanecarboxylic acid ethyl ester (0.62 g, 2.31 mmol), methanol (10 ml), and lithium hydroxide monohydrate (0.48 g, 5 11.6 mmol) were heated at a gentle reflux for 2 h. The solution was concentrated *in vacuo* and the residue taken up in 1 N hydrochloric acid (30 ml) and extracted with ethyl acetate (3x10 ml). The combined organic extracts were dried over anhydrous sodium sulfate and concentrated *in vacuo* to afford 2-(3-Cyano-1H-indol-5-ylmethyl)-cyclopropanecarboxylic acid (0.45 g, 81%) as a light brown oil which 10 solidified upon standing. LC-MS: 1.21 min; 263.2 (MNa)⁺.


A solution of 2-(3-cyano-1H-indol-5-ylmethyl)-cyclopropanecarboxylic acid (0.080 g, 0.33 mmol), *N,N*-dimethylhydroxylamine hydrochloride (0.065 g, 0.67 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.077 g, 0.40 mmol), triethylamine (0.13 g, 1.33 mmol), and dichloromethane (5 ml) was stirred at 15 ambient temperature for 1 h then diluted further with an additional 10 ml dichloromethane. The solution was washed with 1N hydrochloric acid (1x5ml), 1N sodium hydroxide (1x5ml), and brine (1x5ml) and dried over anhydrous sodium sulfate. The filtrate was concentrated *in vacuo* to afford 2-(3-cyano-1H-indol-5-ylmethyl)-cyclopropanecarboxylic acid methoxy-methyl-amide (0.075 g, 79%) as a 20 light brown film. ¹H-NMR (400 MHz, CDCl₃) 7.69 (1 H, m), 7.57 (1 H, s), 7.22 (1 H, d, J = 2.7 Hz), 7.11 (1 H, d, J = 1.52 Hz), 3.69 (3 H, s), 3.20 (3H, s), 2.81 (2 H, m), 2.10 (1 H, m), 1.73 (1 H, m), 1.28 (1 H, m), 0.91 (1 H, m).

A suspension of lithium aluminum hydride (0.020 g, 0.53 mmol) in anhydrous tetrahydrofuran (5 ml) at -45°C was treated with a solution 2-(3-cyano- 25 1H-indol-5-ylmethyl)-cyclopropanecarboxylic acid methoxy-methyl-amide in 5 ml tetrahydrofuran. After 30 min at -45°C an additional 0.53 mmol lithium aluminum hydride was added. The reaction was quenched with water followed by 1 N sodium hydroxide after another 30 min. The aluminum salts were removed by filtration and the filtrate was concentrated *in vacuo* to afford 5-(2-Formyl-cyclopropylmethyl)-1H- 30 indole-3-carbonitrile (0.034 g, 57%) as a light yellow film. ¹H-NMR (400 MHz, CDCl₃) 9.07 (1 H, d, J = 5.16 Hz), 7.71 (1 H, s), 7.58 (1 H, s), 7.39 (1 H, d, J = 8.2 Hz), 7.22 (1 H, m), 6.98 (1 H, s), 2.80 (2 H, m), 1.86 (2 H), 1.40 (1 H, m), 1.11 (1 H, m).

A solution of 2-(3-cyano-1H-indol-5-ylmethyl)-cyclopropanecarboxylic acid methoxy-methyl-amide (0.029 g, 0.13 mmol), dimethylamine (0.7 ml, 1.4 mmol, 2M/THF), and methyl alcohol (5 ml) was treated with sodium triacetoxyborohydride (0.28 g, 1.13 mmol) and stirred at ambient temperature for 1 h. The solution was concentrated *in vacuo* and the residue applied directly to a silica gel column and eluted with chloroform, methyl alcohol, triethylamine 95:5:0.1 to afford 5-(2-Dimethylaminomethyl-cyclopropylmethyl)-1H-indole-3-carbonitrile (23 mg, 69%) as a light salmon colored solid. ¹H-NMR (400 MHz, CDCl₃) 8.88 (1 H, br s), 7.66 (2 H, dd, J = 19.4, 2.3 Hz), 7.33 (1 H, d, J = 8.4 Hz), 7.18 (1 H, dd, J = 8.4, 1.5 Hz), 2.72 (2 H, m), 2.25 (6 H, s), 2.24 (2 H, m), 0.88 (2 H, m), 0.53 (1 H, m), 0.45 (1 H, m). LC-MS: 0.90; 254.2 (MH)⁺.

Example 154

Methyl-[2-(5-trifluoromethyl-1H-indol-3-yl)-cyclopropylmethyl]-amine



A mixture of 4-Nitrobenzotrifluoride (25.0 g, 131 mmol) and 4-chlorophenoxyacetonitrile (24.1g, 144 mmol) in dry DMF (200 mL) was added dropwise over 1 h to a stirred solution of potassium tert-butoxide (32.3 g, 288 mmol) in dry DMF (200 mL) at -10°C. After complete addition the resulting purple solution was maintained at -10°C for 3 h then poured into a mixture of ice water (200 mL) and 5 N aqueous HCl (200mL). The resulting mixture was extracted with dichloromethane (3 x 300 mL). The combined extracts were washed with 10 % aqueous NaOH, 5 N HCl, brine, dried over sodium sulfate, and concentrated *in vacuo* to give the crude (2-nitro-5-trifluoromethylphenyl) acetonitrile. The crude (2-nitro-5-trifluoromethylphenyl) acetonitrile (24.6 g, 107 mmol) was dissolved in 9:1 EtOH:H₂O (300 mL) and glacial acetic acid (3.0 mL). This mixture was hydrogenated over 10 % Pd/C (10.0 g) at 50 psi for 16 h at room temperature. The reaction was filtered through celite and evaporated *in vacuo*. The residue was partitioned between saturated aqueous sodium carbonate and dichloromethane (2x 200 mL) and the combined organic extract was dried over sodium sulfate, filtered, and concentrated *in vacuo*. The crude material was purified by silica gel column

chromatography (hexanes/ethyl acetate, 20:1, 9:1, 5:1) to afford 12.9 g (65 % yield) of 5-trifluoromethyl-1H-indole as a yellow solid: ^1H NMR (400 MHz, CDCl_3) 8.34, (1H, br s), 7.95 (1 H, s), 7.45 (2 H, m), 7.32 (1 H, m), 6.65 (1 H, m); MS m/e 184 (M-H) $^-$. Anal calcd. for $\text{C}_9\text{H}_6\text{F}_3\text{N} \cdot 0.15 \text{ H}_2\text{O}$: C, 57.55; H, 3.38; N, 7.46. Found: C, 57.25; H, 2.98; N, 7.29.

(5-trifluoromethylindol-3-yl)carboxaldehyde (6.35 g, 43%) was prepared from 5-trifluoromethyl-1H-indole to afford from in a similar manner to (5-cyanoindol-3-yl)carboxaldehyde in Example 1. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) 12.5, (1H, br s), 10.0 (1 H, s), 8.50 (1 H, s), 8.41 (1 H, s), 7.73 (1 H, d, $J = 8.6$ Hz); MS m/e 212 (M-H) $^-$. Anal calcd. for $\text{C}_{10}\text{H}_6\text{F}_3\text{NO} \cdot 0.10 \text{ H}_2\text{O}$: C, 55.88; H, 2.91; N, 6.52. Found: C, 55.82; H, 2.64; N, 6.62.

(5-trifluoromethyl-1-(p-toluenesulfonyl)indol-3-yl)carboxaldehyde (8.40 g, 77%) was prepared from (5-trifluoromethylindol-3-yl)carboxaldehyde in a similar manner to (5-cyano-1-(p-toluenesulfonyl)indol-3-yl)carboxaldehyde in Example 1. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) 10.1 (1 H, s), 9.08 (1 H, s), 8.41 (1 H, s), 8.21 (1 H, d, $J = 8.8$ Hz), 8.05 (2 H, d, $J = 8.4$ Hz), 7.80 (1 H, d, $J = 8.8$ Hz), 7.48 (2 H, d, $J = 8.2$ Hz), 2.36 (3H, s); MS m/e 366 (M-H) $^-$. Anal calcd. for $\text{C}_{17}\text{H}_{12}\text{F}_3\text{NO}_3\text{S} \cdot 4.27 \text{ H}_2\text{O}$: C, 55.58; H, 3.29; N, 3.81. Found: C, 55.42; H, 3.29; N, 3.75.

(E)-[5-trifluoromethyl-1-(p-toluenesulfonyl)indol-3-yl]-N-methoxy-N-methyl-acrylamide (9.01 g, 87%) was prepared from (5-trifluoromethyl-1-(p-toluenesulfonyl)indol-3-yl)carboxaldehyde in a similar manner to (E)-[5-cyano-1-(p-toluenesulfonyl)indol-3-yl]-N-methoxy-N-methylacrylamide in Example 1. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) 8.69 (1 H, s), 8.21 (2 H, m), 7.97 (2 H, d, $J = 8.4$ Hz), 7.76 (2 H, m), 7.44 (2 H, d, $J = 8.1$ Hz), 7.22 (1 H, d, $J = 16$ Hz), 3.78 (3 H, s), 3.23 (3H, s), 2.33 (3H, s); MS m/e 453 (M+H) $^+$. Anal calcd. for $\text{C}_{21}\text{H}_{19}\text{F}_3\text{N}_2\text{O}_4\text{S} \cdot 0.5 \text{ H}_2\text{O}$: C, 54.66; H, 4.37; N, 6.07. Found: C, 54.96; H, 4.08; N, 6.05.

Racemic [trans-2-[5-trifluoromethyl-1-(p-toluenesulfonyl)indol-3-yl]cycloprop-1-yl]-N-methoxy-N-methylcarboxamide (5.48 g, 76%) was prepared from (E)-[5-trifluoromethyl-1-(p-toluenesulfonyl)indol-3-yl]-N-methoxy-N-methylacrylamide in a similar manner to [trans-2-[5-cyano-1-(p-toluenesulfonyl)indol-3-yl]cycloprop-1-yl]-N-methoxy-N-methyl-carboxamide in Example 1. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) 8.12 (1 H, d, $J = 8.7$ Hz), 8.03 (1 H, s),


7.90 (2 H, d, $J = 8.4$), 7.84 (1 H, s), 7.68 (1H, dd, $J = 8.7, 1.3$ Hz), 7.40 (2H, d, $J = 8.2$ Hz), 3.64 (3 H, s), 3.16 (3H, s), 2.43 (2H, m), 2.32 (3 H, s), 1.44 (2 H,m); MS m/e 465 (M-H)⁺. Anal calcd. for C₂₂H₂₁F₃N₂O₄S: C, 56.64; H, 4.53; N, 6.00. Found: C, 56.63; H, 4.60; N, 5.93

5 Racemic [*trans*-2-[5-trifluoromethyl-1-(p-toluenesulfonyl)indol-3-yl]-cyclopropane-carboxaldehyde (4.13 g, 95 %) was prepared from racemic [*trans*-2-[5-trifluoromethyl-1-(p-toluenesulfonyl)indol-3-yl]cycloprop-1-yl]-N-methoxy-N-methyl-carboxamide in a similar manner to [*trans*-2-[5-cyano-1-(p-toluenesulfonyl)indol-3-yl]cyclopropane-carboxaldehyde in Example 1. ¹H NMR
10 (400 MHz, DMSO-d₆) 9.06 (1 H, d, $J = 5.7$ Hz), 8.11 (2 H, d, $J = 8.9$ Hz), 7.89 (3 H, m), 7.69 (1 H, d, $J = 8.8$ Hz), 7.40 (2 H, d, $J = 8.0$ Hz), 2.86 (1H, m), 2.32 (3H, s), 2.12 (1 H, m), 1.71 (2H, m); MS m/e 406 (M-H)⁺. Anal calcd. for C₂₀H₁₆F₃NO₃S: C, 58.96; H, 3.95; N, 3.43. Found: C, 58.95; H, 3.96; N, 3.28

 Racemic [*trans*-2-[5-trifluoromethylindol-3-yl]-1-(N-methylaminomethyl)
15 cyclo-propane was prepared (two steps, 24% overall yield) from racemic [*trans*-2-[5-trifluoromethyl-1-(p-toluenesulfonyl)indol-3-yl]-cyclopropane-carboxaldehyde following the procedures outlined for the preparation of (1S,2S)-*trans*-2-[5-cyanoindol-3-yl]-1-(N-methylaminomethyl)cyclopropane in Example 1. LC-MS (column = Phenomenex Luna C18 S5, 4.6 x 50 mm, start %B = 0, final %B = 100,
20 gradient time = 3 min, flow rate = 5 mL/min) m/e 269 (M + H)⁺, t_R 1.43 min. .

Example 155

Methyl-[2-(6-trifluoromethyl-1H-indol-3-yl)-cyclopropylmethyl]-amine



25 The commercially available (2-nitro-4-trifluoromethylphenyl) acetonitrile (14.0 g, 60.8 mmol) was dissolved in 9:1 EtOH:H₂O (50 mL) and glacial acetic acid (1.4 mL). This mixture was hydrogenated over 10 % Pd/C (5.0 g) at 50 psi for 16 h at room temperature. The reaction was filtered over celite and evaporated *in vacuo*. The residue was partitioned between saturated aqueous sodium carbonate and
30 dichloromethane (2x 200 mL) and the combined organic extract was dried over sodium sulfate, filtered, and concentrated *in vacuo*. The crude material was purified

by silica gel column chromatography (hexanes/ethyl acetate, 20:1, 9:1, 5:1) to afford 12.9 g (65 % yield) of 6-trifluoromethyl-1H-indole as a yellow solid: ¹H NMR (400 MHz, CDCl₃) 8.36, (1H, br s), 7.72 (2 H, m), 7.37 (2 H, m), 6.63 (1 H, m); MS m/e 184 (M-H)⁺. Anal calcd. for C₉H₆F₃N: C, 58.38; H, 3.26; N, 7.56. Found: C, 58.30; H, 2.92; N, 7.49.

(6-trifluoromethylindol-3-yl)carboxaldehyde was prepared in 48% yield from 6-trifluoromethyl-1H-indole in a similar manner to (5-cyanoindol-3-yl)carboxaldehyde in Example 1. ¹H NMR (400 MHz, DMSO-d₆) 12.5, (1H, br s), 10.0 (1 H, s), 8.52 (1 H, s), 8.28 (1 H, d, J = 8.3 Hz), 7.86 (1 H, s), 7.54 (1 H, d, J = 8.3 Hz); MS m/e 212 (M-H)⁺. Anal calcd. for C₁₀H₆F₃NO: C, 56.34; H, 2.83; N, 6.57. Found: C, 56.23; H, 2.76; N, 6.61.

(6-trifluoromethyl-1-(p-toluenesulfonyl)indol-3-yl)carboxaldehyde was prepared in a 93% yield from (6-trifluoromethylindol-3-yl)carboxaldehyde in a similar manner to (5-cyano-1-(p-toluenesulfonyl)indol-3-yl)carboxaldehyde in Example 1. ¹H NMR (400 MHz, DMSO-d₆) 10.1 (1 H, s), 9.13 (1 H, s), 8.33 (1 H, d, J = 8.3 Hz), 8.19 (1 H, s), 8.05 (2 H, d, J = 8.4 Hz), 7.77 (1 H, d, J = 8.3 Hz), 7.49 (2 H, d, J = 8.2 Hz), 2.35 (3H, s); MS m/e 366 (M-H)⁺. Anal calcd. for C₁₇H₁₂F₃NO₃S: C, 55.58; H, 3.29; N, 3.81. Found: C, 55.48; H, 3.42; N, 3.82.

(E)-[6-trifluoromethyl-1-(p-toluenesulfonyl)indol-3-yl]-N-methoxy-N-methylacrylamide was prepared in an 85% yield from (6-trifluoromethyl-1-(p-toluenesulfonyl)indol-3-yl)carboxaldehyde in a similar manner to (E)-[5-cyano-1-(p-toluenesulfonyl)indol-3-yl]-N-methoxy-N-methylacrylamide in Example 1. ¹H NMR (400 MHz, DMSO-d₆) 8.75 (1 H, s), 8.21 (1 H, s), 8.13 (1 H, d, J = 8.4 Hz), 7.96 (2 H, d, J = 8.4 Hz), 7.73 (2 H, m), 7.45 (2 H, d, J = 8.2 Hz), 7.22 (1 H, d, J = 16 Hz), 3.78 (3 H, s), 3.23 (3H, s), 2.33 (3H, s); MS m/e 451 (M-H)⁺. Anal calcd. for C₂₁H₁₉F₃N₂O₄S: C, 55.74; H, 4.23; N, 6.19. Found: C, 55.78; H, 4.13; N, 6.13.

Racemic [trans-2-[6-trifluoromethyl-1-(p-toluenesulfonyl)indol-3-yl]cycloprop-1-yl]-N-methoxy-N-methylcarboxamide was prepared in an 83% yield from (E)-[6-trifluoromethyl-1-(p-toluenesulfonyl)indol-3-yl]-N-methoxy-N-methylacrylamide in a similar manner to [trans-2-[5-cyano-1-(p-toluenesulfonyl)indol-3-yl]cycloprop-1-yl]-N-methoxy-N-methylcarboxamide in Example 1. ¹H NMR (400 MHz, DMSO-d₆) 8.15 (1 H, s), 7.89 (4 H, m), 7.62 (1 H, dd, J = 8.3, 1.1 Hz), 7.41 (2 H, d, J = 8.1 Hz), 3.64 (3 H, s), 3.16 (3H, s), 2.41 (2H,

m), 2.32 (3 H, s), 1.50 (1 H, br s), 1.42 (1 H, m); MS m/e 465 (M-H)⁻. Anal calcd. for C₂₂H₂₁F₃N₂O₄S: C, 56.64; H, 4.53; N, 6.00. Found: C, 56.56; H, 4.46; N, 5.95


Racemic [trans-2-[6-trifluoromethyl-1-(p-toluenesulfonyl)indol-3-yl]-cyclopropane-carboxaldehyde was prepared in an 89% yield from racemic [trans-2-
5 [6-trifluoromethyl-1-(p-toluenesulfonyl)indol-3-yl]cycloprop-1-yl]-N-methoxy-N-methyl-carboxamide in a similar manner to [trans-2-[5-cyano-1-(p-toluenesulfonyl)indol-3-yl]cyclopropane-carboxaldehyde in Example 1. ¹H NMR (400 MHz, DMSO-d₆) 9.12 (1 H, d, J = 5.4 Hz), 8.15 (1 H, s), 7.92 (4 H, m), 7.64 (1 H, dd, J = 8.3, 1.1 Hz), 7.41 (2 H, d, J = 8.1 Hz), 2.78 (1H, m), 2.32 (3H, s), 2.15 (1
10 H, m), 1.71 (2H, m); MS m/e 406 (M-H)⁻. Anal calcd. for C₂₀H₁₆F₃NO₃S: C, 58.96; H, 3.95; N, 3.43. Found: C, 58.93; H, 3.93; N, 3.25.

Racemic [trans-2-[6-trifluoromethylindol-3-yl]-1-(N-methylaminomethyl)cyclopropane was prepared in two steps and 56 % overall yield from racemic [trans-2-[6-trifluoromethyl-1-(p-toluenesulfonyl)indol-3-yl]-cyclopropane-carboxaldehyde
15 following the procedures outlined for the preparation of (1S,2S)-trans-2-[5-cyanoindol-3-yl]-1-(N-methylaminomethyl)cyclopropane in Example 1. LC-MS (column = Phenomenex Luna C18 S5, 4.6 x 50 mm, start %B = 0, final %B = 100, gradient time = 3 min, flow rate = 5 mL/min) m/e 269 (M + H)⁺, t_R 1.43 min.


20

Example 156

Ethyl-[2-(6-trifluoromethyl-1H-indol-3-yl)-cyclopropylmethyl]-amine




Racemic [trans-2-[6-trifluoromethylindol-3-yl]-1-(N-ethylaminomethyl)-cyclo-propane was prepared in 49% overall yield in a manner similar to the above
25 example. LC-MS (column = Phenomenex Luna C18 S5, 4.6 x 50 mm, start %B = 0, final %B = 100, gradient time = 3 min, flow rate = 5 mL/min) m/e 283 (M + H)⁺, t_R 1.46 min.

Example 157**Benzyl-methyl-[2-(6-trifluoromethyl-1H-indol-3-yl)-cyclopropylmethyl]-amine**

Racemic [*trans*-2-[6-trifluoromethylindol-3-yl]-1-(N-benzyl-N-methylamino-methyl)-cyclopropane] was prepared in 78% overall yield in a manner similar to the above example. LC-MS (column = Phenomenex Luna C18 S5, 4.6 x 50 mm, start %B = 0, final %B = 100, gradient time = 3 min, flow rate = 5 mL/min) m/e 359 (M + H)⁺, t_R 1.64 min.

10

Example 158**3-(2-Methylaminomethyl-cyclopropyl)-1H-indole-6-carbonitrile**

A mixture of 3-nitro-*p*-tolunitrile (30.0 g, 185 mmol), DMF (100mL), and dimethylformamide dimethylamine (24.3 g, 204 mmol) was heated to 110 °C for 16 h. The deep red solution was poured into H₂O (1L) and extracted with EtOAc (4 x 250 mL). The organic layers were washed with H₂O, brine, dried over sodium sulfate, filtered, and concentrated *in vacuo*. The solid residue was triturated with hexanes to give 4-(2-dimethylamino-vinyl)-3-nitro-benzonitrile (28.5 g, 74%) after filtration. ¹H NMR (400 MHz, DMSO-*d*₆) 8.22 (1 H, s), 7.83 (2 H, m), 7.65 (1 H, m), 5.67 (1 H, d, J = 13 Hz), 2.98 (6 H, s); MS m/e 219 (M+H)⁺. Anal calcd. for C₁₁H₁₁N₃O₂: C, 60.82; H, 5.10; N, 19.34. Found: C, 60.54; H, 4.99; N, 19.40.

4-(2-Dimethylamino-vinyl)-3-nitro-benzonitrile (28.5 g, 131 mmol) was dissolved in MeOH (850 mL) and hydrogenated over 10 % Pd/C (6.0 g) at 60 psi for 1.5 h at room temperature. The reaction was filtered over celite and evaporated *in vacuo*. The residue was partitioned between 5 % aqueous HCl solution and Et₂O (2x 200 mL) and the combined organic extract was washed with brine, dried over sodium sulfate, filtered, and concentrated *in vacuo* to give 6-cyano-1H-indole (13.5 g, 72%) as a light brown solid. ¹H NMR (400 MHz, DMSO-*d*₆) 11.7 (1H, br s), 7.89 (1H, s), 7.72 (1 H, d, J = 8.2 Hz), 7.65 (1 H, m), 7.32 (1 H, m), 6.59 (1H, m); MS m/e

141 (M-H)⁺. Anal calcd. for C₉H₆N₂ • 0.10 H₂O: C, 75.09; H, 4.34; N, 19.46. Found: C, 74.92; H, 4.29; N, 19.34.

(6-Cyanoindol-3-yl)carboxaldehyde was prepared in 64 % yield from 6-cyano-1H-indole in a similar manner to (5-cyanoindol-3-yl)carboxaldehyde in
5 Example 1. ¹H NMR (400 MHz, DMSO-d₆) 12.5, (1H, br s), 10.0 (1 H, s), 8.55 (1 H, m), 8.23 (1 H, d, J = 8.2 Hz), 8.04 (1 H, m), 7.58 (1 H, dd, J = 8.2, 1.4 Hz); MS m/e 169 (M-H)⁺. Anal calcd. for C₁₀H₆N₂O • 0.10 H₂O: C, 69.84; H, 3.63; N, 16.29. Found: C, 69.68; H, 3.54; N, 16.36.

(6-cyano-1-(p-toluenesulfonyl)indol-3-yl)carboxaldehyde was prepared in an
10 88% yield from (6-cyanoindol-3-yl)carboxaldehyde in a similar manner to (5-cyano-1-(p-toluenesulfonyl)indol-3-yl)carboxaldehyde in Example 1. ¹H NMR (400 MHz, DMSO-d₆) 10.1 (1 H, s), 9.14 (1 H, s), 8.46 (1 H, s), 8.27 (1 H, d, J = 8.2 Hz), 8.16 (2 H, d, J = 8.4 Hz), 7.81 (1 H, dd, J = 8.2, 1.3 Hz), 7.48 (2 H, d, J = 8.2 Hz), 2.36 (3H, s); MS m/e 323 (M-H)⁺.


15 (E)-[6-cyano-1-(p-toluenesulfonyl)indol-3-yl]-N-methoxy-N-methylacrylamide was prepared in a 77% yield from (6-cyano-1-(p-toluenesulfonyl)indol-3-yl)carboxaldehyde in a similar manner to (E)-[5-cyano-1-(p-toluenesulfonyl)indol-3-yl]-N-methoxy-N-methylacrylamide in Example 1. ¹H NMR (300 MHz, DMSO-d₆) 8.77 (1 H, s), 8.42 (1 H, m), 8.07 (3 H, dd, J = 8.5, 2.4 Hz),
20 7.73 (2 H, m), 7.45 (2 H, d, J = 8.2 Hz), 7.20 (1 H, d, J = 16 Hz), 3.77 (3 H, s), 3.23 (3H, s), 2.34 (3H, s); MS m/e 408 (M-H)⁺. Anal calcd. for C₂₁H₁₉N₃O₄S: C, 61.60; H, 4.67; N, 10.26. Found: C, 61.43; H, 4.56; N, 10.05.

Racemic [*trans*-2-[6-cyano-1-(p-toluenesulfonyl)indol-3-yl]cycloprop-1-yl]-
25 N-methoxy-N-methylcarboxamide was prepared in a 64% yield from (E)-[6-cyano-1-(p-toluene-sulfonyl)indol-3-yl]-N-methoxy-N-methylacrylamide in a similar manner to [*trans*-2-[5-cyano-1-(p-toluenesulfonyl)indol-3-yl]cycloprop-1-yl]-N-methoxy-N-methyl-carboxamide in Example 1. ¹H NMR (400 MHz, DMSO-d₆) 8.33 (1 H, d, J = 1.0 Hz), 7.98 (3 H, m), 7.83 (1 H, m), 7.67 (1 H, dd, J = 8.2, 1.3 Hz), 7.41 (2H, d, J =
30 8.1 Hz), 3.63 (3 H, s), 3.15 (3H, s), 2.40 (2H, m), 2.33 (3 H, s), 1.45 (2 H, m); MS m/e 422 (M-H)⁺. Anal calcd. for C₂₂H₂₁N₃O₄S: C, 62.39; H, 4.99; N, 9.92. Found: C, 62.15; H, 4.78; N, 9.84.

- Racemic [trans-2-[6-cyano-1-(p-toluenesulfonyl)indol-3-yl]-cyclopropane carboxaldehyde was prepared in a 37% yield from racemic [trans-2-[6-cyano-1-(p-toluenesulfonyl)indol-3-yl]cycloprop-1-yl]-N-methoxy-N-methyl-carboxamide in a similar manner to [trans-2-[5-cyano-1-(p-toluenesulfonyl)indol-3-yl]cyclopropane-carboxaldehyde in Example 1. ¹H NMR (400 MHz, DMSO-d₆) 9.11 (1 H, d, J = 5.5 Hz), 8.33 (1 H, d, J = 1.0 Hz), 7.99 (3 H, m), 7.88 (1 H, d, J = 8.1 Hz), 7.69 (1 H, dd, J = 8.2, 1.4 Hz), 7.41 (2H, d, J = 8.0 Hz), 2.76 (1H, m), 2.33 (3H, s), 2.14 (1 H, m), 1.70 (2H, m); MS m/e 363 (M-H)⁺. Anal calcd. for C₂₀H₁₆N₂O₃S: C, 65.91; H, 4.42; N, 7.68. Found: C, 65.91; H, 4.45; N, 7.47.
- Racemic [trans-2-[6-cyanoindol-3-yl]-1-(N-methylaminomethyl)cyclopropane was prepared in two steps and 33 % overall yield from racemic [trans-2-[6-cyano-1-(p-toluenesulfonyl)indol-3-yl]-cyclopropane-carboxaldehyde following the procedures outlined for the preparation of (1S,2S)-trans-2-[5-cyanoindol-3-yl]-1-(N-methylaminomethyl)-cyclopropane in Example 1. LC-MS (column = Phenomenex Luna C18 S5, 4.6 x 50 mm, start %B = 0, final %B = 100, gradient time = 3 min, flow rate = 5 mL/min) m/e 266 (M + H)⁺, t_R 1.07 min.

Example 159


3-(2-Ethylaminomethyl-cyclopropyl)-1H-indole-6-carbonitrile



- Racemic [trans-2-[6-cyanoindol-3-yl]-1-(N-ethylaminomethyl)-cyclopropane was prepared in 35% overall yield in a manner similar to the above example. LC-MS (column = Phenomenex Luna C18 S5, 4.6 x 50 mm, start %B = 0, final %B = 100, gradient time = 3 min, flow rate = 5 mL/min) m/e 240 (M + H)⁺, t_R 1.08 min.

Example 160


3-(2-Diethylaminomethyl-cyclopropyl)-1H-indole-6-carbonitrile



Racemic [*trans*-2-[6-cyanoindol-3-yl]-1-(N,N-diethylaminomethyl)-cyclopropane was prepared in 60 % overall yield in a manner similar to the above example. LC-MS (column = Phenomenex Luna C18 S5, 4.6 x 50 mm, start %B = 0, final %B = 100, gradient time = 3 min, flow rate = 5 mL/min) m/e 268 (M + H)⁺, t_R 1.10 min.

Example 161


3-{2-[(Ethyl-methyl-amino)-methyl]-cyclopropyl}-1H-indole-6-carbonitrile



Racemic [*trans*-2-[6-cyanoindol-3-yl]-1-(N-ethyl-N-methylaminomethyl)-cyclopropane was prepared in 55 % overall yield in a manner similar to the above example. LC-MS (column = Phenomenex Luna C18 S5, 4.6 x 50 mm, start %B = 0, final %B = 100, gradient time = 3 min, flow rate = 5 mL/min) m/e 254 (M + H)⁺, t_R 1.05 min.

Example 162


3-{2-[(Benzyl-methyl-amino)-methyl]-cyclopropyl}-1H-indole-6-carbonitrile



Racemic [*trans*-2-[6-cyanoindol-3-yl]-1-(N-benzyl-N-methylaminomethyl)-cyclopropane was prepared in 70% overall yield in a manner similar to the above example. LC-MS (column = Phenomenex Luna C18 S5, 4.6 x 50 mm, start %B = 0, final %B = 100, gradient time = 3 min, flow rate = 5 mL/min) m/e 316 (M + H)⁺, t_R 1.34 min.

Example 163

3-(2-Dimethylaminomethyl-cyclopropyl)-1H-indazole-5-carbonitrile



n-BuLi (1.9 M, 26.3 mL, 50 mmol) was added dropwise to a solution of diisopropylamine (7.71 mL, 55 mmol) in 100 mL anhydrous THF under N₂ at 0°C. After 10 minutes, the reaction was cooled to -78°C. A solution of 4-fluorobenzonitrile (6.06 g, 50 mmol) in 20 mL anhydrous THF was added dropwise, at such a rate to maintain an internal temperature of -78°C. After stirring for 1 h at this temperature, trimethyl borate (8.41 mL, 75 mmol) was added dropwise at such a rate to maintain an internal temperature of -78°C. The reaction was stirred and gradually warmed to room temperature over 16 h. The reaction was cooled to 10°C and 25 mL 6N HCl was added. After stirring at room temperature for 4 h, the reaction was partitioned between water and ethyl acetate. The organic layer was washed three times with 100 mL 2N NaOH. The aqueous layers were pooled and adjusted to pH 6 with 6N HCl. The white solid which forms was extracted by three washes of 100 mL Ethyl acetate. The organic layers were pooled, dried over sodium sulfate, concentrated and dried under high vacuum to give 2-fluoro-5-cyanophenyl boronic acid (5.74 g, 70%). ¹H NMR (500 MHz, acetone-d₆) 8.08 (1 H, dd, J = 2.14, 5.5 Hz), 7.90 (1 H, m), 7.31 (1 H, t, J = 8.85 Hz). Anal. calcd. for C₇H₅BFNO₂: C, 50.97; H, 3.05; N, 8.49. Found: C, 51.19; H, 3.19; N, 8.26.

To a solution of 2-chlorocarbonyl-cyclopropanecarboxylic acid ethyl ester (5.30 g, 30 mmol) and 4-methylbenzene thiol (3.73 g, 30 mmol) in 150 mL hexane at 0°C was added a solution of Et₃N in 25 mL hexane dropwise. The reaction was warmed to room temperature and stirred for 3 h. The solid precipitate was removed by filtration and washed with hexane. The filtrate was concentrated *in vacuo* to give 7.88 g (99%) of 2-p-tolylsulfanylcarbonyl-cyclopropanecarboxylic acid ethyl ester as an oil: ¹H NMR (500 MHz, CDCl₃) 7.30 (2 H, d, J = 7.93 Hz), 7.22 (2 H, d, J = 7.93 Hz), 4.17 (2 H, q, J = 7.02 Hz), 2.60 (1 H, m), 2.37 (3 H, s), 2.31 (1 H, m), 1.54 (2 H, m), 1.29 (3 H, t, J = 7.02 Hz). MS m/e 262.92 (M - H)⁺. Anal. calcd. for C₁₄H₁₆O₃S: C, 63.61; H, 6.10. Found: C, 63.68; H, 6.17.

To a mixture of 2-fluoro-5-cyanophenyl boronic acid (3.10 g, 18.8 mmol), 2-p-tolylsulfanylcarbonyl-cyclopropanecarboxylic acid ethyl ester (3.30 g, 12.5 mmol), copper thiophene-2-carboxylate (3.58 g, 18.8 mmol), tris(dibenzylideneacetone)-dipalladium(0)•CHCl₃ adduct (150 mg, 0.14 mmol), and tri-2-furyl phosphine (0.86 mmol) under N₂ was added 125 mL anhydrous THF. The reaction was stirred for 4

h, then poured into 500 mL water and extracted with 500 mL Et₂O. The organic layer was extracted with 0.1 N HCl, water, saturated NaHCO₃, and water. The organic extract was dried over sodium sulfate, concentrated, and purified by flash chromatography on silica gel using ethyl acetate/hexane (0-10%) as the eluent to yield 2-(5-cyano-2-fluoro-benzoyl)-cyclopropanecarboxylic acid ethyl ester (2.17 g, 66%). ¹H NMR (500 MHz, CDCl₃) 8.09 (1 H, dd, J = 2.14, 6.41 Hz), 7.83 (1 H, m), 7.31 (1 H, dd, J = 8.55, 10.07 Hz), 4.18 (2 H, q, J = 7.02 Hz), 3.10 (1 H, m), 2.42 (1 H, m), 1.68 (2 H, m), 1.28 (3 H, t, J = 7.02 Hz). Anal. calcd. for C₁₄H₁₂FNO₃: C, 64.36; H, 4.63; N, 5.36. Found: C, 64.62; H, 4.53; N, 5.26.

2-(5-cyano-2-fluoro-benzoyl)-cyclopropanecarboxylic acid ethyl ester (1.62 g, 6.2 mmol) and p-toluenesulfonhydrazide (2.31 g, 12.4 mmol) were refluxed in 50 mL ethanol for 36 h. The reaction was concentrated *in vacuo*, then purified by flash chromatography on silica gel using ethyl acetate/hexane (0-25%) as the eluent to give 2-[1-(5-cyano-2-fluoro-phenyl)-2-(toluene-4-sulfonylamino)-vinyl]-cyclopropanecarboxylic acid ethyl ester (1.77 g, 66%) as a mixture of cis and trans isomers. ¹H NMR (500 MHz, CDCl₃) 7.87 (1 H, d, J = 8.24 Hz), 7.78 (0.5 H, m), 7.76 (1 H, d, J = 8.24 Hz), 7.65 (0.5 H, m), 7.61 (0.5 H, dd, J = 2.14, 6.71 Hz), 7.44 (0.5 H, dd, J = 2.14, 5.80 Hz), 7.36 (2 H, dd, J = 3.96, 7.93 Hz), 7.31 (0.5 H, t, J = 8.54 Hz), 7.18 (0.5 H, t, J = 8.54 Hz), 4.22 (1 H, m), 4.12 (2 H, dq, J = 7.32, 4.27 Hz), 2.46 (3 H, 2s), 2.20 (0.5 H, m), 1.99 (0.5 H, m), 1.66 (0.5 H, m), 1.43 (0.5 H, m), 1.31 (2 H, m), 1.27 (3 H, dt, J = 7.02, 3.67 Hz). MS m/e 430.13 (M + H)⁺.

2-[1-(5-Cyano-2-fluoro-phenyl)-2-(toluene-4-sulfonylamino)-vinyl]-cyclopropane-carboxylic acid ethyl ester (1.84 g, 4.3 mmol) and K₂CO₃ (1.8 g, 13 mmol) were stirred in 10 mL anhydrous DMF for 15 minutes. The reaction was poured into 150 mL saturated Na₂CO₃ solution and extracted three times with 75 mL Ethyl acetate. The organic layers were pooled and extracted three times with 75 mL brine, then dried over Mg₂SO₄. Flash chromatography on silica gel with a step gradient of 0-15% Ethyl acetate in hexane yielded 2-(1-benzenesulfonyl-5-cyano-1H-indazol-3-yl)-cyclopropanecarboxylic acid ethyl ester (796 mg, 45%). ¹H NMR (500 MHz, CDCl₃) 8.27 (1 H, d, J = 8.86 Hz), 8.07 (1 H, s), 7.83 (2 H, d, J = 8.24 Hz), 7.76 (1 H, dd, J = 8.85, 1.52 Hz), 7.28 (2 H, d, J = 8.24 Hz), 4.2 (2 H, q, J = 7.02 Hz), 2.71 (1 H, m), 2.39 (3 H, s), 2.30 (1 H, m), 1.67 (2 H, m), 1.29 (3 H, t, J = 7.02 Hz). MS m/e

410.0 (M + H)⁺. Anal. calcd. for C₂₁H₁₉N₃O₄S: C, 61.60; H, 4.67; N, 10.26. Found: C, 61.63; H, 4.89; N, 10.07.

2-(1-Benzenesulfonyl-5-cyano-1H-indazol-3-yl)-cyclopropanecarboxylic acid ethyl ester (1.12 g, 2.74 mmol) was dissolved in 30 mL anhydrous THF under N₂ and cooled to -40°C. LAH (0.83 g, 22 mmol) was added portionwise over a 15 min. period. The reaction was stirred for 5 h at -40°C, then quenched with 50 mL ethyl acetate, followed by 10 mL water. After stirring at room temperature for 30 min, 50 mL saturated tartrate solution was added and stirred for 30 min. The precipitate was removed by filtration and washed with ethyl acetate. The precipitate was washed with more ethyl acetate, and the organic layer was washed with brine and dried over Na₂SO₄. Flash chromatography on silica gel using ethyl acetate/hexane (25-50%) as the eluent gave 3-(2-hydroxymethyl-cyclopropyl)-1-(toluene-4-sulfonyl)-1H-indazole-5-carbonitrile (580 mg, 58%). ¹H NMR (500 MHz, CDCl₃) 8.26 (1 H, d, J = 8.85 Hz), 8.08 (1 H, s), 7.83 (2 H, d, J = 8.24 Hz), 7.74 (1 H, dd, J = 8.85, 1.22 Hz), 7.27 (2 H, d, J = 8.24 Hz), 3.78 (1 H, dd, J = 11.29, 6.10 Hz), 3.61 (1 H, dd, 11.29, 6.71 Hz), 2.38 (3 H, s), 2.10 (1 H, p, J = 4.88 Hz), 1.82 (1 H, m), 1.39 (1 H, dt, J = 8.55, 4.88 Hz), 1.11 (1 H, dt, J = 8.55, 4.88 Hz). MS m/e 366.15 (M - H)⁻. Anal. calcd. for C₁₉H₁₇N₃O₃S: C, 62.11; H, 4.66; N, 11.43. Found: C, 62.16; H, 4.76; N, 11.19.


Anhydrous DMSO (0.20 mL, 2.8 mmol) was added dropwise to a solution of oxalyl chloride (0.21 mL, 2.4 mmol) in 20 mL anhydrous CH₂Cl₂ under N₂ at -78°C and stirred for 30 min. A solution of 3-(2-hydroxymethyl-cyclopropyl)-1-(toluene-4-sulfonyl)-1H-indazole-5-carbonitrile (634 mg, 1.63 mmol) in 20 mL anhydrous CH₂Cl₂ was then added and stirring continued for 40 min. at -78°C. Et₃N (1.25 mL, 8.98 mmol) was added and stirring continued for 10 min at -78°C. The reaction was warmed to room temperature and 25 mL water was added. The layers were partitioned, and the aqueous layer was extracted with CH₂Cl₂. The organic layers were pooled, extracted with brine, and dried over MgSO₄, and concentrated *in vacuo* to give 3-(2-formyl-cyclopropyl)-1-(toluene-4-sulfonyl)-1H-indazole-5-carbonitrile (637 mg, 100%). ¹H NMR (500 MHz, CDCl₃) 9.54 (1 H, d, J = 3.66 Hz), 8.20 (1 H, d, J = 8.85 Hz), 8.05 (1 H, s), 7.83 (2 H, d, J = 8.24 Hz), 7.77 (1 H, dd, J = 8.85, 1.53

Hz), 7.29 (2 H, d, $J = 8.24$ Hz), 2.82 (1 H, m), 2.62 (1 H, m), 2.39 (3 H, s), 1.82 (2 H, m).

3-(2-Formyl-cyclopropyl)-1-(toluene-4-sulfonyl)-1H-indazole-5-carbonitrile (74 mg, 0.2 mmol) was dissolved in 2 mL ethanol and 2 mL THF, and to this was added a 2.0 M solution of dimethylamine in THF (1.0 mL, 2.0 mmol). After stirring for 5 min, sodium triacetoxyborohydride (170 mg, 0.8 mmol) was added the reaction continued for 2 h. At this point, 1 mL water, 1 mL 50% NaOH, and 2 mL MeOH were added and stirring continued for 30 min. The reaction was then diluted with 20 mL water and extracted three times with 30 mL ethyl acetate. The organic layers were pooled, washed with brine, dried over Na_2SO_4 , and concentrated *in vacuo*. Purification by preparative reverse phase HPLC gave 3-(2-dimethylaminomethyl-cyclopropyl)-1H-indazole-5-carbonitrile as an oily trifluoroacetic acid salt (54 mg, 76%). ^1H NMR (500 MHz, $\text{d}_4\text{-MeOH}$) 8.33 (1 H, s), 7.59 (2 H, s), 3.31 (2 H, d, $J = 7.63$ Hz), 2.97 (6 H, d, $J = 2.74$ Hz), 2.48 (1 H, m), 1.84 (1 H, m), 1.47 (1 H, dt, $J = 8.55, 5.19$ Hz), 1.24 (1 H, dt, $J = 8.85, 5.19$). LC-MS: 0.73 min; 241.17 (MH)+.


Example 164

3-{2-[(Ethyl-methyl-amino)-methyl]-cyclopropyl}-1H-indazole-5-carbonitrile




3-{2-[(Ethyl-methyl-amino)-methyl]-cyclopropyl}-1H-indazole-5-carbonitrile was prepared (54 mg, 73%) in a manner and scale similar to the above example. ^1H NMR (500 MHz, $\text{d}_4\text{-MeOH}$) 8.34 (1 H, s), 7.61 (2 H, s), 3.38 (2 H, m), 3.24 (2 H, m), 2.94 (3 H, d, $J = 2.44$ Hz), 2.48 (1 H, m), 1.84 (1 H, m), 1.48 (1 H, dt, $J = 8.85, 5.19$ Hz), 1.36 (3 H, t, $J = 7.33$ Hz), 1.25 (1 H, m). LC-MS: 0.78 min; 255.17 (MH)+.

-124-

Example 165**3-(2-Diethylaminomethyl-cyclopropyl)-1H-indazole-5-carbonitrile**


3-(2-Diethylaminomethyl-cyclopropyl)-1H-indazole-5-carbonitrile was prepared (45 mg, 59%) in a manner and scale similar to the above example. ¹H NMR (500 MHz, d4-MeOH) 8.34 (1 H, s), 7.60 (2 H, s), 3.33 (6 H, m), 2.49 (1 H, m), 1.83 (1 H, m), 1.47 (1 H, dt, J = 8.54, 5.19 Hz), 1.36 (6 H, t, J = 7.32 Hz), 1.25 (1 H, m). LC-MS: 0.82 min; 269.19 (MH)⁺.

10

Example 166**3-(2-Pyrrolidin-1-ylmethyl-cyclopropyl)-1H-indazole-5-carbonitrile**

3-(2-Pyrrolidin-1-ylmethyl-cyclopropyl)-1H-indazole-5-carbonitrile was prepared (41 mg, 54%) in a manner and scale similar to the above example. ¹H NMR (500 MHz, d4-MeOH) 8.34 (1 H, s), 7.60 (2 H, s), 3.72 (2 H, m), 3.36 (2 H, d, J = 7.32 Hz), 3.18 (2 H, m), 2.48 (1 H, m), 2.17 (2 H, m), 2.03 (2 H, m), 1.86 (1 H, m), 1.45 (1 H, dt, J = 8.55, 5.19 Hz), 1.24 (1 H, m). LC-MS: 0.79 min; 267.18 (MH)⁺.

20

Example 167**(2-Benzo[b]thiophen-3-yl-cyclopropylmethyl)-dimethyl-amine**

Diethyl (*N*-methoxy-*N*-methylcarbamoylmethyl)phosphonate (6.13 g, 25.6 mmol) was added dropwise via syringe to a stirred suspension of sodium hydride (1.02 g, 25.6 mmol) in anhydrous THF (75 ml) at 0 °C. The reaction was warmed to room temperature and was stirred for 1 h. After cooling to 0°C, benzo[b]thiophene-3-carbaldehyde (3.78 g, 23.3 mmol) was added. The resulting mixture was stirred at room temperature for 1 hr. The reaction was quenched with 100 mL aqueous HCl (0.1 N) and extracted with ethyl acetate (250 ml). The combined organic layers were

washed with brine (50 ml) and dried over anhydrous magnesium sulfate. The filtrate was concentrated *in vacuo* and triturated with hexane to give (*E*)-3-benzo[b]thiophen-3-yl-N-methoxy-N-methyl-acrylamide (5.38 g, 93%) as a yellow solid. ¹H NMR (500 MHz, CDCl₃) 8.06-8.01 (2 H, 2 superimposed d, J = 8.24, 15.87 Hz), 7.89 (1 H, d, J = 7.94 Hz), 7.78 (1 H, s), 7.47 (1 H, t, J = 7.93 Hz), 7.41 (1 H, t, J = 8.24 Hz), 7.13 (1 H, d, J = 15.87 Hz), 3.79 (3 H, s), 3.34 (3 H, s); MS m/e 248.07 (M + H)⁺.

The following procedure was carried out behind a safety shield using plastic coated glassware free of scratches and ground glass joints. 1-Methyl-3-nitro-1-nitrosoguanidine (14.4 g, 98 mmol) was carefully added portionwise over 30 min to a Erlenmeyer flask containing a swirled mixture of aqueous sodium hydroxide (100 ml, 5 N) and diethyl ether (250 ml) at 0°C. After vigorous bubbling had ceased, the organic layer (containing diazomethane) was decanted into a chilled (0°C) Erlenmeyer flask containing potassium hydroxide chips (20 g). The mixture was swirled for 10 min and the yellow solution was decanted into a dropping funnel. The solution of diazomethane was added over 30 min to an open flask containing a stirred mixture of (*E*)-3-benzo[b]thiophen-3-yl-N-methoxy-N-methyl-acrylamide (4.85 g, 19.6 mmol) and palladium acetate (170 mg, 0.76 mmol) in dichloromethane (200 ml) maintained at 0 °C. After stirring for 1 h, a second batch of freshly prepared diazomethane (98 mmol) in ~250 ml of diethyl ether was added over 30 min. After stirring for 18 h, the reaction was quenched with glacial acetic acid (4 ml) and poured into an aqueous saturated solution of sodium bicarbonate (250 ml). The aqueous layer was extracted with ethyl acetate (3 x 100 ml). The organic layers were washed with brine, dried over anhydrous magnesium sulfate, and concentrated *in vacuo*. The crude product was purified by flash chromatography on silica gel with a step gradient of 10-25% ethyl acetate in hexane to give, after concentration and drying under high vacuum, 2-benzo[b]thiophen-3-yl-cyclopropanecarboxylic acid methoxy-methyl-amide (3.51 g, 69%). ¹H NMR (500 MHz, CDCl₃) 7.90 (1 H, d, J = 7.32 Hz), 7.84 (1 H, d, J = 7.33 Hz), 7.39 (2 H, m), 7.05 (1 H, s), 3.71 (3 H, s), 3.28 (3 H, s), 2.71 (1 H, m), 2.41 (1 H, m), 1.66 (1 H, m), 1.37 (1 H, m); MS m/e 262.10 (M + H)⁺.


Powdered lithium aluminum hydride (3.05 g, 80.4 mmol) was carefully added portionwise to a stirred solution of 2-benzo[b]thiophen-3-yl-cyclopropanecarboxylic acid methoxy-methyl-amide (3.50 g, 13.4 mmol) in anhydrous tetrahydrofuran (300 ml) at -40 °C under N₂. The resulting mixture was stirred at -40 °C for 3 h. The

reaction was quenched with ethyl acetate (100 ml) and allowed to warm to room temperature. After 20 min, water (5 ml) was added followed by a solution of aqueous sodium hydroxide (5N, 5 ml). After stirring for 30 min at room temperature the aluminum salts were removed by vacuum filtration. The salts were washed with ethyl acetate (100 ml) and the combined filtrates were concentrated *in vacuo*. The crude material was purified by silica gel column chromatography (10% ethyl acetate in hexane) to give trans-2-benzo[b]thiophen-3-yl-cyclopropanecarbaldehyde (2.02 g, 75%). ¹H NMR (500 MHz, CDCl₃) 9.48 (1 H, d, J = 4.57 Hz), 7.84 (2 H, dd, J = 17.09, 7.33 Hz), 7.41 (2 H, m), 2.80 (1 H, m), 2.17 (1 H, m), 1.78 (1 H, m), 1.59 (1 H, m); MS m/e 203.22 (M + H)⁺.

Trans-2-benzo[b]thiophen-3-yl-cyclopropanecarbaldehyde (202 mg, 1.0 mmol) was dissolved in 10 mL ethanol. To this solution was added a 2.0 M solution of dimethylamine in THF (5.0 mL, 10.0 mmol). After stirring for 15 min, sodium triacetoxyborohydride (850 mg, 4.0 mmol) was added and the reaction continued for 1 h. The reaction was diluted with 10 mL 0.1 N HCl, then solid sodium bicarbonate was added in portions to adjust pH to 7. The mixture was extracted with ethyl acetate (2 X 20 mL), and the organic extracts were pooled, washed with brine, dried over sodium sulfate, and concentrated *in vacuo*. Purification by preparative reverse phase high-performance liquid chromatography afforded (2-benzo[b]thiophen-3-yl-cyclopropylmethyl)-dimethyl-amine (246 mg, 71%) as an oily trifluoroacetic acid salt. ¹H NMR (500 MHz, d₄-MeOH) 7.94 (1 H, d, J = 7.94 Hz), 7.86 (1 H, d, J = 7.93 Hz), 7.42 (1 H, t, J = 7.94), 7.37 (1 H, t, J = 7.94), 7.21 (1 H, s), 3.44 (1 H, dd, J = 13.12, 6.71 Hz), 3.22 (1 H, dd, J = 13.12, 8.24 Hz), 2.97 (6 H, s), 2.28 (1 H, p, J = 4.6 Hz), 1.56 (1 H, m), 1.20 (2 H, m). LC-MS: 1.10 min; 232.2 (MH)⁺.

Example 168

(2-Benzo[b]thiophen-3-yl-cyclopropylmethyl)-methyl-amine




(2-Benzo[b]thiophen-3-yl-cyclopropylmethyl)-methyl-amine was prepared (191 mg, 58%) in a manner and scale similar to the above example. ¹H NMR (500 MHz, d₄-MeOH) 8.00 (1 H, d, J = 7.94 Hz), 7.91 (1 H, d, J = 7.93 Hz), 7.47 (1 H, t, J

-127-


= 7.94), 7.42 (1 H, t, J = 7.94), 7.23 (1 H, s), 3.34 (1 H, dd, J = 13.12, 7.02 Hz), 3.14 (1 H, dd, J = 12.82, 7.94 Hz), 2.82 (3 H, s), 2.29 (1 H, p, J = 4.9 Hz), 1.54 (1 H, m), 1.20 (2 H, m). LC-MS: 1.12 min; 218.12 (MH)⁺.

5

Example 169**(2-Benzo[b]thiophen-3-yl-cyclopropylmethyl)-ethyl-amine**


(2-Benzo[b]thiophen-3-yl-cyclopropylmethyl)-ethyl-amine was prepared (184 mg, 53%) in a manner and scale similar to the above example. ¹H NMR (500 MHz, d4-MeOH) 7.94 (1 H, d, J = 7.63 Hz), 7.85 (1 H, d, J = 7.94 Hz), 7.42 (1 H, t, J = 7.93), 7.36 (1 H, t, J = 7.93), 7.17 (1 H, s), 3.31 (1 H, m [partially obscured by solvent peak]), 3.13 (2 H, q, J = 7.32 Hz), 3.07 (1 H, dd, J = 12.82, 7.94 Hz), 2.23 (1 H, m), 1.48 (1 H, m), 1.34 (3H, t, J = 7.32 Hz), 1.15 (2 H, t, J = 7.32 Hz). LC-MS: 1.16 min; 232.15 (MH)⁺.

15

Example 170**(2-Benzo[b]thiophen-3-yl-cyclopropylmethyl)-ethyl-methyl-amine**


(2-Benzo[b]thiophen-3-yl-cyclopropylmethyl)-ethyl-methyl-amine was prepared (274 mg, 76%) in a manner and scale similar to the above example. ¹H NMR (500 MHz, d4-MeOH) 7.94 (1 H, d, J = 7.94 Hz), 7.86 (1 H, d, J = 7.94 Hz), 7.42 (1 H, t, J = 7.93), 7.37 (1 H, t, J = 7.93), 7.21 (1 H, s), 3.52 (0.5 H, dd, J = 13.43, 6.71 Hz), 3.39 (1.5 H, m), 3.22 (2 H, m), 2.95 (3 H, s), 2.28 (1 H, m), 1.55 (1 H, m), 1.37 (3H, t, J = 7.33 Hz), 1.20 (2 H, m). LC-MS: 1.14 min; 246.14 (MH)⁺.

25

Example 171**(2-Benzo[b]thiophen-3-yl-cyclopropylmethyl)-diethyl-amine**

-128-


(2-Benzo[b]thiophen-3-yl-cyclopropylmethyl)-diethyl-amine was prepared (314 mg, 84%) in a manner and scale similar to the above example. ¹H NMR (500 MHz, d₄-MeOH) 7.94 (1 H, d, J = 7.93 Hz), 7.84 (1 H, d, J = 7.93 Hz), 7.41 (1 H, t, J = 7.93), 7.35 (1 H, t, J = 7.93), 7.19 (1 H, s), 3.45 (1 H, dd, J = 13.73, 6.71 Hz), 3.33 (4 H, m), 3.22 (1 H, dd, J = 13.74, 7.93 Hz), 2.28 (1 H, m), 1.52 (1 H, m), 1.34 (6H, 2t, J = 7.33 Hz), 1.19 (2 H, m). LC-MS: 1.17 min; 260.16 (MH)⁺.

Example 172**1-(2-Benzo[b]thiophen-3-yl-cyclopropylmethyl)-pyrrolidine**

10

1-(2-Benzo[b]thiophen-3-yl-cyclopropylmethyl)-pyrrolidine was prepared (318 mg, 86%) in a manner and scale similar to the above example. ¹H NMR (500 MHz, d₄-MeOH) 7.93 (1 H, d, J = 7.93 Hz), 7.84 (1 H, d, J = 7.93 Hz), 7.41 (1 H, t, J = 7.93), 7.35 (1 H, t, J = 7.93), 7.18 (1 H, s), 3.70 (2 H, m), 3.44 (1 H, dd, J = 13.12, 6.71 Hz), 3.26 (1 H, dd, J = 13.12, 7.94 Hz), 3.15 (2 H, m), 2.25 (1 H, m), 2.15 (2 H, m), 2.02 (2 H, m), 1.55 (1 H, m), 1.15 (2H, m). LC-MS: 1.15 min; 258.13 (MH)⁺.

15

Example 174***Trans*-2-[5-cyanoindol-3-yl]-1-(3-(N,N-dimethylamino)propyl)cyclopropane**

20

Sodium hydride (60% in oil, 120 mg, .02 mmol) was washed with hexanes to remove oil and was then suspended in THF (60 mL). Triethylphosphonoacetate (0.60 mL, 3.02 mmol) was added dropwise and the solution was stirred for 1.5 h. *Trans*-2-[5-Cyano-1-(*p*-toluenesulfonyl)indol-3-yl]cyclopropane-carboxaldehyde (1.0g, 2.74 mmol) was added as a solid and the reaction stirred for a further 3 h. The solvent was removed *in vacuo* and the residue was taken up in water (20 mL) and extracted with ethyl acetate (3 x 20 mL). The organic layer was dried and the solvent was removed *in vacuo*. The material was purified by chromatography on silica gel (20% ethyl acetate in hexanes) to provide 0.91 g (76%) of ethyl *trans*-2-[5-cyano-1-(*p*-toluenesulfonyl)indol-3-yl]cyclopropaneacrylate as a white solid: ¹H NMR (400

25

30

MHz, CDCl₃) 8.04 (1 H, d, J = 8.6 Hz), 7.87 (1 H, s,), 7.75 (2 H, d, J = 6.7 Hz), 7.57 (1 H, dd, J = 8.6, 1.6 Hz), 7.36 (1 H, s), 7.27 (2 H, d, J = 6.8 Hz), 6.61 (1 H, dd, J = 15.4, 9.8 Hz), 5.96 (1 H, d, J = 15.4 Hz), 4.21 (2 H, q, J = 7.1 Hz), 2.37 (3 H, s), 2.10 (1 H, m), 1.75 (1 H, m), 1.42 (1 H, m), 1.34 (1 H, m), 1.32 (3 H, t, J = 7.0 Hz); MS m/e 457.1 (M+ Na).

Trans-2-[5-cyano-1-(*p*-toluenesulfonyl)indol-3-yl]cyclopropaneacrylate (850 mg, 1.96 mmol) was dissolved in THF and cooled to -40 °C. Lithium aluminum hydride was added and the reaction stirred at -25 °C for 30 min. The reaction was quenched with ethyl acetate (20 mL) and stirred 10 min. Then water (0.15 mL) was added and the reaction stirred 2 min. Sodium hydroxide (1N, 0.45 mL) was added and the reaction was stirred 2 min, followed by final addition of water (0.15 mL) and stirring 15 min. The reaction was filtered through celite and sand and the filtrate was evaporated. The residue was dissolved in ethyl acetate (5 mL) and then ethanol (20 mL) and 10% palladium on carbon (200 mg) were added. The reaction was stirred under an atmosphere of hydrogen for 1 h. The reaction was filtered through celite and sand and the filtrate was evaporated. The residue was purified on a silica gel column (33% to 40% ethyl acetate in hexanes) to provide 318 mg of a 1:1 mixture of *Trans*-2-[5-cyanoindol-3-yl]-1-(3-hydroxypropyl)cyclopropane and an unidentified compound: ¹H NMR (400 MHz, CDCl₃) 8.04 (0.5 H, d, J = 7.6 Hz), 8.02 (0.5 H, d, J = 8.0 Hz), 7.92 (0.5 H, s), 7.85 (0.5 H, s), 7.74 (2 H, d, J = 8.4 Hz), 7.52 (1 H, m), 7.42 (0.5 H, s), 7.25 (2 H, d, J = 8.0 Hz), 7.25 (0.5 H, buried), 3.72 (1 H, t, J = 6.5 Hz), 3.61 (1 H, t, J = 6.4 Hz), 2.92 (0.5 H, 6 peaks, J = 6.9 Hz), 2.36 (3 H, s), 1.78-1.24 (6 H, m), 1.04 (0.5 H, m), 0.90 (0.5 H, m), 0.83 (0.5 H, m); MS m/e 417.1 (M+ Na).

Oxalyl chloride (0.10 mL, 1.19 mmol) in methylene chloride (50 mL) was cooled to -78 °C and DMSO (0.095 mL, 1.34 mmol) was added dropwise. After stirring 10 min, an impure sample of *Trans*-2-[5-cyanoindol-3-yl]-1-(3-hydroxypropyl)cyclopropane (318 mg) in methylene chloride (5 mL) was added dropwise. Stirred 20 min and added triethylamine (0.61 mL) dropwise. Allowed reaction to slowly warm to room temperature and added water (10 mL). The organic layer was dried with magnesium sulfate and the solvent was removed *in vacuo*. The residue was purified by chromatography on silica gel (33% to 40% ethyl acetate in


-130-

hexanes) to give 296 mg of a 1:1 mixture of *Trans*-2-[5-cyanoindol-3-yl]-1-(3-oxopropyl)cyclopropane and an unknown compound: ^1H NMR (400 MHz, CDCl_3) 9.85 (0.5 H, t, $J = 1.4$ Hz), 9.73 (0.5 H, t, $J = 1.4$ Hz), 8.04 (0.5 H, d, $J = 8.7$ Hz), 8.03 (0.5 H, $J = 8.7$ Hz), 7.90 (0.5 H, s), 7.83 (0.5 H, s), 7.75 (2 H, m), 7.54 (1 H, m), 7.45 (0.5 H, s), 7.25 (2.5 H, buried), 2.93 (0.5 H, 6 peaks 7.0 Hz), 2.65 (1 H, t, $J = 7.1$ Hz), 2.43 (1 H, t, $J = 6.1$ Hz), 2.36 (3 H, s), 1.92-1.35 (4 H, m), 1.32 (1.5 H, d, $J = 7.0$ Hz), 1.07 (0.5 H, m), 0.93 (0.5 H, m), 0.83 (0.5 H, m); MS m/e 393.2 ($\text{M} + \text{H}$).

A mixture of *Trans*-2-[5-cyanoindol-3-yl]-1-(3-oxopropyl)cyclopropane and byproduct (33 mg of mixture) was dissolved in THF (0.25 mL) and placed in a vial along with ethanol (2 mL) and an amine (0.25 mmol). Finally sodium triacetoxyborohydride (53 mg, 0.25 mmol) was added and the vial was sealed and shaken while being heated at 45 °C for 1 h. Then 0.5 mL of aqueous sodium hydroxide (5N) was added to the vial. The vial was sealed and shaken while being heated at 65 °C for 45 min. Most of the solvent was removed *in vacuo*, and the residue was taken up in aqueous sodium bicarbonate (10 mL) and extracted with ethyl acetate (2 x 5 mL). The organic layer was dried with magnesium sulfate and evaporated. The residue was purified using reverse phase preparative HPLC with a methanol/water gradient containing 0.1% trifluoroacetic acid to give *trans*-2-[5-cyanoindol-3-yl]-1-(3-(N,N-dimethylamino)propyl)cyclo-propane. LC-MS (column = YMC ODS s7, 3 x 50 mm, start %B = 0, final %B = 100, gradient time = 2 min, flow rate = 5 mL/min) m/e 268.3 ($\text{M} + \text{H}$) $^+$, t_R 1.05.

Example 175


Trans-2-[5-cyanoindol-3-yl]-1-(3-(N-methylamino)propyl)cyclopropane




25

This compound was prepared in a manner similar to the above example. LC-MS (column = YMC ODS s7, 3 x 50 mm, start %B = 0, final %B = 100, gradient time = 2 min, flow rate = 5 mL/min) m/e 254.3 ($\text{M} + \text{H}$) $^+$, t_R 1.09.

-131-

Example 176***Trans-2-[5-cyanoindol-3-yl]-1-(3-(N-ethylamino)propyl)cyclopropane***


This compound was prepared in a manner similar to the above example. LC-MS (column = YMC ODS s7, 3 x 50 mm, start %B = 0, final %B = 100, gradient time = 2 min, flow rate = 5 ml/min) m/e 268.3 (M + H)⁺, t_R 1.13.

Example 177***Trans-2-[5-cyanoindol-3-yl]-1-(3-(N,N-diethylamino)propyl)cyclopropane***

10


This compound was prepared in a manner similar to the above example. LC-MS (column = YMC ODS s7, 3 x 50 mm, start %B = 0, final %B = 100, gradient time = 2 min, flow rate = 5 ml/min) m/e 296.3 (M + H)⁺, t_R 1.15.

15

Example 178***Trans-2-[5-cyanoindol-3-yl]-1-(3-(N-ethyl-N-methylamino)propyl)-cyclopropane***

This compound was prepared in a manner similar to the above example. LC-MS (column = YMC ODS s7, 3 x 50 mm, start %B = 0, final %B = 100, gradient time = 2 min, flow rate = 5 ml/min) m/e 282.3 (M + H)⁺, t_R 1.12.

20

Example 179***Trans-2-[5-cyanoindol-3-yl]-1-(3-(1-pyrrolidino)propyl)cyclopropane***


-132-

This compound was prepared in a manner similar to the above example. LC-MS (column = YMC ODS s7, 3 x 50 mm, start %B = 0, final %B = 100, gradient time = 2 min, flow rate = 5 ml/min) m/e 294.2 (M + H)⁺, t_R 1.07.

5

Example 180


***Trans*-2-[5-cyanoindol-3-yl]-1-(3-(N-benzyl-N-methylamino)propyl)cyclopropane**



This compound was prepared in a manner similar to the above example. LC-MS (column = YMC ODS s7, 3 x 50 mm, start %B = 0, final %B = 100, gradient time = 2 min, flow rate = 5 ml/min) m/e 344.3 (M + H)⁺, t_R 1.28.

Example 181

***cis*-1-(N-methylaminomethyl)-2-[5-fluoroindol-3-yl]-cyclopropane**




15

This compound was prepared in a manner similar to Example 117. LC-MS (column = YMC ODS s7, 3 x 50 mm, start %B = 0, final %B = 100, gradient time = 2 min, flow rate = 5 ml/min) m/e 219.2 (M + H)⁺, t_R 0.85.

20

Example 182


***cis*-1-(N-ethylaminomethyl)-2-[5-fluoroindol-3-yl]-cyclopropane**




This compound was prepared in a manner similar to Example 117. LC-MS (column = YMC ODS s7, 3 x 50 mm, start %B = 0, final %B = 100, gradient time = 2 min, flow rate = 5 ml/min) m/e 233.3 (M + H)⁺, t_R 0.92.

25

-133-

Example 183***cis*-1-(N,N-diethylaminomethyl)-2-[5-fluoroindol-3-yl]-cyclopropane**


5 This compound was prepared in a manner similar to Example 117. LC-MS (column = YMC ODS s7, 3 x 50 mm, start %B = 0, final %B = 100, gradient time = 2 min, flow rate = 5 ml/min) m/e 261.2 (M + H)⁺, t_R 1.00.

Example 184***cis*-1-(N-ethyl-N-methylaminomethyl)-2-[5-fluoroindol-3-yl]-cyclopropane**


10

This compound was prepared in a manner similar to Example 117. LC-MS (column = YMC ODS s7, 3 x 50 mm, start %B = 0, final %B = 100, gradient time = 2 min, flow rate = 5 ml/min) m/e 247.2 (M + H)⁺, t_R 0.96.

15

Example 185***cis*-1-(1-pyrrolidino)-2-[5-fluoroindol-3-yl]-cyclopropane**

20 This compound was prepared in a manner similar to Example 117. LC-MS (column = YMC ODS s7, 3 x 50 mm, start %B = 0, final %B = 100, gradient time = 2 min, flow rate = 5 ml/min) m/e 259.2 (M + H)⁺, t_R 0.97.

Example 186***cis*-1-(N-benzyl-N-methylaminomethyl)-2-[5-fluoroindol-3-yl]-cyclopropane**


-134-

This compound was prepared in a manner similar to Example 117. LC-MS (column = YMC ODS s7, 3 x 50 mm, start %B = 0, final %B = 100, gradient time = 2 min, flow rate = 5 ml/min) m/e 309.2 (M + H)⁺, t_R 1.18.

5

Example 187

S,S-Trans-2-[5-Cyanoindol-3-yl]-1-(trimethylammoniummethyl)cyclopropane trifluoroacetate




A solution of S,S-trans-2-[5-cyanoindol-3-yl]-1-(N,N-dimethylamino)-
10 cyclopropane (82 mg, 0.34 mmol) in THF (10 mL) was treated with ethylmagnesium bromide (1 M, 0.40 mL, 0.40 mmol) and stirred 1 h at room temperature. Iodomethane (0.027 mL, 0.43 mmol) was added, and the reaction was stirred 1 h. The solvent was removed *in vacuo*. The residue was purified using reverse phase preparative HPLC with a methanol / water gradient containing 0.1% trifluoroacetic acid. The product was obtained as a trifluoroacetate salt with a yield of 10 mg (8%) :
15 ¹H NMR (400 MHz, DMSO-d₄) 8.14 (1 H, s), 7.51 (1 H, d, J = 8.6 Hz), 7.43 (1 H, dd, J = 8.4, 1.5 Hz), 7.39 (1 H, d, J = 2.1 Hz), 3.61 (1 H, dd, J = 13.1, 6.3 Hz), 3.31 (1 H, dd, J = 13.0, 6.2 Hz), 3.13 (9 H, s), 2.10 (1 H, m), 1.44 (1 H, m), 1.22 (1 H, m), 1.05 (1 H, m); MS m/e 255.2 (M⁺).

20

Example 188

S,S-trans-2-[5-cyano-1-methylindol-3-yl]-1-(N,N-dimethylamino)-cyclopropane




A solution of S,S-trans-2-[5-cyanoindol-3-yl]-1-(N,N-dimethylamino)-
25 cyclopropane (90 mg, 0.38 mmol) in THF (5 mL) was treated with potassium *tert*-butoxide (46 mg, 0.41 mmol) and stirred for 1 h at room temperature. Dimethyl sulfate (52 mg, 0.41 mmol) was added and the reaction was stirred for 3 h. The THF was removed *in vacuo* and the remaining aqueous suspension was extracted with ethyl acetate (4 x 5 mL). The organic layer was dried with magnesium sulfate and the

-135-

solvent was removed *in vacuo*. The residue was purified by chromatography on silica gel (97:3 chloroform / 2M ammonia in methanol) to give *S,S-trans*-2-[5-cyano-1-methylindol-3-yl]-1-(*N,N*-dimethylamino)-cyclopropane in a yield of 62 mg (65%):
¹H NMR (400 MHz, CDCl₃) 8.02 (1 H, d, J = 1.2 Hz), 7.42 (1 H, dd, J = 8.8, 1.2 Hz),
5 7.28 (1 H, d, J = 8.4 Hz), 6.84 (1 H, s), 3.73 (3 H, s), 2.44 (1 H, dd, J = 13.2, 6.8 Hz),
2.34 (1 H, dd, J = 13.1, 6.8 Hz), 2.33 (6 H, s), 1.75 (1 H, m), 1.21 (1 H, m), 0.90 (1 H, m), 0.84 (1 H, m); MS m/e 254.1 (M + H).

Example 189


10 *S,S-trans*-2-[5-cyano-1-ethylindol-3-yl]-1-(*N,N*-dimethylamino)-cyclopropane



Using the above method with diethyl sulfate as the reagent produced *S,S-trans*-2-[5-cyano-1-ethylindol-3-yl]-1-(*N,N*-dimethylamino)-cyclopropane: ¹H NMR (400 MHz, CDCl₃) 8.03 (1 H, d, J = 1.5 Hz), 7.40 (1 H, dd, J = 8.8, 1.6 Hz), 7.31 (1 H, d, J = 8.4 Hz), 6.90 (1 H, s), 4.10 (2 H, q, J = 7.2 Hz), 2.44 (1 H, dd, J = 12.9, 6.5 Hz),
15 2.34 (1 H, dd, J = 13.0, 6.8 Hz), 2.33 (6 H, s), 1.74 (1 H, m), 1.23 (1 H, m), 0.88 (1 H, m), 0.81 (1 H, m); MS m/e 268.1 (M + H).

Example 190

20 Resolution of (2-Benzo[b]thiophen-3-yl-cyclopropylmethyl)-dimethyl-amine



Racemic (2-Benzo[b]thiophen-3-yl-cyclopropylmethyl)-dimethyl-amine (68 mg) was resolved by preparative chiral HPLC on a Chiracel Prep OD column using as the eluant 5% EtOH, 0.1% diethylamine in hexane at 60 mL/min. Two fractions
25 were isolated and concentrated *in vacuo*.


Example 190A:

(-)-(2-Benzo[b]thiophen-3-yl-cyclopropylmethyl)-dimethyl-amine (28 mg).

Example 190B:

- 5 (+)-(2-Benzo[b]thiophen-3-yl-cyclopropylmethyl)-dimethyl-amine (19 mg): ¹H NMR (300 MHz, CDCl₃) 7.93 (1 H, d, J = 7.32 Hz), 7.84 (1 H, d, J = 6.95 Hz), 7.38 (2 H, m), 7.26 (1 H, s), 2.49 (2 H, m), 2.37 (6 H, s), 1.91 (1 H, m), 1.34 (1H, m), 0.94 (2 H, m). LC-MS: 1.56 min; 232.10 (MH)⁺.

10

Example 191**[2-(1H-Indol-6-yl)-cyclopropylmethyl]-dimethyl-amine**

- 6-Methoxyindole (1.47 g, 10.00 mmol) was cooled to 0 °C in methylene chloride and BBr₃ (2 M in methylene chloride, 25 mL, 50.00 mmol) was added. After stirring 16h at room temperature, TLC analysis indicated the reaction was complete. The reaction was quenched with water and the layers separated. The organic layers were washed with 1 N NaOH. The basic aqueous layers were acidified with conc. HCL, extracted with methylene chloride, dried over anhydrous magnesium sulfate, and concentrated *in vacuo* to give the crude 6-hydroxyindole which was used directly for the next reaction.

- The crude 6-hydroxyindole and N-phenyltrifluoromethanesulfonimide (3.93 g, 11.00 mmol) were dissolved in methylene chloride and cooled to 0 °C. Triethylamine (1.20 g, 12.00 mmol) was added and the reaction allowed to warm to room temperature and stirred for 16 h. TLC analysis showed complete conversion to product. The reaction was washed with 1 N HCl, 2 M K₂CO₃, dried over anhydrous magnesium sulfate, filtered, and concentrated *in vacuo* to give 6-trifluoromethanesulfonyl-1H-indole as an oil which solidified on standing. This material was used directly for the next reaction.

- Tris(dibenzylideneacetone) dipalladium (45 mg, 0.05 mmol) and tri-*o*-tolylphosphine (120 mg, 0.20 mmol) were stirred in DMF at room temperature for 30 min. The 4-trifluoromethanesulfonyl-1H-indole, N-methoxy-N-methyl acrylamide

(1.26 g, 11.00 mmol), and triethylamine (2.20 g, 22.00 mmol) were added and the reaction was heated to 120 °C for 4h. The reaction was allowed to cool and the solvent removed *in vacuo*. The residue was taken up in methylene chloride, washed with water, dried over anhydrous magnesium sulfate, filtered, and concentrated *in vacuo* to give a brown solid. The solid was purified by flash chromatography (EtOAc, hexanes) to give 3-(1H-indol-6-yl)-N-methoxy-N-methyl-acrylamide (0.90 g, 39% yield for the three reactions). ¹H NMR (CDCl₃): δ 8.385 (bs, 1H), 7.86 (d, *J* = 18.6 Hz, 1H), 7.62 (d, *J* = 8.5 Hz, 1H), 7.57 (s, 1H), 7.25 (d, *J* = 8.5 Hz, 1H), 7.25 (m, 1H), 7.03 (d, *J* = 18.6 Hz, 1H), 6.55 (m, 1H), 3.78 (s, 3H), 3.32 (s, 3H).

10 Trimethylsulfoxonium iodide (2.20 g, 10.00 mmol) was added to a suspension of sodium hydride (60% dispersion in oil, 0.40 g, 10.00 mmol) in anhydrous THF and stirred at room temperature for 1 h. 3-(1H-Indol-6-yl)-N-methoxy-N-methyl-acrylamide (0.90 g, 3.90 mmol) was dissolved in anhydrous THF and added dropwise to the cloudy white suspension. The mixture was stirred for 16 h at room temperature. The reaction was quenched with a solution of saturated ammonium chloride. Water was added and the solution was extracted with methylene chloride. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated *in vacuo* to give 2-(1H-indol-6-yl)-cyclopropanecarboxylic acid methoxy-methyl-amide as a yellowish solid (0.96 g, 100%). LCMS: MH⁺: 245.12, 20 72% AP.

Lithium aluminum hydride (30 mg, 7.86 mmol) was suspended in anhydrous THF at -45 °C (dry ice/acetonitrile) with stirring. The 2-(1H-indol-6-yl)-cyclopropanecarboxylic acid methoxy-methyl-amide was dissolved in anhydrous THF and added dropwise over a period of 10 min. The reaction was stirred for 3 h at 25 this temperature, diluted with ether, then quenched with 1.5 mL of 1 N sodium hydroxide solution. The mixture was allowed to warm to room temperature and the resulting white solid was filtered and washed with ether. The ether layer was then concentrated *in vacuo* to give 2-(1H-indol-6-yl)-cyclopropanecarbaldehyde as a yellow solid. This material was used immediately for the next reaction.

30 The crude 2-(1H-indol-6-yl)-cyclopropanecarbaldehyde was dissolved in methanol at room temperature with stirring. Dimethylamine (1M solution in THF, 20.00 mL, 20.00 mmol) was added followed by sodium triacetoxyborohydride (4.24 g, 20.00 mmol) After 15 h of stirring at room temperature, the solution was


-138-

concentrated to dryness *in vacuo*. The residue was then partitioned between methylene chloride and 1 N NaOH solution. The layers were separated, and the organic layer dried over anhydrous magnesium sulfate, filtered, and concentrated *in vacuo*. The crude amine was purified by flash chromatography (50% MeOH/EtOAc) to give [2-(1H-indol-6-yl)-cyclopropylmethyl]-dimethyl-amine as a yellow solid (0.62 g, 74% for the two reactions). ¹H NMR (CDCl₃): δ 8.61 (bs, 1H), 7.51 (d, *J*= 8.4 Hz, 1H), 7.08 (t, *J*= 2.7 Hz, 1H), 7.06 (s, 1H), 6.86 (dd, *J*= 11.4, 1.8 Hz, 1H), 6.47 (m, 1H), 2.51 (m, 1H), 2.35 (s, 7H), 1.85 (m, 1H), 0.99 (m, 1H), and 0.85 (m, 1H); LCMS: MH⁺: 215.16, 78% AP.

10

Example 192

6-(2-Dimethylaminomethyl-cyclopropyl)-1H-indole-3-carbonitrile



Phosphorous oxychloride (0.23 g, 1.47 mmol) was added to dimethylformamide (2 mL) at room temperature with stirring. After 15 min, [2-(1H-indol-6-yl)-cyclopropylmethyl]-dimethyl-amine (0.35 g, 1.64 mmol) in DMF (3 mL) was added dropwise. After 20 h, the reaction was quenched with ice and 1 N NaOH. The solution was extracted with methylene chloride, dried over anhydrous magnesium sulfate, filtered, and concentrated *in vacuo* to give 6-(2-dimethylaminomethyl-cyclopropyl)-1H-indole-3-carbaldehyde of an oil (0.25 g, 63%) that was used for the next reaction without purification. ¹H NMR (CDCl₃): δ 9.84 (s, 1H), 8.14 (d, *J*= 8.4 Hz, 1H), 7.97 (s, 1H), 7.14 (d, *J*= 8.4 Hz, 1H), 7.05 (s, 1H), 2.64 (s, 1H), 2.56 (s, 7H), 1.91 (m, 1H), 1.27 (m, 1H), 1.06 (m, 1H), and 0.92 (m, 1H).


In 5 mL of acetic acid were combined the crude 6-(2-dimethylaminomethyl-cyclo-propyl)-1H-indole-3-carbaldehyde, ammonium hydrogen phosphate (0.99 g, 7.50 mmol), and nitropropane (0.09 g, 1.03 mmol.). The mixture was stirred and heated to a gentle reflux for 16 h. Water was added after cooling reaction to room temperature, and the mixture was made basic by the addition of 1 N NaOH. The mixture was extracted with methylene chloride, dried over anhydrous magnesium sulfate, filtered, and concentrated *in vacuo* to give a brown oil. The oil was purified

-139-

by flash chromatography (50% methanol/ethyl acetate) to give 6-(2-dimethylaminomethyl-cyclopropyl)-1H-indole-3-carbonitrile as an amber oil (93 mg, 38%). ¹H NMR (CDCl₃): δ 7.58 (m, 2H), 6.99 (m, 2H), 5.75 (s, 1H), 2.46 (m, 1H), 2.33 (s, 7H), 1.89 (m, 1H), 1.20 (m, 1H), 0.98 (m, 1H), 0.86 (m, 1H); FIMS: 238.2 (M-H); LCMS: 72% AP.

Example 193

3-[2-(2-Dimethylamino-ethyl)-cyclopropyl]-1H-indole-5-carbonitrile



A procedure similar to Example 144, but using dimethylamine in the last step, was used to give 3-[2-(2-Dimethylamino-ethyl)-cyclopropyl]-1H-indole-5-carbonitrile (25.5mg, 48%). MS m/e 254.22 (MH⁺)

LCMS Method

Products were analyzed on a Shimadzu analytical high-performance liquid chromatography system equipped with a Micromass ESI mass spectrometer (positive ion mode). Elution was through a 3 X 50 mm YMC ODS-A C-18 S7 reverse phase column using the following gradient method:

Start mobile phase composition: 10 % methanol – 90 % water – 0.1 % trifluoroacetic acid

Final mobile phase composition: 90 % methanol – 10 % water – 0.1 % trifluoroacetic acid

Gradient time = 2 min

Hold time = 1 min

Flow rate = 5 ml/min

Wavelength = 220 nm

Serotonin Transporter Binding Assay

HEK-293 cells that stably express human serotonin transporters (HEK-hSERT cells) were grown at 37 °C in 5% CO₂ as a monolayer in medium consisting

-140-

of EMEM supplemented with 10% fetal bovine serum and G418 sulfate (500 μ g/ml). To prepare membranes for radioligand binding experiments, cells were rinsed twice with phosphate-buffered saline (138 mM NaCl, 4.1 mM KCl, 5.1 mM Na₂PO₄, 1.5 mM KH₂O₄, 11.1 mM glucose, pH 7.4). Cells were transferred from plates to
5 polypropylene tubes (16 x 100 mm), centrifuged at 1,200 x g for 5 min and were frozen at -80 °C until assay. Following centrifugation, pellets were resuspended by homogenization in buffer consisting of 50 mM Tris (pH 7.7 at 25 °C), 120 mM NaCl and 5 mM KCl and then centrifuged at 32,000 x g for 10 min. Following centrifugation, supernatants were discarded and pellets were resuspended in buffer
10 consisting of 50 mM Tris (pH 7.4 at 25 °C), 150 mM NaCl and 5 mM KCl. Membrane homogenates (200 μ l/plate) were incubated with 1 nM [³H]-citalopram (specific activity = 85 Ci/mmol) and increasing concentrations of test compounds for 1 hr at 25 °C in a total volume of 250 μ l. The assay buffer consisted of 50 mM Tris (pH 7.4 at 25 °C), 120 mM NaCl and 5 mM KCl (pH 7.4 with conc. HCl). Plates
15 were incubated for 1 hr at 25 °C, then filtered through 0.5% PEI treated Whatman GF/B filters using a Brandel cell harvester. Filters were washed three times with 3 ml of ice-cold tris wash buffer. Non-specific binding was defined with 10 μ M fluoxetine. Amount of radioligand bound in the presence and absence of competitor was analyzed by plotting (-)log drug concentration versus the amount of radioligand
20 specifically bound. The midpoint of the displacement curve (IC₅₀, nM), signifies the potency. K_i values were calculated using the method of Cheng and Prusoff (1973).

Dopamine Binding Assay

HEK-293 cells that stably express recombinant human dopamine D_{2L}
25 receptors (HEK-D_{2L} cells) were grown at 37°C in 5% CO₂ as a monolayer in medium consisting of EMEM supplemented with 10% fetal bovine serum and G418 sulfate (500 μ g/ml). To prepare membranes for radioligand binding experiments, cells were rinsed twice with phosphate-buffered saline (138 mM NaCl, 4.1 mM KCl, 5.1 mM Na₂PO₄, 1.5 mM KH₂PO₂, 11.1 mM glucose, pH 7.4), and incubated for 5-10 min. at
30 4°C in hypotonic lysis buffer consisting of 10 mM Tris (pH 7.4) and 5 mM EDTA. Cells were transferred from plates to polypropylene tubes (16 x 100 mm), homogenized and centrifuged at 32,000 x g for 20 min. Following centrifugation, pellets were resuspended by homogenization in buffer consisting of 50 mM Tris (pH

7.7 at 25°C) and 1 mM EDTA. Homogenates were stored at -80°C until needed. On the day of an experiment, homogenates were thawed then centrifuged at 32,000 x g for 20 min. Following centrifugation, supernatants were discarded and pellets were resuspended in assay buffer consisting of 50 mM Tris (pH 7.4 at 25°C), 1 mM EDTA and 6 mM MgCl₂. Membrane homogenates (~5 µg) were incubated with 150 pM [³H]-spiperone (Amersham Life Science) and increasing concentrations of test compounds for 1.5 hr at 22°C in a total volume of 400 µl. Reactions were stopped by addition of ice-cold assay buffer and filtration over glass fiber filters (Whatman GFB, pre-soaked in 0.05% polyethylenimine) using a microtitre format Brandel cell harvester. Filters were washed with 3 ml of ice-cold assay buffer. Non-specific binding was defined with 2 µM (+)butaclamol. K_i values were calculated using the method of Cheng and Prusoff (1973). Protein concentrations were determined by the method of Bradford (1976) with BSA as a standard.

Compounds of the present invention demonstrating greater SERT binding than hD_{2L} binding may be useful for the treatment of depression, anxiety disorders, premature ejaculation, chronic pain, obsessive-compulsive disorder, feeding disorders, premenstrual dysphoric disorder and panic disorders. Compounds of the present invention demonstrating greater hD_{2L} binding than SERT binding may be useful for the treatment of various psychotic disorders including bipolar disorder and schizophrenia. Compounds which have a strong affinity to the hD_{2L} receptor may exhibit dopamine receptor-related side effects such as rigidity, stiff posture and tics such as lip smacking, head turning and sudden arm movements.

In the table below, binding results are denoted as follows:

- 25 A: K_i < 1 nM;
B: 1 nM < K_i < 10 nM;
C: 10 nM < K_i < 100 nM;
D: 100 nM < K_i < 1000 nM;
E: K_i ≥ 1000 nM.

-142-

Results

Example	SERT Ki (nM)	D2L Ki (nM)	Example	SERT Ki (nM)	D2L Ki (nM)
1	A	E	95	B	E
2	B	D	96	B	D
3	A	D	97	B	D
4	A	E	98	B	D
5	A	E	99	B	D
6	B	E	100	C	E
7	B	D	102	B	D
8	B	D	103	B	D
9	B	D	104	C	D
10	B	D	105	C	D
11	B	D	106	C	D
12	B	D	107	C	D
13	B	D	108	C	D
14	C	D	109	B	D
15	C	D	110	B	D
16	C	D	111	B	C
17	B	C	112	C	D
18	B	C	113	C	D
19	B	C	114	C	D
20	B	E	115	C	D
21	B	C	117	B	E
22	B	D	118	C	E
23	C	C	119	B	D
24	C	D	120	B	D
25	B	D	121	A	E
26	B	C	122A	A	E
27	B	C	122B	B	E
28	C	E	123	C	E
29	C	C	124	B	E


Example	SERT Ki (nM)	D2L Ki (nM)	Example	SERT Ki (nM)	D2L Ki (nM)
30	B	C	125	B	D
31	C	C	126	C	D
32	C	C	127a	C	E
33	C	D	128a	C	E
34	B	B	129a	C	E
35	B	E	129b	B	E
36	C	C	130a	D	E
37	C	C	130b	B	E
38	B	E	131	B	D
39	B	C	132	C	D
40	B	C	133	C	D
41	B	C	134	B	E
42	B	C	135	B	C
43	B	C	136	C	E
44	B	B	137	C	E
45	C	D	138	C	E
46	B	D	139	C	C
47	C	D	140	D	D
48	B	D	141	C	D
49	C	D	142	C	D
50	B	C	143	C	E
51	B	D	144	C	D
52	C	D	145	C	D
53	C	D	147	C	D
54	C	D	148	C	D
55	C	D	149	B	D
56	C	D	150	C	
57	C	C	151	B	
58	C	C	152	B	E
59	C	C	153	C	E
60	C	D	154	C	

Example	SERT Ki (nM)	D2L Ki (nM)	Example	SERT Ki (nM)	D2L Ki (nM)
61	C	C	155	C	E
62	B	C	156	D	
63	C	C	157	D	
64	C	C	158	C	E
65	C	C	159	D	
66	C	D	160	C	E
67	C	C	161	D	
68	B	C	162	C	D
69	C	D	164	D	
70	C	D	165	D	
71	C	C	166	D	
72	C	D	167	C	E
73	B	C	168	C	
74	B	E	169	C	D
75	C	C	170	D	
76	C	C	171	D	
77	C	D	172	D	
78	B	D	174	C	D
80	C	C	175	B	D
81	C	C	176	C	D
82	C	C	177	C	
83	B	B	178	C	D
84	B	D	179	C	D
85	C	E	180	C	D
86	C	D	181	C	D
87	C	D	182	C	D
88	B	E	183	C	E
89	B	E	184	C	E
90	B	D	185	C	E
91	B	C	186	B	E
92	C	E	187	A	

Example	SERT Ki (nM)	D2L Ki (nM)	Example	SERT Ki (nM)	D2L Ki (nM)
93	B	E	188	B	
94	A	E	189	B	
			190A	D	
			190B	C	E
			191	C	
			192	B	
			193	B	

What is claimed is:

1. A compound of Formula (I)



or a pharmaceutically acceptable salt or solvate thereof

wherein

A^1 and A^2 are each independently C_{1-4} alkylene or a bond;

A^3 is C_{1-4} alkylene or C_{1-4} alkylidene;

A^4 is C_{1-4} alkylene or a bond and is attached to X, X^1 or X^2 ;

X, X^1 , X^2 and X^3 are independently C or CH;

J is C_{1-4} alkyl;

p is 0 or 1;

R^1 and R^2 are independently H, C_{1-3} alkyl, C_{3-6} cycloalkyl, phenyl, -O-phenyl, -N(H)C(O)O- C_{1-4} alkyl or C_{1-4} alkyl-N(H)C(O)O-;

said C_{3-6} cycloalkyl, phenyl or O-phenyl being independently and optionally substituted with C_{1-4} alkyl, C_{1-3} alkoxy or halo;

or are independently selected from the group of heterocyclic moieties consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl,

-147-

pyridyl, pyrimidinyl, piperidinyl, piperazinyl,
morpholino, adamantyl, indolyl, isoindolyl, indolinyl,
quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl,
isoquinolinyl, dihydroisoquinolinyl and
5 tetrahydroisoquinolinyl, wherein said heterocyclic
moieties are optionally substituted with halo, C₁₋₄alkyl,
C₁₋₄alkoxy or cyano;

or wherein -A¹-R¹ and -A²-R² together with the nitrogen to
which they are attached form pyrrolyl, pyrrolinyl,
10 pyrrolidinyl, imidazolyl, imidazoliny, imidazolidinyl,
pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl,
pyrimidinyl, piperidinyl, piperazinyl, morpholino,
adamantyl, indolyl, isoindolyl, indolinyl, quinolinyl,
dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl,
15 dihydroisoquinolinyl or tetrahydroisoquinolinyl and are
optionally substituted with halo, C₁₋₄alkyl, C₁₋₄alkoxy,
cyano or benzyl;

R³ is H or C₁₋₄alkyl;

m is 0 or 1;

20 R⁴ and R⁵ are independently hydrogen, cyano, halo, nitro or C₁₋₃perfluoroalkyl;

wherein said R⁴ or R⁵ may be independently attached to X, X¹,
X² or X³;

n is 0 or 1;

25 G is N, O or S;

G¹ is N or CH;

Y is (D)H wherein D is C; and

Z is (E)H wherein E is C;

provided that

-148-

both R⁴ and R⁵ are not attached to the same of said X, X¹, X² or X³;

if G is O or S, then m is 0;

if G is N, then m is 1;

5 if R¹ is -N(H)C(O)OC₁₋₄alkyl, C₁₋₄alkyl-N(H)C(O)O- or said heterocyclic moiety wherein said heterocyclic moiety contains a nitrogen atom and said nitrogen atom is attached to A¹, then A¹ is C₂₋₄alkylene;

10 if R² is -N(H)C(O)OC₁₋₄alkyl, C₁₋₄alkyl-N(H)C(O)O- or said heterocyclic moiety wherein said heterocyclic moiety contains a nitrogen atom and said nitrogen atom is attached to A², then A² is C₂₋₄alkylene;

15 if R¹ is N(H)C(O)O-C₁₋₄alkyl, C₁₋₄alkyl-N(H)C(O)O- or a heterocyclic moiety selected from the group consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazoliny, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, isoindolyl, indolinyl, quinolinyl, 20 dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl and tetrahydroisoquinolinyl, wherein said heterocyclic moieties are optionally substituted with halo, C₁₋₄alkyl, C₁₋₄alkoxy or cyano, then R² is H or C₁₋₃alkyl;

25 if R² is -N(H)C(O)O-C₁₋₄alkyl, C₁₋₄alkyl-N(H)C(O)O- or a heterocyclic moiety selected from the group consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazoliny, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, 30 piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, isoindolyl, indolinyl, quinolinyl,

dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl and tetrahydroisoquinolinyl, wherein said heterocyclic moieties are optionally substituted with halo, C₁₋₄alkyl, C₁₋₄alkoxy or cyano, then R¹ is H or C₁₋₃alkyl;

if A⁴, R⁴ or R⁵ are attached to X, then X is C;

if A⁴, R⁴ or R⁵ are attached to X¹, then X¹ is C;

if A⁴, R⁴ or R⁵ are attached to X², then X² is C;

if R⁴ or R⁵ are attached to X³, then X³ is C;

if R⁴ is F and is attached to X and if A³ is methylene, then - A¹-R¹ and -A²-R² together with the nitrogen to which they are attached is not N-methyl-piperazinyl; and
if R⁴ is F and is attached to X and if A³ is methylene, then -A¹-R¹ and -A²-R² together with the nitrogen to which they are attached is not tetrahydroquinolinyl.

2. A compound according to claim 1 wherein p is 0.
3. A compound according to claim 1 wherein G is N and G¹ is CH.
4. A compound according to claim 1 wherein G is S and G¹ is CH.
5. A compound according to claim 1 wherein G is N and G¹ is N.
- 20 6. A compound according to claim 1 wherein A¹ is a bond, R¹ is methyl, A² is a bond and R² is methyl.
7. A compound according to claim 1 wherein R³ is H and m is 1.
8. A compound according to claim 1 wherein R⁴ and R⁵ are halo.
9. A compound according to claim 1 wherein R⁴ is hydrogen.
- 25 10. A compound according to claim 1 wherein R⁴ is fluoro.
11. A compound according to claim 1 wherein R⁴ is cyano.
12. A compound according to claim 1 wherein R⁴ and R⁵ are each fluoro.
13. A compound according to claim 1 wherein D in relation to the four moieties to which it is attached has an absolute configuration of S; E in relation to the four
30 moieties to which it is attached has an absolute configuration of S; and wherein

the hydrogen atom attached to D is in the *trans* configuration to the hydrogen atom attached to E.

14. A compound according to claim 1 wherein A³ is C₁₋₄alkylene.
15. A compound according to claim 1 wherein A³ is C₁₋₄alkylidene.
- 5 16. A compound according to claim 1 wherein A³ is methylene.
17. A compound according to claim 1 wherein A⁴ is a bond.
18. A compound according to claim 1 wherein A⁴ is methylene.
19. A compound according to claim 1 wherein A⁴ is attached X¹.
20. A compound according to claim 1 wherein A⁴ is attached X.
- 10 21. A compound according to claim 1 wherein R⁴ is attached X.
22. A compound according to claim 1 wherein A¹ is a bond, A² is a bond, R¹ is methyl and R² is methyl.
23. A compound according to claim 1 wherein R¹ is independently selected from the group of heterocyclic moieties consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl, 15 pyrrolidinyl, imidazolyl, imidazoliny, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, isoindolyl, indoliny, quinoliny, dihydroquinoliny, tetrahydroquinoliny, isoquinoliny, dihydroisoquinoliny and tetrahydroisoquinoliny, wherein said heterocyclic moieties are optionally substituted with halo, C₁₋₄alkyl, C₁₋₄alkoxy or cyano; A¹ is C₁₋₄alkylene; R² is H or C₁₋₃alkylene; and A² is a bond.
- 20 24. A compound according to claim 1 wherein R¹ is independently selected from the group of heterocyclic moieties consisting of thienyl, imidazolyl, pyridyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, tetrahydroquinoliny and tetrahydroisoquinoliny; A¹ is C₁₋₄alkylene; R² is H or C₁₋₃alkylene; and A² is 25 a bond.
25. A compound according to claim 1 wherein R² is independently selected from the group of heterocyclic moieties consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazoliny, imidazolidinyl, pyrazolyl, pyrazolinyl, 30 pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, isoindolyl, indoliny, quinoliny, dihydroquinoliny, tetrahydroquinoliny, isoquinoliny, dihydroisoquinoliny and tetrahydroisoquinoliny, wherein said heterocyclic moieties are optionally

substituted with halo, C₁₋₄alkyl, C₁₋₄alkoxy or cyano; A² is C₁₋₄alkylene; R¹ is H or C₁₋₃alkylene; and A¹ is a bond.

26. A compound according to claim 1 wherein R² is independently selected from the group of heterocyclic moieties consisting of thienyl, imidazolyl, pyridyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, tetrahydroquinoliny and tetrahydroisoquinoliny; A² is C₁₋₄alkylene; R¹ is H or C₁₋₃alkylene; and A¹ is a bond.
27. A compound according to claim 1 wherein R¹ and R² are independently H, C₁₋₃alkyl, C₃₋₆cycloalkyl, phenyl, -O-phenyl, or -N(H)C(O)O-C₁₋₄alkyl.
28. A compound according to claim 1 wherein R¹ and R² are independently H, C₁₋₃alkyl, or -N(H)C(O)O-C₁₋₄alkyl.
29. A compound according to claim 1 wherein R¹ and R² are independently H, C₁₋₃alkyl, C₃₋₆cycloalkyl, phenyl, or -O-phenyl.
30. A compound according to claim 1 wherein R¹ and R² are independently H, C₁₋₃alkyl, or are independently selected from the group of heterocyclic moieties consisting of thienyl, imidazolyl, pyridyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, tetrahydroquinoliny and tetrahydroisoquinoliny.
31. A compound according to claim 1 wherein R² is H or C₁₋₃alkyl and R¹ is C₃₋₆cycloalkyl, phenyl, -O-phenyl, or -N(H)C(O)O-C₁₋₄alkyl.
32. A compound according to claim 1 wherein R² is H or C₁₋₃alkyl and R¹ is N(H)C(O)O-C₁₋₄alkyl.
33. A compound according to claim 1 wherein R² is H or C₁₋₃alkyl and R¹ is C₃₋₆cycloalkyl, phenyl or -O-phenyl.
34. A compound according to claim 1 wherein R² is H or C₁₋₃alkyl and R¹ is selected from the group of heterocyclic moieties consisting of thienyl, imidazolyl, pyridyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, tetrahydroquinoliny and tetrahydroisoquinoliny.
35. A compound according to claim 1 wherein R¹ is H or C₁₋₃alkyl and R² is C₃₋₆cycloalkyl, phenyl, -O-phenyl, or -N(H)C(O)O-C₁₋₄alkyl.
36. A compound according to claim 1 wherein R¹ is H or C₁₋₃alkyl and R² is N(H)C(O)O-C₁₋₄alkyl.
37. A compound according to claim 1 wherein R¹ is H or C₁₋₃alkyl and R² is C₃₋₆cycloalkyl, phenyl or -O-phenyl.

38. A compound according to claim 1 wherein wherein R^1 is H or C_{1-3} alkyl and R^2 is selected from the group of heterocyclic moieties consisting of thienyl, imidazolyl, pyridyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, tetrahydroquinoliny and tetrahydroisoquinoliny.
- 5 39. A compound according to claim 1 wherein $-A^1-R^1$ and $-A^2-R^2$ together with the nitrogen to which they are attached form pyrrolidinyl, piperidinyl, piperazinyl, morpholino, adamantyl, tetrahydroquinoliny or tetrahydroisoquinoliny and are optionally substituted with benzyl.
40. A compound according to claim 1 wherein
- 10 A^1 and A^2 are each independently C_{1-4} alkylene or a bond;
 A^3 is C_{1-4} alkylene;
 A^4 is a bond and is attached to X or X^1 ;
 R^1 and R^2 are independently H, C_{1-3} alkyl, C_{3-6} cycloalkyl, phenyl, -O-phenyl or -N(H)C(O)O- C_{1-4} alkyl;
- 15 said C_{3-6} cycloalkyl, phenyl or O-phenyl being independently and optionally substituted with C_{1-4} alkyl, C_{1-3} alkoxy or halo;
- or are independently selected from the group of heterocyclic moieties consisting of thienyl, imidazolyl, pyridyl,
- 20 piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, tetrahydroquinoliny and tetrahydroisoquinoliny;
- or wherein $-A^1-R^1$ and $-A^2-R^2$ together with the nitrogen to which they are attached form pyrrolidinyl, piperidinyl,
- 25 piperazinyl, morpholino, adamantyl, tetrahydroquinoliny or tetrahydroisoquinoliny and are optionally substituted with benzyl;
- R^3 is H or C_{1-4} alkyl;
- m is 0 or 1;
- 30 R^4 is cyano or halo and is attached to X or X^1 ;

n is 0;

X and X¹ are each C;

X² and X³ are each CH;

G is N, O or S;

5 G¹ is N or CH;

Y is (D)H wherein D is C; and

Z is (E)H wherein E is C;

provided that

if G is O or S; then m is 0;

10 if G is N, then m is 1;

if R¹ is -N(H)C(O)OC₁₋₄alkyl or said heterocyclic moiety
wherein said heterocyclic moiety contains a nitrogen
atom and said nitrogen atom is attached to A¹, then A¹
is C₂₋₄alkylene;

15 if R² is -N(H)C(O)OC₁₋₄alkyl or said heterocyclic moiety
wherein said heterocyclic moiety contains a nitrogen
atom and said nitrogen atom is attached to A², then A²
is C₂₋₄alkylene;

20 if R¹ is -N(H)C(O)O-C₁₋₄alkyl or said heterocyclic moiety,
then R² is H or C₁₋₃alkyl;

if R² is -N(H)C(O)O-C₁₋₄alkyl or said heterocyclic moiety,
then R¹ is H or C₁₋₃alkyl;


25 if R⁴ is F and is attached to X and if A³ is methylene, then -
A¹-R¹ and -A²-R² together with the nitrogen to which
they are attached is not N-methyl-piperazinyl; and

if R⁴ is F and is attached to X and if A³ is methylene, then -A¹-
R¹ and -A²-R² together with the nitrogen to which they
are attached is not tetrahydroquinolinyl.

41. *Trans*-2-[5-Cyanoindol-3-yl]-1-(*N,N*-dimethylaminomethyl)cyclopropane; *Trans*-1-(*N,N*-dimethylaminomethyl)-2-[5-fluoroindol-3-yl]cyclopropane; *Trans*-2-[5-Cyanoindol-3-yl]-1-[*N,N*-methyl-benzylaminomethyl]-cyclopropane; (1*S*,2*S*)-*trans*-1-(*N,N*-dimethylaminomethyl)-2-[5-fluoroindol-3-yl]-cyclopropane;
- 5 (1*S*,2*S*)-*trans*-2-[5-cyanoindol-3-yl]-1-(*N,N*-dimethylaminomethyl)-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[*N,N*-methyl-2-amino(isopropylcarbonyl)ethylaminomethyl]-cyclopropane; *trans*-1-(*N*-Benzylaminomethyl)-2-[5-cyanoindol-3-yl]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[*N*-3-phenylpropylaminomethyl]-cyclopropane; *trans*-2-[5-
- 10 Cyanoindol-3-yl]-1-[*N*-2-(3-indolyl)ethylaminomethyl]-cyclopropane; *trans*-1-(4-Benzyl-piperidin-1-ylmethyl)-2-[5-cyanoindol-3-yl]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[*N,N*-dipropylaminomethyl]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[*N,N*-methyl-phenylethylaminomethyl]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[*N*-phenylethylamino]-cyclopropane; *trans*-2-[5-
- 15 Cyanoindol-3-yl]-1-[*N*-2-(2-methoxyphenyl)ethylamino]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[*N*-2-(3-methoxyphenyl)ethylamino]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[*N*-2-(4-methoxyphenyl)ethylamino]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[*N*-2-phenoxy-ethylamino]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[pyrrolidin-1-yl-methyl]-cyclopropane; *trans*-2-[5-
- 20 Cyanoindol-3-yl]-1-[*N,N*-ethyl-2-amino(methylcarbonyl)ethylamino methyl]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[*N,N*-ethyl-2-amino(ethylcarbonyl)ethylaminomethyl]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[*N,N*-ethyl-2-amino(propyl carbonyl)ethylamino methyl]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[*N,N*-ethyl-2-amino(isopropylcarbonyl)ethylaminomethyl]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[*N,N*-ethyl-2-amino(methylcarbonyl)propyl aminomethyl]-cyclopropane; *trans*-2-[5-
- 25 Cyanoindol-3-yl]-1-[*N,N*-ethyl-2-amino(ethylcarbonyl)propylaminomethyl]-cyclopropane; *Cis*-2-[5-Cyanoindol-3-yl]-1-(*N,N*-dimethylaminomethyl)cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-(*N*-methylaminomethyl)cyclopropane; (1*S*,2*S*)-*trans*-2-[5-Cyanoindol-3-yl]-1-(*N*-methylaminomethyl)cyclopropane; *trans*-3-[2-(1-Dimethylamino-ethyl)-cyclopropyl]-1*H*-indole-5-carbonitrile; *trans*-3-[2-(1-Pyrrolidin-1-yl-ethyl)-cyclopropyl]-1*H*-indole-5-carbonitrile; (-)*Cis*-2-[5-Cyanoindol-3-yl]-1-(*N,N*-
- 30

-155-


- dimethylaminomethyl)cyclopropane; 5-(2-Dimethylaminomethyl-cyclopropyl)-1H-indole-3-carbonitrile; [2-(5,6-Difluoro-1H-indol-3-yl)-cyclopropylmethyl]-dimethyl-amine; *Trans*-2-[5-cyanoindol-3-yl]-1-(3-(N-methylamino)propyl)cyclopropane; S,S-*Trans*-2-[5-Cyanoindol-3-yl]-1-(trimethylammoniummethyl)cyclopropane trifluoroacetate; S,S-*trans*-2-[5-cyano-1-methylindol-3-yl]-1-(N,N-dimethylamino)-cyclopropane; S,S-*trans*-2-[5-cyano-1-ethylindol-3-yl]-1-(N,N-dimethylamino)-cyclopropane; or 6-(2-Dimethylaminomethyl-cyclopropyl)-1H-indole-3-carbonitrile or pharmaceutically acceptable salts or solvates thereof.
- 5
42. A pharmaceutically acceptable formulation comprising a compound according to claim 1.
43. A method of treating depression, anxiety disorders, premature ejaculation, urinary incontinence, chronic pain, obsessive-compulsive disorder, feeding disorders, premenstrual dysphoric disorder, hot flashes, panic disorders, posttraumatic stress disorder or social phobia comprising the administration to a human in need thereof an effective amount of a pharmaceutically acceptable formulation comprising a compound according to claim 1.
- 15
44. A method of treating premature ejaculation comprising the administration to a human in need thereof an effective amount of a pharmaceutically acceptable formulation comprising a compound according to claim 1.
- 20
45. A process for the preparation of a compound of Formula (d)




(d)

by reacting a compound of formula (b)

-156-




with a compound of formula (c)




in the presence of ethyl diazoacetate and toluene, wherein R^4 is cyano, halo, nitro or C_{1-3} perfluoroalkyl and X is *p*-toluenesulfonyl, benzenesulfonyl, methanesulfonyl or trifluoromethanesulfonyl.

46. According to another embodiment of the eleventh aspect of the present invention is provided a process for the preparation of a compound of Formula (d')




by reacting a compound of formula (b)

-157-



with a compound of formula (c)



5

in the presence of tert-butyl diazoacetate and toluene, wherein R^4 is cyano, halo, nitro or C_{1-3} perfluoroalkyl and X is *p*-toluenesulfonyl, benzenesulfonyl, methanesulfonyl or trifluoromethanesulfonyl.

- 10 47. A method of treating sexual dysfunction in a mammal in need thereof comprising the administration of a pharmaceutically acceptable salt or solvate of a compound according to claim 1 and an erectile dysfunction agent.
48. A method of treating sexual dysfunction in a mammal in need thereof comprising the administration of a pharmaceutically acceptable salt or solvate of a compound
- 15 according to claim 1 and sildenafil.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US02/06627

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) :C07D 209/14

US CL :548/503

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 548/503

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS ONLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	HORWELL et al. Conformationally Constrained Amino-Acids: Synthesis of Novel B,B-,2,3-, and 3,4-Cyclised Tryptophans. Tetraheydron Letters. November 1998, Vol. 39, pages 8729-8732, especially compound 14, page 8730.	41

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Z" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 13 MAY 2002	Date of mailing of the international search report 13 JUN 2002
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3930	Authorized officer <i>R. W. RAMSUEER</i> R. W. RAMSUEER Telephone No. (703) 308-1235

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US02/06627

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos.: 1-40 and 42-48
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

Please See Extra Sheet.

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

BOX I. OBSERVATIONS WHERE CLAIMS WERE FOUND UNSEARCHABLE

2. Where no meaningful search could be carried out, specifically:

In these claims, the numerous variables and their voluminous, complex meanings and their seemingly endless permutations and combinations plus the massive proviso section(claim 1) and the lengthy list of named compounds in claim 41, make it virtually impossible to determine the full scope and complete meaning of the claimed subject matter. As presented, the claimed subject matter cannot be regarded as being a clear and concise description for which protection is sought and as such the listed claims do not comply with the requirements of PCT Article 6. Thus it is impossible to carry out a meaningful search on same. A search will be made on the first discernable invention of claim 41, the first compound therein.